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Thrombosis and cancer  
Thrombosis and cancer are among the most frequent diseases in the developed 
world of today. According to the latest publication by the World Health Organi-
zation (WHO) on global burden of disease, ischemic heart diseases followed by 
cancer are the leading causes of death in developed countries.[1] The associa-
tion between thrombosis and cancer is complex, and the interacting mechan-
isms include non-specific factors related to the host response to tumor (i.e. in-
flammation, paraproteinemia and venous stasis), anti-cancer treatment and 
cancer-cell prothrombotic activities.  
 
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is a significant cause of morbidity and mortality in 
cancer patients.[2-3] Patients with active cancer have a 6 - 7 times increased 
risk of developing symptomatic VTE compared to noncancer patients.[4-5] In 
addition, VTE can be the first symptom of an occult cancer. In the large popula-
tion-based studies, from 10% to 20% of all patients presenting with an idi-
opathic or unprovoked VTE were diagnosed with underlying cancer within the 
next 1-2 years.[6-7]  
 
The risk of developing VTE varies according to the type of malignancy, being 
highest in patients with malignant brain tumors, hematological malignancies, 
and tumors of the pancreas, uterus, ovary, stomach, lung, and kidney.[4, 8-10]  
 
Conventional cytotoxic chemotherapy is an independent risk factor for throm-
bosis with an incidence rate between 10-20% per year. [5, 11] Recently, a pre-
dictive model for a symptomatic VTE during the first four cycles of chemothe-
rapy has been established, grouping the patients into three categories based on 
their total risk score. [12]  
 
Primary anticoagulant prophylaxis is recommended in all cancer patients hos-
pitalized for medical or surgical reasons.[13] The initial treatment of acute VTE 
in cancer patients is identical as in non-cancer patients. Differently, for the long 
term therapy of VTE in cancer, low-molecular-weight heparin (LMWH) is pre-
ferred as monotherapy for at least 3 months followed by LMWH or warfarin as 
long as the cancer is active.[14] 
Thrombosis in Essential Thrombocythemia and Polycythemia 
Vera 
Essential thrombocythemia (ET) and Polycythemia Vera (PV) are two Myelo-
proliferative Neoplasms (MPNs) characterized by an excessive hematopoietic 
progenitor cell proliferation leading to an overproduction of one or more circu-
lating blood cells.[15] ET patients typically present with high platelet count and 
PV patients with high red cell count. Diagnosis of ET and PV is currently accord-
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ing to WHO criteria, based on clinical and laboratory criteria (Figure 1). PV di-
agnosis requires meeting either both major criteria and one minor criterion or 
the first major criterion and two minor criteria. ET diagnosis requires meeting 
all four major criteria.[16] The clinical course of ET and PV is frequently com-
plicated by thrombotic events, progression to myelofibrosis, and hemorrhages 
responsible for 41%, 13% and 4% of patients’ mortality, respectively.[17]  
 
Figure 1. 2008 WHO diagnostic criteria for ET and PV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arterial thrombosis, including coronary, cerebral and peripheral artery occlu-
sions, is more frequent than venous thrombosis and accounts for 60% of all 
vascular events.[18] Venous thrombosis is more frequent in PV patients ac-
counting for approximately one-third of total vascular events.[17] Most com-
mon are deep venous thrombosis of the lower limbs, which may cause pulmo-
nary embolism, and superficial vein phlebitis of the legs. The occurrence of 
thrombosis in unusual sites, i.e splanchnic and cerebral vein thrombosis, is not 
rare as in the general population and is often the presenting feature of an un-
diagnosed MPN. In addition, these latter events have been often reported as a 
severe complication in relatively young female patients.[19-20] Microcirculato-
ry disturbances such as erythromelalgia, Raynaud phenomenon and transient 
neurological events are more common in ET patients due to platelet rich micro-
thrombi occlusion of the end arterial circulation.[21]  
 
Multiple factors have been associated with the pathogenesis of thrombosis in 
MPN patients. The hypercoagulable state in these patients has been attributed 
to blood hyperviscosity, particularly in PV patients, due to overproduction of 
red blood cells and platelets. Recently, a high leukocyte count and the presence 
 Major criteria Minor criteria 
1. Sustained platelet count > 450 x 10
9
/L. 
2. Megakaryocyte proliferation with large 
and mature morphology. 
3.  Not meeting WHO criteria for CML, PV, 
PMF, MDS, or other myeloid neoplasm 
4. Demonstration of JAK2V617F or other 
clonal marker or no evidence of reac-
tive thrombocytosis. 
E
T
 d
ia
g
n
o
si
s 
1. Hgb > 18.5 g/dL (men) > 16.5 g/dL 
(women) or other evidence of increased 
red cell volume.  
2. Presence of JAK2V617F or JAK2 exon 12 
mutation. P
V
 d
ia
g
n
o
si
s 1. Bone marrow biopsy showing hy-
percellularity for age with triline-
age myeloproliferation. 
2.  Serum erythropoietin level below 
the normal reference range. 
3.  Endogenous erythroid colony for-
mation in vitro.  
 
PMF= primary myelofibrosis, CML= chronic myelogenous 
leukemia, MDS= myelodysplastic syndrome  
 
 General Introduction 
13 
 
of the somatic V617F mutation of the Janus 2 tyrosine kinase (JAK2) gene have 
been associated with an increased thrombotic risk in both ET and PV 
patients.[22-24] Many studies have investigated the contribution of platelets in 
the onset of the thrombophilic state in these diseases, and it is now clear that 
the increased platelet count is not a major element in the risk of 
thrombosis.[25] Rather, platelet qualitative abnormalities have been implicated 
in the pathogenesis of hypercoagulability in ET and PV patients. Increased ex-
pression of P-selectin, thrombospondin, and the activated fibrinogen receptor 
GPIIb/IIIa by platelets has been found to correlate with thrombosis.[26-27] The 
formation of platelet-leukocyte aggregates, platelet activation and micropar-
ticles shedding are also implicated in the pathogenesis of thrombosis in these 
patients.[28]     
 
The current management of MPN patients is highly dependent on patient’s 
thrombotic risk. Age, previous thrombotic event and cardiovascular risk factors 
(hypertension, smoking, hypercholesterolaemia and diabetes mellitus) are well 
established predictors of arterial and venous thrombosis. In this regard treat-
ment is tailored individually based on patients’ vascular risk (Table 1)[29].   
 
Table 1. Risk based treatment algorithm in ET and PV patients. 
 
Risk category Risk factors ET Treatment PV Treatment 
Low risk 
Age<60 and no his-
tory of thrombosis* 
Low dose aspirin Low dose aspirin + phlebotomy 
High risk 
Age ≥60 and/or a 
positive history of 
thrombosis* 
Low dose aspirin 
+ hydroxyurea 
Low dose aspirin + phlebotomy 
+ hydroxyurea 
*Arterial and/or venous thrombosis. 
Platelets and cancer 
Studies from recent years provided increasing evidence for a much wider role 
of platelets, beyond maintaining hemostasis. Despite representing the smallest 
anucleated hematopoietic blood cells formed from megakaryocytes’ cytoplasm, 
platelets are as active and biologically influential as the other blood cells. Expe-
rimental studies indicate that platelets have an important connecting function 
between coagulation and cancer progression.[30-31] 
 
The platelet membrane, rich in phospholipids, also contains glycoproteins and 
integrins essential for platelet mediated hemostasis.[32] In addition, these mo-
lecules have been implicated in platelet-tumor cell adhesion and activation. In-
deed, agents inhibiting platelet glycoprotein IIb-IIIa, fibronectin and von Wille-
brand factor, remarkably inhibited adhesion of tumor cells to platelets and con-
sequently experimental hematogenous metastasis.[33] Platelets contain several 
types of secretory granules, such as alfa granules, dense granules and lysosomal 
granules that store and secrete proteins that in addition to coagulation can re-
gulate other processes such as angiogenesis and cancer metastasis. Platelets 
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can be activated directly by the tumor cells or indirectly by tumor secreted ac-
tivators.[34] Once activated, platelets increasingly interact through specific ad-
hesion molecules with other cells such as leukocytes, endothelial cells as well as 
the circulating tumor cells.[35] Platelets binding to tumor cells promote the 
malignant process by protecting circulating tumor cells from lysis by natural 
killer cells.[36] Upon activation, platelets release various angiogenesis-
regulating factors (i.e vascular endothelial growth factor (VEGF), platelet de-
rived growth factor, insulin-like growth factor, CD40 etc.). Some studies suggest 
that platelets are the major source of VEGF in the serum, known as essential 
factor in tumor growth and development.[37]      
 
Another important molecule recently appreciated for the process of tumor me-
tastasis is P-selectin, an adhesion molecule stored in the alfa granules. P-
selectin facilitates direct binding of platelets to tumor cells and augments tumor 
metastasis. In addition, P-selectin binding to P-selectin glycoligand-1 (PSGL-1) 
mediates the release of procoagulant microparticles from platelets and leuko-
cytes, shown to accumulate in the developing thrombi.[38] Recent experimen-
tal evidence suggests that specific inhibition of P-selectin represents a potential 
treatment target in thrombosis, cancer metastasis and inflammation.[39] 
Thrombin generation and cancer 
Tumor cells cause thrombin generation via several pathways, such as directly 
activating the hemostatic system (production of procoagulant proteins, micro-
particles and fibrinolytic inhibitors), or indirectly by engaging procoagulant 
and proadhesive properties of the host vascular cells (i.e. platelets, leukocytes, 
endothelial cells.)[40] On the other hand, thrombin is the key coagulation en-
zyme that promotes angiogenesis and contributes significantly to a more ma-
lignant tumor phenotype. As shown in Figure 2, thrombin has been linked to 
several steps of tumor progression, i.e. it stimulates tumor-platelet adhesion, 
adhesion to endothelium, tumor implantation, tumor cell proliferation and me-
tastasis. Thrombin is one of the most potent physiological activators of plate-
lets, via the platelet protease-activated thrombin receptors (PAR-1 and PAR-4), 
leading to overexpression of glycoprotein IIb/IIIa, von Willebrand factor, P-
selectin and fibronectin, found important in tumor cell-platelet interactions. 
Thrombin pre-treated platelets enhance tumor cell-platelet adhesion, inhibita-
ble by agents known to interfere with the platelet glycoprotein IIb/IIIa integrin, 
von Willebrand factor and fibronectin.[33] The Karpatkin laboratory has also 
demonstrated enhanced adhesion of thrombin-treated melanoma cells to endo-
thelial cells and subendothelial matrix, the first barrier to tumor invasion and 
metastasis.[41] Thrombin’s mitogenic effect was first demonstrated in the 
1970’s on chick embryo fibroblasts.[42] Since then, many investigators demon-
strated thrombin’s mitogenic potential on fibroblasts, endothelial cells and 
smooth muscle cells.[43-45] Many studies have clearly showed that thrombin is 
a growth factor for different tumor cells, evidenced by in vitro and in vivo expe-
riments. Ogiichi et al. showed that human glioma cells can generate thrombin 
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and this thrombin generation induces glioma cell proliferation in vitro.[46] Fur-
thermore, a recent study evidenced that osteosarcomas cells are capable to 
generate thrombin resulting in direct activation of cellular proliferation and 
thrombus formation in the microenvironment. Treatment with low molecular 
weight heparin reduced in vitro osteosarcoma proliferation and procoagulant 
activity as well as tumor growth in vivo.[47] The role of thrombin in tumor cell 
invasion has been demonstrated after incubation of thrombin and U2-OS osteo-
sarcoma cells that resulted in migration of malignant cells through a Matrigel 
barrier.[48] Finally, the role of thrombin in tumor metastasis has been demon-
strated in vivo when thrombin pre-treated colon carcinoma and melanoma cell 
lines showed dramatic increase in pulmonary metastasis. [49-50] 
 
Figure 2. Thrombin-mediated tumor progression. 
 
 
 
Activation of PARs, found on the surface of many tumor cell lines, by thrombin, 
is an important molecular mechanism linked to angiogenesis and tumor pro-
gression. Thrombin activation of PARs leads to upregulation of many angioge-
nesis-related genes, including VEGF, VEGF receptors, tissue factor, bFGF and 
metalloproteinase-2. A recent study showed that thrombin stimulates prostate 
tumor growth after PAR-1 activation.[51] Activation of PAR-1 was also shown 
to increase pulmonary metastasis in melanoma and colon carcinoma cell lines, 
to promote cell growth in NIH3T3 cells and cell invasion in breast cancer expe-
rimental model.[52-54] 
THROMBIN
Adhesion
Adhesion
= von Willebrand factor =P selectin = Fibronectin =GP IIb/IIIa=PAR1/PAR4
=tumor cell =resting platelet =endothelial cell= activated platelet
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Knowledge gained from in vitro studies and in vivo animal models suggests that 
targeting thrombin could lead to a potential therapeutic benefit in cancer pa-
tients.   
Outline of the thesis 
Chapter 1 is the General Introduction to the work described in this thesis. It 
provides the background of the thrombotic complications associated to cancer, 
particularly to patients with ET and PV. These patients are at high risk for 
thrombosis affecting patients’ mortality, morbidity and quality of life. The pa-
thogenesis of this hemostatic imbalance is mostly related to both quantitative 
and qualitative abnormalities of circulating blood cells, specifically the in-
creased leukocyte count, formation of platelet-leukocyte aggregates, platelet 
activation and microparticles shedding. The role of platelets in the pathogenesis 
of thrombosis in MPN patients is still under investigation. While a high platelet 
count is no major determinant of the risk of thrombosis, platelet qualitative 
abnormalities have been increasingly recognized as important contributors to 
hypercoagulability in these patients. Recently, the role of platelets beyond he-
mostasis has been implicated in cancer related processes like inflammation, 
angiogenesis and tumor growth and dissemination.  
 
Tumor cells generate thrombin, the most potent physiological activator of 
platelets. Activated platelets generate thrombin on their surface, engage in 
platelet-tumor and platelet-tumor- endothelial cell interactions thus promoting 
the malignant process. 
 
On the basis of this background it follows that identification of platelet proth-
rombotic potential, by measuring the platelet- associated thrombin generation, 
in MPN patients, can be considered an important determinant of a risk of 
thrombosis as well as a pathophysiologically relevant factor in the progression 
of malignant disease.  
Part one 
Chapter 2 is a review summarizing the prothrombotic mechanisms of tumor 
cells and their role in both coagulation and tumor progression. In particular, 
this chapter focuses on the capacity of tumor cells to promote activation of the 
coagulation system, and on the mechanisms by which clotting proteins may 
promote tumor growth and metastasis.    
 
Chapter 3 is a review of the current recommendations for prevention and 
treatment of VTE in cancer patients. In addition, this review provides an insight 
into the new anticoagulant drugs potentially suitable for use in oncology. 
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Part two 
Chapter 4 is a study investigating the influence of in-vitro contact activation on 
in-vitro measurement of thrombin generation at low tissue factor concentra-
tions using the new calibrated automated thrombinoscopy.  
Part three 
Chapter 5 presents the results of the first study demonstrating platelet-
dependent hypercoagulability in MPN patients, characterized by increased 
thrombin generation and tissue factor levels, particularly in those patients posi-
tive for the JAK2V617F mutation.   
 
Chapter 6 Increased levels of circulating immature platelets have been asso-
ciated with MPN, and other conditions at increased risk for thrombosis (i.e. 
acute coronary syndrome, cardioembolic stroke). We measured the immature 
platelet parameters using a new automated hematology analyser in a group of 
ET and PV patients and correlated the results to JAK2V617F mutation and mye-
losuppressive treatment with hydroxyurea. 
 
Chapter 7 Antiplatelet therapy with aspirin is now a standard regimen for pre-
vention of thrombosis in low and high risk MPN patients. We performed a study 
in a group of ET and PV patients to monitor the effects of aspirin on platelet-
mediated hemostatic and procoagulant activity by measuring platelet adhesive 
and procoagulant function using platelet function analyser -100 and thrombin 
generation assay, respectively.  
 
Chapter 8 Since platelet adhesion and aggregation in vivo is influenced by a 
number of different agonists that act on pathways that are not all blocked by 
thromboxane inhibition, in this study we investigated adenosine diphosphate 
induced platelet aggregation and platelet associated thrombin generation in a 
group of ET and PV patients.  
 
Chapter 9 Cytoreductive therapy with hydroxyurea is a recommended ap-
proach in high risk ET and PV patients in order to minimize their risk of throm-
bosis. In this study we evaluated the effect of hydroxyurea therapy on plasma 
levels of nitric oxide derivatives and soluble selectins of platelet, endothelial 
cell and leukocyte origin in a group of ET and PV patients.  
 
Finally, in Chapter 10 the principal findings of this thesis and relevance into 
understanding the pathogenesis of thrombotic complications in ET and PV are 
discussed in relation to literature.  
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Abstract 
Pathogenesis of the prothrombotic state of cancer patients is due, at least in 
part, to the ability of cancer cells to activate the coagulation system. Several 
complex and not fully recognized interactions between the malignant cell and 
the clotting system promote a shift in the haemostatic balance compared with a 
procoagulant state. Tumour cells possess the capacity to interact with the hae-
mostatic system in multiple ways. The principal mechanisms include the ex-
pression of haemostatic proteins by tumour cells, the production of inflamma-
tory cytokines by tumour and/or host cells, and the direct adhesion of tumour 
cells to normal cells, including platelets, endothelial cells and monocytes. This 
chapter will summarize the prothrombotic mechanisms of tumour cells and 
their role in both coagulation and tumour progression. In particular, this chap-
ter will focus on the capacity of tumour cells to promote activation of the coagu-
lation system, and on the mechanisms by which clotting proteins may promote 
tumour growth and metastasis. 
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Introduction 
Patients with malignancy have an acquired thrombophilic condition and are at 
high risk of venous thromboembolism (VTE) [1]. The prothrombotic state of 
these patients is due to complex and not fully recognized interactions between 
cancer and the haemostatic system that promote a shift in the balance of pro-
coagulant activities over anticoagulant activities. Recent advances in biochemi-
stry, cell biology and molecular biology have helped to provide a better under-
standing of these interactions [2]. As shown in Fig. 1, the principal prothrom-
botic mechanisms associated with cancer cells are: the expression of haemos-
tatic proteins, including procoagulant, and antifibrinolytic activities; the pro-
duction of inflammatory cytokines by tumour and/or host cells with subse-
quent activation of vascular cells; and the direct adhesion of tumour cells to 
normal cells, including platelets, endothelial cells (ECs) and monocytes [1]. On 
the other hand, tumour growth, neoangiogenesis and tumour dissemination 
appear to be influenced by tumour-associated coagulation activation and feed-
back on the coagulation cascade, further enhancing thrombogenesis [3].  
 
The impact of biological factors on the risk of thrombosis in patients with can-
cer is still largely unknown. Differently the contribution of several clinical risk 
factors (i.e. surgery, chemotherapy, hormonal therapy and erythropoiesis-
stimulating agents) is better characterized [4]. Recent data show that the pri-
mary site of cancer, prechemotherapy platelet count >350x109/L, erythropoie-
tin administration, leukocytosis and high body mass index are independent risk 
factors for VTE [5]. Furthermore, a high level of plasma-soluble P-selectin were 
also found to be an independent predictive parameter for the development of 
VTE [6].  
 
Clearly the pathogenesis of thrombosis in cancer is unique in that the tumour 
tissues per se activate blood coagulation, and mechanisms that are involved in 
the malignant transformation may also be involved in the regulation of tumour 
cell procoagulant factors. In human malignancies this appears to be true for the 
JAK2V617F mutation expression in patients with myeloproliferative disorders 
[7], and for PML-RARα hybrid gene expression in patients with acute promye-
locytic leukaemia (APL) [8]. In both cases, the genetic lesion is associated with 
expression of a prothrombotic phenotype. This chapter provides an overview of 
the prothrombotic properties of tumour cells and their role in coagulation and 
tumour progression. In particular, the chapter will focus on the capacity of tu-
mour cells to promote activation of the clotting system, and on the mechanisms 
by which clotting proteins may promote tumour growth and metastasis. Finally, 
the inhibition of coagulation as a bifunctional tool to control both thrombosis 
and malignancy will be explored. 
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Fig. 1. Tumour cell mechanisms of blood clotting activation. Cancer cells can activate the 
haemostatic system through the production of haemostatic factors (i.e. procoagulant proteins, mi-
croparticles and fibrinolysis inhibitors), the release of inflammatory cytokines and the expression 
of adhesion molecules. 
 
 
 
Mechanisms by which tumour cells activate the coagulation 
system 
The principal mechanisms by which tumour cells activate blood coagulation 
involve the production of haemostatic factors, the release of inflammatory cy-
tokines and the expression of adhesion receptors (Fig. 1). 
Haemostatic factors 
 
Tumour cells can express haemostatic factors including: procoagulant proteins, 
such as tissue factor (TF) and cancer procoagulant (CP); microparticles (MPs); 
and fibrinolysis proteins. 
Procoagulant proteins 
 
TF is a transmembrane glycoprotein that is the primary initiator of normal 
blood coagulation. TF forms a complex with factor VIIa (TF/FVIIa) to trigger 
blood coagulation by proteolytically activating factor IX and factor X. Normal 
cells, including ECs and monocyte-macrophages, do not express TF unless they 
are adequately stimulated [9]. In normal conditions, TF is very low in the circu-
lation of normal subjects. However, constitutive TF expression characterizes 
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numerous malignant tumour tissues. In addition, TF expression can be induced 
on tumour-associated macrophages and ECs either by inflammatory endogen-
ous agonists, i.e. tumour necrosis factor alpha (TNF-a) and interleukin (IL)-1b, 
or by exogenous agonists, i.e. bacterial lipopolysaccharide or tumour-specific 
antigens. In breast cancer, the expression of TF in tumour stroma correlates 
with progression to invasive cancer. Similarly, the expression of TF by glioma 
cell lines and glioma surgical specimens correlates with the histological grade 
of malignancy. In some instances, the expression of TF in the primary tumour 
correlates with circulating TF antigen, suggesting that TF released by tumour 
cells contributes to an increased concentration of circulating TF [10].  
 
CP is a cysteine protease that activates factor X directly in the absence of acti-
vated factor VII. CP is synthesized by malignant cells, and its activity has been 
found in extracts of different tumours [11–13]. The presence of CP antigen and 
CP procoagulant activity (PCA) has been identified in the sera of cancer pa-
tients. Although CP is found almost exclusively in malignant cells, its role as a 
tumour marker or as a factor predictive of clinical thrombosis has not been 
demonstrated successfully. Of interest, in APL blasts, CP expression parallels 
the degree of malignant transformation and is lost upon cellular differentiation 
by therapy with all-trans-retinoic acid (ATRA). In contrast, cells resistant to 
ATRA maintain their malignant phenotype and CP expression [14]. Similar ob-
servations have been reported for breast cancer [15]. 
Microparticles 
 
MPs are small membrane vesicles released from cells following activation or 
apoptosis. MPs released by tumour cells have been associated with the hyper-
coagulable state of cancer. The first demonstration of tumour-shed vesicles 
with procoagulant activity was by Dvorak et al in 1981 [16]; they showed that a 
mouse breast carcinoma cell line and a guinea pig hepatocarcinoma cell line-
were able to release PCA in tissue culture and in vivo. This PCAwas associated 
with small vesicles shed by the tumour cell surface. More recently, circulating 
MPs have been described in plasma of patients with various tumours such as 
pancreas and breast adenocarcinoma, giant cell lung carcinoma, colorectal can-
cer and acute leukaemias [17–19]. MPs seem to contribute to intravascular 
thrombin generation by exposure of phosphatidilserine and procoagulant pro-
teins such as TF [20], and may explain the increased level of TF in the circula-
tion of cancer patients. As shown recently by Hron et al [21], patients with colo-
rectal cancer had two-fold higher TF-positive MPs compared with controls, and 
the MP levels correlated positively with the D-dimer level as a marker of clot-
ting activation. In another study, elevated MP-associated TF activity was signifi-
cantly related to the development of VTE in patients with disseminated mucin-
ous carcinoma [17]. Further research is ongoing to demonstrate that MPs de-
rived from tumour cells may bear active TF and can be considered as a bio-
marker of increased thrombotic risk [9]. 
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Fibrinolysis proteins 
 
All fibrinolytic system molecules that are important in the maintenance of 
proper haemostasis are expressed on the surface of tumour cells. They possess 
both urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen 
activator, and can also produce plasminogen activator inhibitors 1 and 2 (PAI-1 
and PAI-2). There are specific receptors on tumour cells that support the as-
sembly of all the fibrinolytic components (i.e. u-PAR), thus facilitating activation 
of the fibrinolytic cascade [22]. In patients with leukaemia, the expression of 
these activities by blast cells may play a role in the pathogenesis of bleeding 
symptoms. On the other hand, a defect in the generation of normal plasma fi-
brinolytic activity due to increased production of the fibrinolysis inhibitor PAI-
1 has been found in patients with solid tumours, and may represent another 
mechanism for the tendency of these patients to develop VTE [1]. Fibrinolytic 
proteins are under evaluation as potentially valuable predictors of disease-free 
interval and long-term survival in malignant disease. Breast cancer patients 
with low levels of u-PA and PAI-1 have significantly better survival than pa-
tients with high levels of either factor, particularly in node-negative breast can-
cer [23].  
Fibrinolysis is also a key component in tumour biology. It is essential for the 
release of tumour cells from their primary site, and has numerous functions in 
promoting cell mobility and motility, and facilitating tumour neoangiogenesis 
[24]. 
Inflammatory cytokines 
 
Tumour cells synthesize and release a variety of cytokines including pro-
inflammatory (i.e. TNF-a, IL-1b) and pro-angiogenic factors [i.e. vascular endo-
thelial growth factor (VEGF), basic fibroblast growth factor (bFGF)]. Cytokine 
overproduction also derives from normal inflammatory tissues as part of the 
reactive process of the host in response to the tumour insult. Most of these cy-
tokines activate and induce the expression of a procoagulant phenotype by 
normal monocytes and ECs.  
 
Monocyte activation has been described to occur in malignancy both in vitro 
and in vivo. Indeed, tumour-associated macrophages harvested from experi-
mental and human tumours express significantly more TF than control cells. In 
addition, circulating monocytes from patients with different types of cancer 
express increased TF activity. The generation of PCA by monocyte-
macrophages in vivo is probably one mechanism for clotting activation in ma-
lignancy [1]. 
 
Cytokines stimulate ECs to increase production of the fibrinolysis inhibitor PAI-
1. In addition, they upregulate EC surface TF expression and downregulate 
thrombomodulin (TM) expression [25,26]. TM is a membrane receptor of vas-
cular ECs with a potent anticoagulant function [26]. It binds and forms a com-
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plex with thrombin to activate the natural anticoagulant protein C. Upregula-
tion of the procoagulant TF with downregulation of the anticoagulant 
TM/protein C system converts the normal anticoagulant endothelium into a 
prothrombotic endothelium. 
Adhesion molecules 
 
The expression of tumour cell surface adhesion molecules and/or their counter 
receptors permits direct interaction of these cells with host cells, including ECs, 
platelets and leukocytes. The attachment of tumour cells to vascular ECs is rele-
vant to promote localized clotting activation to the vessel wall and to start 
thrombus formation. The adhesion can occur directly or via the cooperation of 
granulocytes. The interaction between tumour cells and ECs is mediated by dif-
ferent pathways of adhesion molecules expressed by different types of tumour 
[27]. In flow conditions, the interaction involves rolling and firm adhesion, de-
pending on the respective adhesive properties of both ECs and tumour cells. 
Some tumour cell types roll and adhere using E-selectin molecules, while others 
adhere without rolling using vascular cell adhesion molecule-1 (VCAM-1) re-
ceptors [28]. Thus, various molecules expressed on ECs, including selectins, 
integrins and immunoglobulins, are necessary for the adhesion of cancer cells 
and their migration to distant sites to form metastases. P-selectin (CD62P) is an 
important cell adhesion molecule expressed by stimulated ECs and activated 
platelets. It mediates heterotypic aggregation of activated platelets to cancer 
cells, and the adhesion of cancer cells to stimulated ECs. In addition, P-selectin 
mediates the homotypic aggregation of activated platelets and the transfer of 
procoagulant MPs between cells, which further contributes to fibrin deposition 
and microthrombi formation [29]. 
 
Tumour cells also induce platelet activation and aggregation by the release of 
soluble factors, such as ADP and a cysteine proteinase, or by thrombin generat-
ed via activation of the coagulation cascade [1]. These phenomena lead to in-
creased exposure of adhesion molecules on the platelet surface, including plate-
let glycoprotein (GP) IIb/IIIa, fibronectin and von Willebrand factor (vWF), 
which are required for the adhesion of tumour cells to platelets [30,31]. 
Thrombin activates and enhances exposure of GPIIb/IIIa on both the platelet 
membrane and the tumour surface, and stimulates the expression of platelet 
fibronectin and vWF, which further anchor platelets to tumour cells. Thrombin 
increases tumour cell/platelet adhesion in vitro and metastasis formation in 
vivo [32].  
 
In recent years, at least three molecular mechanisms mediating tumour 
cell/platelet adhesion have been well characterized. The first mechanism is 
based on the binding of platelet integrin αIIb/β3 to the tumour cell integrin 
αV/β3 [33,34]. Another mechanism involves platelet P-selectin binding to gly-
coprotein s-Le(x) on mucin-producing carcinomas [35,36], or to sulphatides on 
the plasma membranes of granulocytes and tumour cells [37]. The third me-
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chanism identifies the central role of the platelet adhesion receptor GPIbα in 
promoting tumour metastasis [38]. 
Role of the coagulation system in tumour progression 
Tumour growth and formation of metastases involve a multistep cascade of 
events by which cancer cells proliferate, detach from the primary site, and mi-
grate to establish new colonies in distant sites. Tumour growth is largely due to 
the capacity of cancer cells to promote the process of neoangiogenesis by se-
creting angiogenic factors (i.e. VEGF and bFGF). The formation of new vessels is 
essential for the provision of nutrients to the malignant tissues [39]. The metas-
tatic process involves adhesion of bloodborne malignant cells to the vascular 
ECs, degradation of the surrounding extracellular matrix (ECM), extravasation 
into the blood stream, and finally migration and proliferation to a secondary 
site. 
Procoagulant proteins such as TF, activated factor X (FXa), thrombin and fibrin 
have the capacity to support the malignant process by promoting neoangioge-
nesis and formation of metastases (Fig. 2). Cellular components of haemostasis, 
i.e. platelets and leukocytes, also contribute to these processes. 
 
Fig. 2. Coagulation protein in tumour biology. Procoagulant proteins induce tumour growth, 
neoangiogenesis, tumour cell invasionand metastasis. 
 
 
 
 
Coagulation and neoangiogenesis 
 
In addition to their primary role in haemostasis and blood coagulation, haemos-
tatic proteins play several roles in tumour neoangiogenesis.  
TF induces angiogenesis via clotting-dependent mechanisms by downstream 
generation of thrombin and fibrin, and by thrombin-induced platelet activation. 
In addition, formed fibrin induces upregulation of TF on tumour cells and ECs, 
and secretion of the pro-angiogenic factor IL-8, thus generating a vicious circle 
of clot formation and tumour growth [40]. 
The function of TF in tumour angiogenesis can also be mediated through me-
chanisms independent of thrombin generation and fibrin deposition. These me-
chanisms are induced via phosphorylation of the TF cytoplasmic tail and subse-
quent signal transduction cascades. In the protease-receptor pathway, the 
TF/FVIIa complex activates one or more protease-activated receptors (PARs), 
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which couple to G proteins to impact multiple signalling pathways. Recent re-
search provided evidence that TF/VIIa targets PAR-2 to support angiogenesis 
in vivo [41]. TF can also promote increased expression of the angiogenic factor 
VEGF and decreased expression of the anti-angiogenic peptide thrombospon-
din.  
 
FXa also exerts cell-signal-inducing effects independent of downstream acti-
vated coagulation proteases. Most of these signals originate via a number of 
different receptors, including effector protease receptor-1 (EPR-1). The binding 
of FXa to EPR-1 results in the proteolytic cleavage of PAR-2 and subsequent 
intracellular calcium signalling. PAR-1 has also been identified as a candidate 
receptor for the cellular effects of FXa. Both FXa and thrombin can induce ex-
pression of the angiogenesis promoting gene Cyr61 and connective tissue 
growth factor (CTGF). Cyr61 and CTGF are immediate early response genes and 
belong to a novel class of the cysteine rich secreted protein family involved in a 
wide array of important biological processes including angiogenesis, wound 
healing, fibrosis and atherosclerosis [42]. 
 
Thrombin is an effective activator of angiogenesis via clotting-dependent me-
chanisms involving platelet activation and fibrin deposition. Furthermore, 
thrombin induces angiogenesis through clotting- independent mechanisms me-
diated by PAR activation and resulting signal transduction cascades (Fig. 3). 
Thrombin activation of PARs leads to upregulation of many angiogenesis-
related genes, including VEGF, vascular endothelial growth factor receptors 
(VEGFR), TF, bFGF and metalloproteinase-2. In addition, thrombin stimulates 
the release of VEGF and angiopoietin from platelets, which induce tube forma-
tion from ECs. 
 
Finally, fibrin formation plays an important role in thrombogenesis as well as in 
tumour progression. Fibrin deposited within the vascular endothelium of new 
tumour vessels, or attached around inflammatory cells or tumour cells, is sug-
gested to facilitate angiogenesis. Local deposition of fibrin can stabilize the ad-
hesion of tumour cells or tumour-cell-associated emboli to the endothelium, 
particularly in a high shear stress environment. In addition, the fibrin matrix 
provides an excellent scaffold for the formation of new vessels [43]. Fibrin also 
induces EC expression of TF and the pro-angiogenic cytokine IL-8. The fibrin 
matrix protects the pro-angiogenic growth factors bFGF, VEGF and insulin-like 
growth factor-1 from proteolytic degradation [3]. Of note, fibrin degradation 
products also contribute to tumour progression by expressing angiogenic, che-
mo-attractant and immunomodulatory properties [43]. Finally, activated plate-
lets support the angiogenic process by releasing VEGF and platelet-derived 
growth factor [44]. Activated platelets can also release phospholipids, which 
enhance the chemoattractant activity and pro-angiogenic features of ECs, thus 
providing another link between haemostasis and angiogenesis [45]. 
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Figure 3. Thrombin is an effective activator of angiogenesis and tumour invasion and metastasis 
via both clotting-dependent (involving platelet activation and fibrin deposition) and clotting inde-
pendent mechanisms [mediated by protease activated receptor (PAR) activation and upregulation 
of angiogenesis-related genes]. EC, endothelial cell. 
 
 
 
 
 
Coagulation and tumour invasion and metastasis 
 
There is substantial evidence for the role of procoagulant proteins (i.e. TF and 
thrombin), and circulating platelets and leukocytes in tumour invasion and me-
tastasis. 
 
Mechanisms associated with TF include: the capacity of the TF/VIIa-Xa complex 
to promote local thrombin generation with subsequent proteolytic activation of 
platelet and endothelial PARs and fibrin deposition; the capacity of the tumour-
associated TF/VIIa-Xa to activate PAR-1 and PAR-2 signaling pathways directly; 
and the capacity of the TF/FVIIa complex to cooperate with TF pathway inhibi-
tor expressed by tumour vessels in inducing cell adhesion and migration by a 
thrombin-independent circle. However, the finding that genetic defects in plate-
lets and fibrinogen, as key thrombin targets, significantly reduce the metastatic 
potential of TF-expressing cells, suggests that the TF-related metastatic poten-
tial is mainly directed through thrombin generation and thrombin-mediated 
proteolysis [46]. 
 
Thrombin contributes significantly to a more malignant phenotype by inducing 
platelet/tumour aggregation, tumour adhesion to ECs and the ECM, and tumour 
cell proliferation and metastases. Important in this setting is the capacity of 
thrombin to trigger the release of growth factors, chemokines and extracellular 
proteins that promote the proliferation and migration of tumour cells (Fig. 3). 
The prometastatic activity of thrombin is demonstrated by experimental pul-
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monary metastasis models, in which lung metastasis is increased by thrombin-
treated tumour cells compared with untreated tumour cells [47–49]. Activation 
of PAR-1 by thrombin stimulates chemokines of melanoma and prostate tu-
mour cells [50]. Additionally, overexpression of PAR-1 in B16 malignant mela-
noma cells leads to a five-fold increase in experimental pulmonary metastasis 
[32]. A strong correlation also exists between elevated PAR expression and in-
vasive potential in a model of breast cancer cells [51]. PAR-1 expression confers 
invasive properties to non-invasive cancer cells, and, conversely, knockdown of 
PAR-1 blunts invasive properties of aggressive cell lines [51,52]. Furthermore, 
thrombin-mediated activation of PAR-1 produces direct or indirect activities 
that stimulate cellular proliferation [3]. 
 
An important role in the steps of tumour invasion and metastasis is played by 
cellular components such as platelets and leukocytes. 
The role of thrombin-activated platelets is shown by murine models, in which 
the elimination of circulating platelets results in a significant reduction in the 
formation of tumour metastases. Indeed, activated platelets facilitate the adhe-
sion of tumour cells to EC and favour their migration through the vessel wall by 
the release of heparanase. Additionally, tumour-cell-associated platelets may 
support metastasis formation by preventing interactions between tumour cells 
and innate immune cells, as shown by immunodepletion studies in vivo [53]. 
 
Leukocytes, particularly polymorphonuclear cells (PMNCs), promote tumour 
growth and metastases [54–57], as the interaction of tumour cells with PMNCs 
or ECs represents a crucial step in the early phase of extravasation and forma-
tion of new metastatic lesions [58]. In fact, PMNCs may adhere to tumour cells, 
facilitating their migration across the endothelial barrier. In addition, PMNCs 
release numerous metalloproteinases that hydrolyse ECM components and fa-
vour cancer cell dissemination. Circulating PMNCs are activated in cancer pa-
tients by locally generated mediators (i.e. TNF-α) or by direct cell-to-cell inte-
ractions leading to expression of surface adhesion molecules, including the β2- 
integrin CD11b/CD18. Increased PMNC CD11b/CD18 expression significantly 
enhances cancer cell/PMNC adhesion [59]. Furthermore, the selectins, includ-
ing L-, E- and P-selectin, mediate the initial interactions between circulating 
PMNCs, activated ECs and tumour cells. During haematogeneous metastasis, 
tumour cells carrying selectin ligands enter the circulation and may encounter 
vascular selectins, thus supporting cancer progression, as shown by different 
studies using mouse models and carcinoma cell lines [58].  
Anticoagulant therapies to improve cancer outcome 
The hypothesis that inhibition of clotting mechanisms may limit cancer disease 
has attracted many researchers since the early experimental evidence of a poss-
ible involvement of the haemostatic system in tumour progression. Clinical tri-
als with anticoagulant drugs were started in the early 1980s to test the effects 
of anticoagulation on the survival of cancer patients. The first randomized con-
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trolled trial found an improvement in overall survival among small cell lung 
cancer patients receiving warfarin in addition to chemotherapy [60]. Since 
then, different studies with warfarin or heparin, first unfractioned heparin 
(UFH) and subsequently low-molecular-weight heparin (LMWH), have been 
conducted with the endpoint of mortality in patients with cancer without 
thrombosis. 
The efficacy and safety of anticoagulants as antineoplastic therapy were eva-
luated by a recent meta-analysis of clinical studies involving both warfarin and 
heparin. The study shows a significant reduction of 13.3% in cancer mortality 
associated with the use of LMWH, and a non-significant reduction of 5.8% asso-
ciated with the use of warfarin. Bleeding complications were increased signifi-
cantly in anticoagulant-treated patients [61]. In another meta-analysis involv-
ing only clinical trials of LMWH, the use of LMWH in addition to standard can-
cer treatment improved the survival of patients with solid tumours, with a mor-
tality risk reduction of 13% in the first year and 10% in the second year, with-
out increasing the bleeding risk [62]. The biological rationale for using anticoa-
gulant drugs (i.e. heparin and vitamin K antagonist) in cancer patients relies on 
their capacity to block the clotting cascade activation. However, these drugs, 
particularly LMWH, show several clotting-independent activities against cancer 
[63]. 
 
A better understanding of the molecular interactions between the haemostatic 
system and the tumour may provide appropriate targets for the production of 
bifunctional drugs; agents that will reverse the coagulopathy and attack the 
malignant process. A recent series of experimental and clinical studies with 
well-defined types of cancer cells reveal how oncogenic events may deregulate 
the haemostatic system. Activated oncogenes (K-ras, EGFR, PML-RARa and 
MET) or inactivated tumour suppressors (i.e. p53 or PTEN) increase TF levels 
and activity, which is postulated to promote not only hypercoagulability but 
also tumour aggressiveness and angiogenesis [64–66]. In human glioma cells, 
inactivation of PTEN tumour suppressor gene resulted in upregulation of TF, 
especially under hypoxic conditions. Some oncogenes also upregulate fibrino-
lytic proteins such as PAI-1 [66]. As shown in the study by Boccaccio et al, using 
a mouse model, hepatoma induced by MET oncogene transcription is associated 
with, apparently independent of TF, a lethal and symptomatic thrombohaemor-
ragic event [64]. This event was associated with upregulation of PAI-1 and cyc-
lo-oxygenase -2 (COX-2) genes.  
 
Concerning human tumours, two possible examples come from haematological 
malignancies where activation of blood coagulation may result from gene-
triggered signalling pathways. In APL cells, the t15–17 translocation, which re-
sults in fusion of the nuclear retinoic acid receptor (RARα) gene on chromo-
some 17 with part of the PML gene on chromosome 15, induces hyperexpres-
sion of TF in the leukaemic cell, linking the primary oncogenic event with in-
duction of hypercoagulability [67]. Treatment of APL with ATRA blocks the ac-
tions of the PML-RARα oncoprotein and leads to lower TF expression by leu-
kaemic cells [68]. Another example is from patients with essential thrombocy-
CHAPTER II 
36 
 
thaemia (ET), where the molecular abnormality, the JAK2V617F gain of function 
mutation, translates into increased clotting activation. In particular, ET patients 
carrying the mutation have an increase in platelet surface TF expression, plate-
let/PMNC aggregates and plasma thrombotic markers [7]. On the other hand, 
cytoreductive treatment with hydroxyurea of patients with ET downregulates 
TF expression by PMNCs and decreases circulating platelet/PMNC aggregates 
[69]. 
 
As the molecular basis for activation of clotting in malignancies becomes better 
elucidated, the development of new drugs that will target both the malignant 
process and the resultant prothrombotic diathesis can be predicted. 
Summary and conclusions 
Tumour-induced procoagulant mechanisms are multiple and complex. The two-
way relationship with cancer on one side and haemostasis on the other pro-
motes a hypercoagulable state in patients, and enhances thromboembolic com-
plications. Cancer cells exhibit a procoagulant phenotype, but the oncogenic 
events leading to the malignant transformation can deregulate the haemostatic 
system. The abnormal coagulation, in turn, modulates tumour growth and en-
hances tumour dissemination. Consequently, a vicious cycle is formed where 
tumour growth leads to increased clotting, and increased clotting accelerates 
tumour growth. New therapeutic approaches to test the use of anticoagulants 
as adjuvant therapy for cancer are under investigation. New agents capable of 
targeting specific pathways of clotting proteins and blocking cancer represent 
important future perspectives. 
Practice points 
 haemostatic proteins support the malignant phenotype by promoting 
neoangiogenesis and metastasis formation 
 TF expression characterizes many malignant tumours, and some stu-
dies suggest that tumour related TF contributes to circulating TF 
 in APL blasts, CP expression correlates with the degree of malignant 
phenotype 
 tumour-derived cytokines activate the endothelial surface to express a 
procoagulant and proadhesive phenotype 
 the use of anticoagulant drugs (i.e. LMWH) in addition to standard an-
tineoplastic treatment may improve the survival of cancer patients 
 in patients with APL, treatment with ATRA has a bifunctional role to 
block both the malignant process and the hypercoagulable state 
 the JAK2V617F mutation expressed in a high proportion of patients 
with essential thrombocythaemia and polycythaemia vera increases 
the expression of procoagulant proteins by platelets and leukocytes, 
and increases thrombotic risk. 
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Research agenda 
 tumour-derived MPs as a probable biomarker for increased thrombotic 
risk 
 fibrinolytic proteins as possible predictors of long-term survival in ma-
lignant diseases 
 development of new drugs that will target the malignant process and 
the specific pathways of the clotting proteins 
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Abstract 
Importance of the field: Cancer patients are at increased risk for developing ve-
nous thromboembolism (VTE). The occurrence of VTE predicts worse progno-
sis in cancer patients, and while the 1 year survival in cancer patients free of 
thrombosis is 36%, differently in patients with diagnosed VTE is 12%. The 
management of VTE in cancer patients is challenging, because the anticoagulant 
treatment in these patients can be less effective and carry considerable morbid-
ity.  
Areas covered in this review: This review covers the treatment strategies for 
cancer patients with VTE and highlights the new anticoagulant agents and their 
potential use in oncology. In writing this review, a literature search was per-
formed using the PUB MED database with the following subject headings: can-
cer, venous thromboembolism and anticoagulant treatment. 
What the reader will gain: The readers of this article will gain a comprehensive 
overview of the current recommendations for prevention and treatment of VTE 
in cancer patients. In addition, this review provides an insight into the new an-
ticoagulant drugs potentially suitable for use in oncology, in particular 
idraparinux, apixaban, rivaroxaban and dabigatran etexilate. 
Take home message: Low-molecular-weight heparin remains the best treatment 
option for initial and long term treatment of VTE in cancer patients.  
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Introduction 
Cancer patients are at increased risk for developing venous thromboembolism 
(VTE), either as deep vein thrombosis (DVT) or pulmonary embolism (PE) or 
both. Many studies have shown that VTE occurs commonly and is associated 
with decreased survival in these patients [1-3]. Patients with active cancer have 
a 6 to 7 times increased risk of developing symptomatic VTE compared to non-
cancer patients [4-5]. In addition, VTE can be the first symptom of an occult 
cancer. A large population based study shows that 18% of all VTE in the com-
munity is associated with an underlying cancer [6]. The first report that throm-
bosis is associated with an underlying cancer was published in 1865 by the 
French internist Armand Trousseau [7]. Patients who present with unprovoked 
or idiopathic VTE or PE have a 2 to 3 fold increased risk of having an occult can-
cer compared to patients with secondary VTE [8-10]. 
 
The risk of developing VTE varies according to the type of malignancy, being 
highest in patients with malignant brain tumors, haematological malignancies, 
and tumors of the pancreas, uterus, ovary, stomach, lung and kidney [2, 4, 11-
12]. VTE incidence rates can also vary according to the histology and as shown 
in the study by Blom et al., lung cancer patients with adenocarcinoma have 
higher VTE incidence compared to squamous cell carcinoma [13]. In addition, 
patients diagnosed with metastatic disease have much higher VTE incidence 
compared to patients diagnosed with local stage cancer. The incidence of VTE is 
the highest in the initial period after the cancer diagnosis. One possible expla-
nation for this observation might be the cancer aggressiveness. The study by 
Alcalay et al. with colon cancer patients and the later study by Rodriguez et al., 
with ovarian cancer patients, have shown that faster-growing cancers are asso-
ciated with a higher rate of VTE [14-15]. Aside the common risk factors for 
thrombosis, such as advanced age, female sex, race, previous history of throm-
bosis, prothrombotic mutations and immobility, the anticancer treatment-
related factors further increase the risk of thrombosis in cancer patients [2, 16-
17]. Non surgical treatments such as chemotherapy, hormonal therapy, antian-
giogenic agents and supportive therapy, all have a prothrombotic effect in can-
cer patients. Conventional cytotoxic chemotherapy is a well defined independ-
ent risk factor for VTE with an incidence rate between 10 and 20% per year [5, 
18]. The new agents used in treatment of multiple myeloma, thalidomide and 
lenalidomide, have been associated with 20 - 40% increased risk for VTE, par-
ticularly when used in combination with dexamethasone or doxorubicin [19-
20]. A systematic review for the use of tamoxifen in early stage breast cancer 
women showed an increased risk of VTE by 2 to 7 fold compared to placebo. 
This risk increased to 20 fold when chemotherapy and tamoxifen were used in 
combination. The risk of VTE in users of tamoxifen was found to increase with 
age, particularly in women above 60 years of age [21]. Therefore chemotherapy 
and hormone therapy should be viewed as independent risk factors for VTE. 
Anastrozole, a new aromatase inhibitors used as adjuvant therapy in early 
breast cancer women, showed lower risk for VTE compared to tamoxifen, yet 
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the incidence of VTE with these new agents was higher than that expected in 
the general population [22]. Increased thrombotic events were also observed in 
patients with haematological malignancy treated with protocols containing L-
asparaginase. According to a meta-analysis of 17 studies, the rate of throm-
botic/haemorrhagic events and DVT in children with acute lymphoblastic leu-
kemia (ALL) is 5.2% and the majority of the events occur during induction 
therapy with L-asparaginase [23]. Adults with ALL who receive asparaginase 
therapy have a reported incidence of VTE between 4.2 and 9.6% [24-25]. Eryt-
hropoiesis stimulating agents (ESAs) and white blood cell growth factors have 
been introduced as important tools for the treatment of cancer patients with 
anaemia and neutropenia. These treatments alleviates fatigue syndrome and 
improves patients’ quality of life when compared to placebo or transfusion 
therapy [26]. However, the use of ESAs and other hematopoietic growth factors 
have been shown as independent risk factors for VTE in cancer patients on 
chemotherapy [27]. Furthermore, the use of central venous catheters (CVCs) 
for chemotherapy administration is associated independently with an in-
creased risk of thrombosis. The trauma of the vessel wall, directly or indirectly 
due to high drug concentration, the type, position or duration of catheteriza-
tion, all may influence the risk of thrombosis [28].  
 
The occurrence of VTE predicts worse prognosis in cancer patients, and while 
the 1 year survival in cancer patients free of thrombosis was 36%, differently in 
patients with diagnosed VTE was 12% [1]. In addition, treatment of VTE in can-
cer patients is challenging because the anticoagulant treatment in cancer pa-
tients can be less effective and carry considerable morbidity [29].  
 
From all the reasons discussed above, it appears that preventing VTE in the 
cancer patients is a very important issue. Equally important is the search for 
more effective and safe treatments for overt VTE in this condition.  Several na-
tional and international scientific societies have recently published guidelines 
for VTE prevention and management in cancer patients, including the American 
College of Chest Physicians (ACCP), the National Comprehensive Cancer Net-
work (NCCN), the American Society of Clinical Oncology (ASCO), the European 
Society of Medical Oncology (ESMO), the International Union of Angiology, the 
Italian Association of Medical Oncology (AIOM), and the French national guide-
lines (FNCLCC) [30-36]. All these guidelines provide recommendations on how 
to appropriately target antithrombotic prophylaxis and treatment of VTE in 
cancer patients. This review focuses only on the treatment strategies for cancer 
patients with VTE and highlights the new antithrombotic agents and their po-
tential use in oncology.  
Management of manifest VTE  
The standard therapy of a first acute VTE episode in patients without cancer 
consists of an initial phase, in which intravenous adjusted dose UFH (APTT 
range=1.5-2.5), or subcutaneous weight-adjusted doses of low-molecular-
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weight-heparin (LMWH) or fondaparinux are administered, followed by a pro-
longed phase in which Vitamin K antagonists (VKA) at  International Ratio 
(INR) 2-3 (range) are given for at least three months. VKA are started within 
the first 24 hours of heparin (or fondaparinux) therapy. When INR values reach 
the level >2, heparins are stopped (usually after 5-7 days) and only VKA is con-
tinued [35]. LMWH are equally effective and safe for treatment of DVT or PE or 
both [37]. Due to their effectiveness they are the first choice in the initial phase 
of VTE treatment. Fondaparinux is also effective and safe in the initial phase of 
VTE treatment.  
1. VTE initial treatment 
 
The initial treatment of an acute VTE episode in cancer patients is not different 
from the recommended initial treatment for patients without cancer. UFH and 
LMWH have shown similar efficacy and safety in the meta-analysis of several 
trials comparing the two drugs for the initial treatment of patients with acute 
VTE [37]. About 20% of patients enrolled in each of these trials had cancer. The 
Matisse-PE randomized trial including 2213 patients with symptomatic pulmo-
nary embolism (PE), compared the efficacy and safety of fondaparinux to UFH. 
In addition, the Matisse-DVT clinical trial compared the efficacy and safety of 
fondaparinux to enoxaparin in 2205 patients with symptomatic deep vein 
thrombosis (DVT). Both studies conclude that fondaparinux is not inferior and 
is safe as UFH or enoxaparin for the initial treatment of symptomatic PE or DVT, 
respectively [38-39]. A recent subgroup analysis of the Matisse clinical trials 
including 240 cancer patients with PE and 237 cancer patients with DVT was 
published. Regarding overall survival and bleeding, fondaparinux was found 
comparable to enoxaparin and UFH in cancer patients. The recurrence rates of 
VTE were not significantly different between the fondaparinux arm and LMWH 
or UFH arms [40].  
2. VTE long-term treatment 
 
The current recommendations for the long-term treatment of VTE in patients 
with cancer differ from the standard treatment in patients without cancer (Fig-
ure 1). Indeed, while in patients with VTE without cancer, VKA therapy is 
started within 24 hours of the start of heparin treatment and continued long-
term, in patients with cancer the continual parenteral administration of LMWH 
is the first recommended approach. In patients with cancer, VKA therapy is 
shown to be less effective than LMWH in preventing VTE recurrences and has 
increased toxicity. In addition, there are other problems for a correct anticoagu-
lation with VKA, due to the difficulties to maintain a tight therapeutic control 
(for anorexia, vomiting, and drug interactions), the possibility of frequent inter-
ruptions for thrombocytopenia and invasive procedures, and difficulties to find 
venous access for INR monitoring. A randomized controlled trial (CLOT study) 
compared the efficacy and safety of LMWH (dalteparin) versus VKA therapy, 
administered for a total 6 months, in preventing VTE recurrences in 672 cancer 
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patients who had acute symptomatic DVT or PE or both. Patients were ran-
domly assigned to standard treatment, i.e. dalteparin administered at a dose of 
200 IU/kg daily for 5 to 7 days followed by VKA for 6 months (target INR=2.5) 
or to the experimental arm, i.e. dalteparin given as monotherapy at 200 IU/kg 
daily for the first month, followed by 75% of the initial dose for 5 more months. 
The results showed that the patients randomized to the experimental arm had 
significantly lower VTE recurrences (27 of 336) compared to the standard long-
term VKA group (53 of 336). The  hazard ratio for recurrent VTE in the long-
term dalteparin group compared to the VKA group was 0.48 (95% confidence 
interval = 0.3-0.77, p=0.002). No significant differences were observed for any 
bleeding events or death between the two groups [41].  
 
Figure 1. Treatment of thromboembolism in cancer patients. Currently recommended treat-
ment of idiopatic venous thromboembolism in patients without (A) and with (B) cancer.  
 
 
 
An open–label trial randomized patients with and without cancer with symp-
tomatic proximal DVT of the lower limbs to receive, for 6 months, either LMWH 
(tinzaparin) or VKA (acenocoumarol). Whereas LMWH showed no advantage in 
the efficacy and safety over VKA in patients without cancer, in patients with 
cancer LMWH was found superior to VKA [42]. Another study compared long 
term VKA to long term enoxaparin given for 3 months in 146 patients with can-
cer and VTE. The results of this randomized controlled study showed that 
enoxaparin is more safe and effective compared to VKA (p=0.04 by the long 
rank test), based on a cumulative end-point of hemorrhages and thrombosis 
[43]. A recent meta-analysis of all randomized controlled trials testing the effi-
cacy and safety of long-term LMWH versus VKA included 1158 adult patients 
with cancer-associated thrombosis. The analysis showed that 6 months treat-
ment with LMWH have a significant superiority over VKA (relative risk 
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(RR)=0.52, p=0.002), without increasing bleeding complications [44]. A Coch-
rane systematic review, including the results of 8 randomized controlled trials, 
showed similar statistically significant benefit of LMWH over VKA (RR=0.53; 
95% CI = 0.35-0.80) for reduction of recurrent VTE [45]. To date all guidelines 
agree on that LMWH is the preferred agent for long-term treatment of cancer 
associated thrombosis. It shows superior efficacy over warfarin without in-
creasing bleeding, has no interaction with cancer treatment, and is more con-
venient. 
3. Duration of anticoagulation 
 
Since malignancy is “per se” an important risk factor for thrombosis and cancer 
patients are at increased risk of recurrent VTE, the anticoagulant treatment for 
a first episode of VTE should be continued as long as the cancer is active, unless 
a severe bleeding risk outweights the risk of VTE recurrence [34]. The ACCP 
guidelines suggest continuing with either LMWH or VKA after 6 months [35]. 
However, no clinical trials demonstrate an optimal duration of anticoagulation. 
In addition, the natural history of recurrent thrombosis after stopping antico-
agulants is not well studied in cancer patients.   
4. Treatments of VTE recurrences during anticoagulation for a first VTE episode. 
 
Recurrences of VTE are an important therapeutic challenge in cancer patients. 
In addition to an increased risk of developing VTE compared to the general 
population, cancer patients also have 3-fold increased risk of recurrent VTE 
while receiving anticoagulant therapy compared to non-cancer patients [29, 
46]. A prospective observational study by Hansson et al, showed that, in pa-
tients with previous VTE, the presence of malignancy is an independent risk 
factor for a recurrent VTE with a RR of 1,97 (95% CI, 1.20-3.23; P<0.001) [47]. 
Figure 2 shows the suggested therapeutic options in case of recurrent VTE dur-
ing anticoagulant treatment. These experience-based recommendations sug-
gest: 1. switching to LMWH for “warfarin failures”, and 2. increasing LMWH 
dose for “LMWH” failures. The efficacy of a LMWH dose increase for patients 
who develop a recurrent VTE while treated with therapeutic doses of LMWH 
was demonstrated by a recent retrospective cohort study evaluating the man-
agement of recurrent VTE and outcome in 70 cancer patients. Patients receiving 
a therapeutic dose LMWH at the time of recurrent VTE received 20% higher 
LMWH dose for 4 weeks, whereas patients on maintenance LMWH received a 
therapeutic LMWH dose for 6-12 weeks. Patients on low dose LMWH and pa-
tients on VKA switched to therapeutic dose of LMWH for 1 month, followed by a 
maintenance dose. During the 3 month follow-up period only 6 patients (8.6%) 
had a second VTE. All these patients continued with an escalated LMWH dose 
and none had any further recurrent thrombotic event in the next 3 month fol-
low up [48].  
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Vena cava filters: 
 
There is limited data on the use, safety and the long term outcome of vena cava 
filters. The results of the few observational studies showed that 4-32% of the 
patients might still develop recurrent thrombosis. No studies have demon-
strated a benefit of their use in reducing the patients’ mortality [49]. The use of 
vena cava filters may affect the risk of PE but not the risk of  DVT [50]. There-
fore, the use of vena cava filters have been considered as an alternative to pre-
vent PE only in patients having a contraindication to anticoagulation (i.e. active 
bleeding, active cerebrovascular hemorrhage, severe, uncontrolled or malig-
nant hypertension, pericarditis, profound and prolonged thrombocytopenia, 
severe head trauma) or patients with recurrent VTE despite adequate treat-
ment.  
 
Figure 2. Treatment of VTE recurrences. 
 
 
 
5. Treatment of VTE in paediatric cancer patients  
 
Like adults, children with cancer are at increased risk for VTE. The most com-
mon cancer in children associated with VTE is the ALL. L-asparaginase and cor-
ticosteroid treatment have been identified as the main risk factors for VTE in 
these patients [51]. The prevalence of VTE in children with ALL ranges from 
1.1-11% when VTE is diagnosed on the basis of clinical symptomsand from 37.5 
to 40% when x-ray screening is used [52-53]. Due to the lack of evidence for the 
benefit and the increased risk of bleeding, antithrombotic prophylaxis is not 
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recommended in the routine practice of children with cancer. Differently, 
LMWH is the preferred choice for VTE treatment in children with cancer with 
duration of 3 months or until the VTE risk factor persists, such as asparaginase 
treatment [54]. 
New antithrombotic drugs  
Despite the prompt treatment of VTE in cancer patients, 9-17 % of patients still 
experience recurrent VTE while on treatment with LMWH or warfarin. The im-
portance for regular monitoring and the long term need for daily treatment 
with parenteral drugs (i.e. LMWH) add an additional burden to cancer patients. 
The need for safer and more effective anticoagulant drug for VTE treatment in 
cancer patients therefore remains a challenge. Several new antithrombotic 
drugs have been developed and are at different stages of clinical testing. Some 
of these drugs might have an impact in the prevention and treatment of VTE in 
cancer patients.   
 
The new anticoagulants under development interfere with either the initial or 
the propagation phase of the coagulation cascade, or with fibrin generation. 
Figure 3 shows the new antithrombotic drugs at stage III of the clinical testing 
in the setting of VTE treatment and their mode of action on the coagulation cas-
cade. This review focuses on data for drugs that, potentially, are suitable for use 
in oncology, such as idraparinux, apixaban, rivaroxaban and dabigatran etexi-
late. 
1. Indirect FXa inhibitor 
 
Idraparinux is a synthetic pentasaccharide and an indirect Factor Xa (FXa) in-
hibitor. It binds antithrombin with very high affinity and has plasma half-life of 
80 hours. It is therefore suitable for subcutaneous administration once a week 
in a fixed dose. In a phase II, dose-finding trial including 659 patients with 
proximal DVT, a dose of 2.5 mg idraparinux was chosen for further investiga-
tion in phase III clinical trials [55]. The phase III clinical trials demonstrated 
that, athough effective in preventing thrombosis, idraparinux administration is 
associated with increased risk of bleeding [56-58]. The focus for further inves-
tigation has therefore shifted to a biotinylated form of idraparinux SSR12517E, 
or idrabiotaparinux. Compared to idraparinux, the new drug has an antidote, 
the avidin, that administered intravenously can completely neutralize the ac-
tion of idrabiotaparinux [59]. The EQUINOX study, which includes patients with 
DVT of the lower limbs, demonstrated similar efficacies between idraparinux 
and idrabiotaparinux and a trend to less bleeding with idrabiotaparinux. Cur-
rently, a phase III clinical trial is on-going in patients with symptomatic PE with 
or without signs of DVT. After a treatment of at least 5 days with LMWH or 
heparin, patients are randomized to receive either idrabiotaparinux or VKA 
[60]. The BOREALIS-AF study was designed to evaluate the efficacy and safety 
of idrabiotaparinux administered once-a-week subcutaneously compared to 
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INR adjusted-dose warfarin in patients with atrial fibrillation. The trial was 
prematurely discontinued in December 2009 because idrabiotaparinux could 
not show significant improvement in the care of these patients.  
 
Figure 3. New anticoagulant drugs’ mode of action on coagulation cascade. 
 
 
 
2. Direct oral Factor Xa inhibitors  
 
Other important drugs that can find its role in VTE management in cancer pa-
tients are the direct FXa inhibitors apixaban and rivaroxaban. Both have an ad-
vantage to be administered orally and have a maximum plasma concentration 
in 3-4 hours after ingestion. Apixaban has a combined hepatic and renal elimi-
nation, while rivaroxaban in 66% is eliminated by the kidneys and therefore is 
contraindicated in patients with creatinine clearance less than 30 ml/min. The 
results of the phase III apixaban study, ADVANCE-1, in which patients undergo-
ing knee replacement were randomly assigned to start either apixaban (2.5 mg) 
or enoxaparin (30 mg) twice daily after surgery, showed no difference in the 
primary efficacy outcome between the two arms (8.99% vs 8.85% respec-
tively). However, the rates of major bleeding were less in the apixaban arm 
(0.69%) than in the enoxaparin arm (1.39%), suggesting that apixaban is an 
effective oral anticoagulant [61]. The results of the ADVANCE-2 study in which 
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patients with total knee replacement surgery were randomized to receive ei-
ther apixaban (2.5 mg) twice daily or enoxaparin (40 mg) once daily were pre-
sented at the International Society of Thrombosis and Haemostasis congress 
held in July 2009 in Boston, Massachusetts. Patients in the apixaban arm had 
significantly lower (p<0.001) VTE events (15.1%) than patients in the enoxa-
parin arm (24.4%). The clinically relevant bleeding was less in the apixaban 
arm (3.5%) but not significantly different from enoxaparin arm (4.8%, p=0.09). 
Apixaban is being studied in patients with symptomatic VTE (AMPLIFY, phase 
III) comparing apixaban (10 mg twice daily for 7 days followed by 5mg twice 
daily for 6 months) to standard strategy with enoxaparin followed by VKA. Tri-
als including patients with acute coronary syndrome (APPRAISE study) and 
atrial fibrillation (ARISTOTLE study) are ongoing. A phase II trial tested apixa-
ban (5, 10 or 20 mg once daily for 12 weeks) versus placebo for prevention of 
VTE in patients with advanced or metastatic cancer undergoing chemotherapy. 
The study enrolled 125 patients and ended January 2009. The results showed 
that 12 weeks of apixaban is well tolerated in patients with advanced cancer on 
chemotherapy. Major bleeding and drug associated side events were very low 
in the apixaban arms. No thrombotic events were registered in the apixaban 
arms, but 3 patients (10.3%) on placebo developed VTE [62].  
Rivaroxaban has already been approved in postoperative orthopaedic prophy-
laxis for the prevention of VTE on base of 4 phase III clinical trials. The results 
of these clinical trials (RECORD 1-4) suggest that 10 mg once daily of oral Ri-
varoxaban is superior as postoperative prophylaxis in patients undergoing 
knee and hip arthroplasty to standard treatment with LMWH. Major bleeding 
was rare in all 4 studies and not significantly different between the two arms 
[63-66]. A dosage of 10 mg daily for prevention of thrombosis and 20 mg daily 
for treatment of established thrombosis are evaluated in the on-going phase III 
studies. In patients with atrial fibrillation, 10 mg of rivaroxaban once daily is 
compared to standard warfarin therapy in prevention of stroke and systemic 
embolism. The same dosage of 10 mg daily rivaroxaban for 35 days has been 
evaluated for prevention of thrombosis in acutely ill medical patients compared 
to enoxaparin 40 mg once daily for 10 days. This large, randomized, double-
blind multicenter study (MAGELLAN) also included patients with active cancer 
who had been hospitalized for chemotherapy or treatment of the complications 
of the active cancer. Study enrolment closed in April 2010. 
3. Direct oral thrombin inhibitors 
 
Dabigatran etexilate is an oral direct thrombin inhibitor that reaches its plasma 
peak after 2 h and has a half-life of approximately 14-17 h. It is primarily elimi-
nated via the kidneys and therefore is contraindicated in patients with renal 
failure. In phase III clinical trials (RE-MODEL, RE-NOVATE and RE- MOBILIZE), 
two different dosages of dabigatran etexilate (150 mg and 220 mg) were com-
pared to enoxaparin in patients undergoing orthopaedic surgery. The results 
showed that dabigatran etexilate is not significantly different in preventing VTE 
in patients undergoing knee or hip surgery compared to the standard treatment 
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with enoxaparin. In addition, no differences in bleeding events were found be-
tween the three arms [67-69]. The phase III RELY study randomized 18,113 
patients with non-valvular atrial fibrillation to receive either 110 or 150 mg 
twice daily dabigatran etexilate, or standard treatment with warfarin (target 
INR 2-3). The results of the study, recently published, show that 110 mg dabiga-
tran etexilate twice daily is not inferior to warfarin in preventing 
stroke/systemic embolism and has significantly lower bleeding events (2.71 vs 
3.36%). The patients receiving higher dosage of 150 mg twice daily dabigatran 
etexilate had significantly lower rate of stroke/systemic embolism (1.11 vs 
1.69% per year) and similar risk of major bleeding compared to patients on 
warfarin. Both doses of dabigatran etexilate used in this study showed similar 
net clinical benefit outcome due to the lower risk of ischemia in 150 mg arm 
and lower risk of bleeding in 110 mg arm [70]. Recently, the results of the RE-
COVER randomized, double-blind study were published showing that dabiga-
tran etexilate at a fixed dose of 150mg twice daily is as effective and similarly 
safe as VKA in the long term treatment of an acute VTE [71]. 
Conclusion 
The published guidelines provide specific recommendations for the use of anti-
coagulants in the prevention and treatments of VTE in cancer patients. How-
ever, the available data are limited and new research is needed, by well de-
signed randomized clinical trials. In addition, the available clinical trials cannot 
recommend anticoagulation to improve cancer patients’ survival and new clini-
cal trials designed specifically for this reason are needed to improve the current 
guidelines. Alternatively, new anticoagulants, such as direct FXa and thrombin 
inhibitors, have the potential to substitute for the current LMWH prevention 
and long term treatment in cancer patients. The preliminary data are sugges-
tive of a potential clinical benefit from several of these agents. However, many 
questions remain and it is therefore important to evaluate the effectiveness and 
safety of the new anticoagulants in cancer setting.   
Expert opinion  
Cancer-associated thrombosis is a common cause of morbidity and mortality in 
patients with malignancy. Due to the introduction of new more thrombogenic 
chemotherapeutic regimens, improved oncology outcomes and an aging popu-
lation, the incidence of thrombosis in cancer is continuously increasing. In this 
setting, thrombosis interferes with cancer treatment, prolongs patient hospi-
talization, increases the use of healthcare resourses and finally increases pa-
tients’ emotional and economic burden. Treatment of thrombosis in cancer is 
critical, as the current treatments strategies still do not meet patient needs; 
even treated cancer patients experience recurrent thrombosis.  
On the basis of the increasing concern about VTE risk in cancer patients, the 
prevention of VTE has become an important issue. The new oral anticoagulants 
could have a potential for the primary prevention of thrombosis, especially in 
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those patients receiving anticancer treatments. Generally, clinical studies of the 
new anticoagulants begin with patients in need of short term prevention of 
VTE. These are typically patients undergoing hip or knee elective surgery. In 
this setting the efficacy and the safety of the drug profile is being examined and 
the eventual adverse events from the drug administration are recognized. The 
next phase of the drug clinical development is evaluating the anticoagulant ef-
fect in patients with a disease such as DVT or PE. Finally, antithrombotic drugs 
are evaluated in patients in need of long term prevention, such as patients with 
atrial fibrillation at risk of stroke or systemic embolism.  
Cancer is a high risk situation for thrombosis. Except for one small phase II trial 
of apixaban in patients with metastatic cancer, no trial has been designed to 
evaluate the effect of the new antithrombotic drugs in cancer patients. It is 
therefore difficult to draw conclusion for this setting based on the results of the 
trials designed for different indications. In addition, even with the risk of 
thrombosis, these patients are also at increased risk of bleeding. Although the 
task is challenging, finding an adequate substitute drug for the current thera-
peutic management of VTE in cancer is important.  
It is particularly important to understand the two-way relationship between 
cancer and haemostasis that promotes a hypercoagulable state and enhances 
thromboembolic complications. Whereas the tumour cells demonstrate a pro-
coagulant phenotype, the thrombosis modulates cancer growth and enhances 
cancer dissemination [72].  Hypercoagulation can be detected in the early 
stages of malignant diseases as low grade intravascular coagulation [73]. The 
principal mechanism by which tumour cells activate blood coagulation is by the 
production of haemostatic factors (i.e. the tissue factor and the cancer proco-
agulant), the release of pro-inflammatory and pro-angiogenic factors and the 
expression of adhesion molecules [72]. A number of preclinical studies suggest 
the potential anticancer properties of the heparin and LMWH [74-75]. It has 
been demonstrated that, as well as blocking the coagulation cascade, LMWH 
also has clotting independent activities against cancer [76]. Therefore, the use 
of anticoagulant drugs is seen not only to restore the hypercoagulable state but 
also to block tumour growth and tumour dissemination. In this sense it is im-
portant to evaluate the effect of the new antithrombotic drugs on tumour pro-
gression and cancer survival. New studies are needed to evaluate whether the 
new agents will retain the same anti-inflamatory, immunomodulatory and anti-
angiogenic properties as LMWH in the cancer setting. The results of clinical tri-
als and meta-analysis indicate that LMWH has an influence beyond its effects in 
coagulation. The available data suggest that LMWH has a direct antitumor effect 
and influence on cancer patients’ survival. However, these studies have several 
limitations, such as heterogeneity in the cancer population, anticoagulant used, 
dosage and duration. Future prospective trials are therefore needed to clarify 
which LMWH is most effective, at what dosage and duration, and which cancer 
population would benefit the most. 
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Article highlights  
 Cancer patients are at increased risk for developing thrombosis either 
as DVT or PE. 
 Cancer-associated thrombosis predicts worse prognosis in patients 
with malignancy. 
 Current guidelines recommend the use of antithrombotic prophylaxis 
only in hospitalized cancer patients in absence of contraindications. 
 LMWH is preferred as monotherapy at least 3 months in patients with 
VTE and cancer followed by LMWH or warfarin as long as the cancer is 
active. 
 In case of recurrent VTE switch to LMWH in “warfarin failures” or in-
crease LMWH dosage in “LMWH failures”. 
 Thrombin and Factor Xa inhibitors are potentially suitable for use in 
oncology due to their advantageous mode of oral administration with-
out need for regular laboratory monitoring. 
 New clinical trails are needed to evaluate the effectiveness and the 
safety profile of the new antithrombotic drugs in cancer patients. 
  
CHAPTER III 
58 
 
References: 
1 Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with 
venous thromboembolism. The New England journal of medicine. 2000; 343: 1846-50. 
2 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, 
and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007; 110: 
2339-46. 
3 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism 
and its effect on survival among patients with common cancers. Archives of internal medicine. 2006; 
166: 458-64. 
4 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, 
and the risk of venous thrombosis. Jama. 2005; 293: 715-22. 
5 Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from 
molecular mechanisms to clinical presentations. J Thromb Haemost. 2007; 5 Suppl 1: 246-54. 
6 Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ, 3rd. 
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-
based study. Archives of internal medicine. 2002; 162: 1245-8. 
7 Donati MB. Thrombosis and cancer: Trousseau syndrome revisited. Best practice & 
research. 2009; 22: 3-8. 
8 Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J. Newly diagnosed malignancy in patients 
with venous thromboembolism. Search or wait and see? Thrombosis and haemostasis. 1997; 78: 
121-5. 
9 Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. 
Occult cancer in patients with venous thromboembolism: which patients, which cancers. 
Thrombosis and haemostasis. 1997; 78: 1316-8. 
10 Iodice S, Gandini S, Lohr M, Lowenfels AB, Maisonneuve P. Venous thromboembolic 
events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost. 2008; 6: 
781-8. 
11 Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. 
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24: 484-90. 
12 Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. 
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record 
linkage study. J Thromb Haemost. 2006; 4: 529-35. 
13 Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer 
patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004; 2: 
1760-5. 
14 Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH. Venous 
thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 
2006; 24: 1112-8. 
15 Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism 
in ovarian cancer. Gynecologic oncology. 2007; 105: 784-90. 
16 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors 
for deep vein thrombosis and pulmonary embolism: a population-based case-control study. 
Archives of internal medicine. 2000; 160: 809-15. 
17 Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, 
Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G. A clinical outcome-based prospective study 
on venous thromboembolism after cancer surgery: the @RISTOS project. Annals of surgery. 2006; 
243: 89-95. 
18 Falanga A. The incidence and risk of venous thromboembolism associated with cancer 
and nonsurgical cancer treatment. Cancer investigation. 2009; 27: 105-15. 
19 Alkindi S, Dennison D, Pathare A. Arterial and venous thrombotic complications with 
thalidomide in multiple myeloma. Archives of medical research. 2008; 39: 257-8. 
Treatment of thromboembolism in cancer patients 
59 
 
20 Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, 
Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, 
Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, 
Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, 
Hussein MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. 
Leukemia. 2008; 22: 414-23. 
21 Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with 
adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004; 101: 439-49. 
22 Lycette JL, Luoh SW, Beer TM, Deloughery TG. Acute bilateral pulmonary emboli 
occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review 
of the literature. Breast cancer research and treatment. 2006; 99: 249-55. 
23 Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, Donati MB. 
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 
prospective studies comprising 1752 pediatric patients. Blood. 2006; 108: 2216-22. 
24 Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, 
Mandelli F. Incidence of thrombotic complications in adult patients with acute lymphoblastic 
leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA 
Group. European journal of haematology. 1992; 49: 63-6. 
25 Melillo L, Grandone E, Colaizzo D, Cappucci F, Valvano MR, Cascavilla N. Symptomatic 
venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center 
experience of 114 patients at diagnosis. Acta haematologica. 2007; 117: 215-20. 
26 Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on 
hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: 
results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19: 2865-74. 
27 Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-
associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104: 
2822-9. 
28 Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. The 
oncologist. 2004; 9: 207-16. 
29 Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, 
Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding 
complications during anticoagulant treatment in patients with cancer and venous thrombosis. 
Blood. 2002; 100: 3484-8. 
30 Mandala M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, Barni S. Venous 
thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). 
Critical reviews in oncology/hematology. 2006; 59: 194-204. 
31 Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer 
patients: ESMO clinical recommendations. Ann Oncol. 2008; 19 Suppl 2: ii126-7. 
32 Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, 
Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quere I, Levesque H, Debourdeau P. 
2008 french national guidelines for the treatment of venous thromboembolism in patients with 
cancer: Report from the working group. Critical reviews in oncology/hematology. 2009. 
33 Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, 
Goldhaber SZ, Grover TS, Haire W, Hassoun H, Jahanzeb M, Leung LL, Linenberger ML, Millenson 
MM, Ortel TL, Salem R, Smith JL, Streiff MB. Venous thromboembolic disease. Clinical practice 
guidelines in oncology. J Natl Compr Canc Netw. 2006; 4: 838-69. 
34 Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, 
Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, 
Francis CW. American Society of Clinical Oncology guideline: recommendations for venous 
thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25: 5490-
505. 
35 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic 
therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 454S-545S. 
36 Prevention and treatment of venous thromboembolism. International Consensus 
Statement (guidelines according to scientific evidence). Int Angiol. 2006; 25: 101-61. 
CHAPTER III 
60 
 
37 Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight 
heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A 
meta-analysis of randomized, controlled trials. Annals of internal medicine. 1999; 130: 800-9. 
38 Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van 
den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus 
intravenous unfractionated heparin in the initial treatment of pulmonary embolism. The New 
England journal of medicine. 2003; 349: 1695-702. 
39 Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, 
Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial 
treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of internal medicine. 
2004; 140: 867-73. 
40 van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, 
Prins MH, Buller HR. Treatment of venous thromboembolism in patients with cancer: subgroup 
analysis of the Matisse clinical trials. Thrombosis and haemostasis. 2009; 101: 762-9. 
41 Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, 
Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of 
recurrent venous thromboembolism in patients with cancer. The New England journal of medicine. 
2003; 349: 146-53. 
42 Romera A, Cairols MA, Vila-Coll R, Marti X, Colome E, Bonell A, Lapiedra O. A randomised 
open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with 
oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 
2009; 37: 349-56. 
43 Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra 
JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary 
prevention of venous thromboembolism in patients with cancer: a randomized controlled study. 
Archives of internal medicine. 2002; 162: 1729-35. 
44 Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular- weight- heparin versus 
vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in 
adults: a systematic review of randomized controlled trials. Thrombosis research. 2009; 123: 837-44. 
45 Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ. 
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. 
Cochrane database of systematic reviews (Online). 2008: CD006650. 
46 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent 
thromboembolic and bleeding complications among patients with venous thromboembolism in 
relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J 
Clin Oncol. 2000; 18: 3078-83. 
47 Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein 
thrombosis: incidence and risk factors. Archives of internal medicine. 2000; 160: 769-74. 
48 Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular 
weight heparin to manage recurrent venous thromboembolic events despite systemic 
anticoagulation in cancer patients. J Thromb Haemost. 2009; 7: 760-5. 
49 Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter 
placement in late-stage cancer. Vascular and endovascular surgery. 2006; 40: 287-94. 
50 Wallace MJ, Jean JL, Gupta S, Eapen GA, Johnson MM, Ahrar K, Madoff DC, Morello FA, 
Murthy R, Hicks ME. Use of inferior vena caval filters and survival in patients with malignancy. 
Cancer. 2004; 101: 1902-7. 
51 Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. 
Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease 
and therapy. Thrombosis research. 2003; 111: 199-212. 
52 Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. 
Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thrombosis research. 
2003; 111: 125-31. 
53 Giordano P, Del Vecchio GC, Saracco P, Zecca M, Molinari AC, De Mattia D. A practical 
approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute 
lymphoblastic leukemia: recommendations of the "Coagulation Defects" AIEOP Working Group. 
Recent patents on cardiovascular drug discovery. 2007; 2: 53-62. 
54 Yang J, Paredes N, Chan AK. Antithrombotic therapy in children with venous 
thromboembolism. Hamostaseologie. 2009; 29: 80-7. 
Treatment of thromboembolism in cancer patients 
61 
 
55 A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for 
secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost. 2004; 2: 
47-53. 
56 Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, 
Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. 
The New England journal of medicine. 2007; 357: 1094-104. 
57 Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, 
Prins MH, Raskob GE. Extended prophylaxis of venous thromboembolism with idraparinux. The 
New England journal of medicine. 2007; 357: 1105-12. 
58 Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, 
Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Torp-Pedersen C, Wyse DG. Comparison of 
idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial 
fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008; 371: 315-21. 
59 Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM. 
Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant 
therapy. J Thromb Haemost. 2008; 6: 1697-706. 
60 Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 234S-56S. 
61 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for 
thromboprophylaxis after knee replacement. The New England journal of medicine. 2009; 361: 594-
604. 
62 M.N. Levine HAL, C.P. Esclanate, J.A. Julian, D. Deitchman, M.C. O'Brien and L.M. Ramirez. 
Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on 
chemotherapy Thrombosis research. 2010; 125: S161-S2. 
63 Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, 
Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for 
thromboprophylaxis after hip arthroplasty. The New England journal of medicine. 2008; 358: 2765-
75. 
64 Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, 
Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the 
prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised 
controlled trial. Lancet. 2008; 372: 31-9. 
65 Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, 
Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. 
The New England journal of medicine. 2008; 358: 2776-86. 
66 Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, 
Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for 
thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 
373: 1673-80. 
67 Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, 
Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR. Oral dabigatran etexilate vs. 
subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee 
replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178-85. 
68 Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, 
Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for 
prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, 
non-inferiority trial. Lancet. 2007; 370: 949-56. 
69 Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, 
Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor 
dabigatran etexilate vs North American enoxaparin regimen for prevention of venous 
thromboembolism after knee arthroplasty surgery. The Journal of arthroplasty. 2009; 24: 1-9. 
70 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, 
Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, 
Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. The New 
England journal of medicine. 2009; 361: 1139-51. 
71 Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, 
Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous 
thromboembolism. The New England journal of medicine. 2009; 361: 2342-52. 
CHAPTER III 
62 
 
72 Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best 
practice & research. 2009; 22: 49-60. 
73 Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer 
patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis 
and Malignancy International Society of Thrombosis and Haemostasis. Thrombosis and haemostasis. 
1993; 70: 540-2. 
74 Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR. The effects of vitamin K-
antagonists on survival of patients with malignancy: a systematic analysis. Thrombosis and 
haemostasis. 2001; 86: 1586-7. 
75 Niers TM, Klerk CP, DiNisio M, Van Noorden CJ, Buller HR, Reitsma PH, Richel DJ. 
Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Critical reviews 
in oncology/hematology. 2007; 61: 195-207. 
76 Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer. Current opinion in 
pulmonary medicine. 2005; 11: 403-7. 
 
 
 
 
  
Treatment of thromboembolism in cancer patients 
63 
 
 
 64 
 
 
 
  
 65 
 
CHAPTER 4 
 
Monitoring thrombin generation: is addi-
tion of corn trypsin inhibitor needed? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Henri M.H. Spronk, Arne W.J.H. Dielis, Marina Panova-Noeva, René 
van Oerle, José W.P. Govers-Riemslag, Karly Hamulyák, Anna Fa-
langa, Hugo Ten Cate 
Thrombosis and Haemostasis. 2009;101(6):1156-62. 
 
 66 
 
 
 
Monitoring thrombin generation: is addition of corn trypsin inhibitor needed? 
67 
 
Summary 
Thrombin generation monitoring has the potential to be used as a clinical diag-
nostic tool in the near future. However, robust pre-analytical conditions may be 
required and one factor that has been reported is in-vitro contact activation 
that might influence in-vitro measurements of thrombin generation and there-
by act as an unpredictable pre-analytical variable. The aim of the current study 
was to investigate the influence of contact activation and the necessity of corn 
trypsin inhibitor (CTI) to abolish contact activation in thrombin generation 
measurements at low tissue factor (TF) concentrations. Thrombin generation 
was performed using the Calibrated Automated Thrombinoscopy (CAT), there-
by determining the endogenous thrombin potential (ETP), peak height, and the 
lag time, in plasma obtained from healthy volunteers. Addition of CTI after 
plasma preparation had no significant influence on thrombin generation trig-
gered with 0.5 pM TF or higher, as demonstrated by unaltered ETP and lag time 
values between analyses with and without CTI. Addition of CTI before blood 
collection reduced thrombin generation triggered with 0.5 pM TF: both the ETP 
and peak height were significantly reduced compared to no CTI addition. In 
contrast, thrombin generation remained unaltered at a 1 pM TF trigger or 
above. This study demonstrates that addition of CTI after plasma separation is 
not necessary when triggering with TF concentrations of 0.5 pM and higher. 
Furthermore, it was demonstrated that it is not needed to pre-fill blood collect-
ing tubes with CTI when measuring thrombin generation at TF concentrations 
of ≥ 1 pM. 
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Introduction 
Thrombin is an essential enzyme in the coagulation cascade [1] and changes in 
thrombin production may be associated with thrombotic as well as haemorr-
hagic conditions in patients [2-9]. One of the more commonly used methods to 
assess thrombin generation in plasma is the Calibrated Automated Thrombo-
gram (CAT, Thrombinoscope BV, Maastricht, The Netherlands). This method 
uses a low affinity fluorogenic substrate (Z-Gly-Gly-Arg-AMC), which is con-
verted into a fluorescent signal by thrombin. The activity of thrombin is thus 
continuously registered over time, resulting in a characteristic thrombin gener-
ation curve. Over the past years this method was validated for pre-analytical 
conditions [10-12] and shown to exert good reproducibility and stability. One 
problem, however, might be the activation of factor (F)XII during blood draw-
ing and/or during analysis. Recently, van Veen and Dargaud demonstrated the 
contribution of contact activation to thrombin generation analysis, especially at 
low concentrations of TF [10, 12], thereby introducing an unpredictable pre-
analytical variable which increased inaccuracy and imprecision [13]. The use of 
the specific FXIIa inhibitor corn trypsin inhibitor (CTI) attenuated the effects of 
contact activation observed during thrombin generation. The consequences of 
contact activation for clinical practice are considerable: addition of CTI to blood 
collection tubes increases the costs and requires an additional tube besides the 
commonly used vacutainer. Since contact activation can occur during venipunc-
ture or in the thrombin generation analysis itself, we hypothesized that the 
blood collection procedure and the used reagents for thrombin generation are 
key determinants in in-vitro activation of FXII. In order to verify the previous 
results of Van Veen and Dargaud, as well as to determine the effects of blood 
collection and used reagents, we analyzed thrombin generation under well de-
fined conditions with and without CTI. 
Methods 
Experimental design 
 
1. Effects of blood collection method.  
Venous blood from four healthy volunteers was simultaneously collected using 
a standard 21-gauge needle (BD, Plymouth, UK) for the right arm and a Winged 
Infusion Set or “butterfly”-needle equipped with a 30 cm long tubing (Push But-
ton Blood Collection Set, BD) for the left arm.  
 
2.  Effects of CTI-addition to plasma.  
Venous blood from twelve healthy volunteers was collected in 3.2% (w/v) ci-
trate using a 21-gauge needle and plasma was prepared as described below. 
Just before thrombin generation analysis CTI was added to the plasmas to ob-
tain a final concentration of 25 or 50 µg/ml. Thrombin generation was analyzed 
using 0.5, 1, 2, or 5 pM TF as trigger.  
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3. Effects of CTI-addition to venous blood. 
Venous blood from twelve healthy volunteers (the same subjects as above) was 
collected in 3.2% (w/v) citrate containing CTI (final concentration of 40 µg/ml 
in plasma) using a 21-gauge needle. Thrombin generation was analyzed using 
0.5, 1, 2, or 5 pM TF as trigger.  
 
Blood collection and plasma preparation 
 
Venous blood from the left and from the right arm of four healthy volunteers 
was collected in 3.2% (w/v) citrate using a 21-gauge needle (BD) or a Winged 
Infusion Set (BD) through venipuncture. The first 10 mL of venous blood were 
discarded. Platelet-poor plasma (PPP) was prepared by two centrifugation 
steps: the first at 2,000 x g for 15 minutes (min) and the second at 11,000 x g 
for 10 min. Plasma aliquots were snap-frozen in liquid nitrogen and stored at -
80 °C until use. All samples were thawed at 37 °C for 15 min before analysis and 
analyzed batch-wise. CTI was obtained from Haematologic Technologies, Inc. 
(Essex Junction, VT) and added to the 3.2% (w/v) citrate collection tubes to 
obtain a final concentration of 40 µg/ml in plasma. To study the effect of CTI 
addition during thrombin generation, CTI was added to plasma before analysis 
to obtain final concentrations of 25 or 50 µg/ml. Kaolin was added to 3.2% 
(w/v) citrate tubes to obtain a final concentration of 1 mg/ml after plasma col-
lection.  
 
Normal pool plasma and FXII-deficient plasmas 
 
Normal pooled plasma was prepared at the departments of Haematology and 
Clinical Chemistry of the Maastricht University Medical Center, The Nether-
lands, by pooling plasma from 85 healthy volunteers not using any medication. 
FXII-deficient plasma was either obtained from the Maastricht University Medi-
cal Center (indicated as FXII-deficient plasma [1]) or George King Bio-Medical 
Inc. (Overland Park, KS, USA; indicated as FXII-deficient plasma [2]) and were 
both from patients with a congenital FXII-deficiency. FXI-deficient plasma was 
obtained from George King Bio-Medical Inc.  
 
Thrombin generation 
 
Thrombin generation in tissue factor (TF)-triggered platelet poor plasma was 
measured by means of the CAT method (Thrombinoscope BV) as described 
previously [14], which makes use of a low affinity fluorogenic substrate for 
thrombin (Z-Gly-Gly-Arg-AMC) to continuously monitor thrombin activity in 
clotting plasma. In order to correct for inner-filter effects and substrate con-
sumption, each thrombin generation measurement was calibrated against the 
fluorescence curve obtained in the same plasma with a fixed amount of throm-
bin-α2-macroglobulin complex (Thrombin Calibrator, Thrombinoscope BV), as 
recommended by the manufacturer. Fluorescence was read in an Ascent Reader 
(Thermolabsystems OY, Helsinki, Finland) equipped with a 390/460 filter set, 
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and thrombin generation curves were calculated with the Thrombinoscope 
software (Thrombinoscope BV).   
 
Unless stated otherwise, thrombin generation was determined under several 
experimental conditions (final plasma concentrations): 0.5, 1, 2, or 5 pM TF and 
4 μM phospholipids. The TF triggers and phospholipids were obtained from 
Thrombinoscope BV.  Three parameters were derived from the thrombin gen-
eration curves: lag time, peak height and endogenous thrombin potential (ETP, 
area under the curve).  
 
FXIIa- C1-esterase inhibitor complex measurement 
 
Complexes of FXIIa and FXIa with their natural inhibitor C1 esterase inhibitor, 
respectively, were measured with enzyme-linked immunosorbent assays (ELI-
SAs), using monoclonal antibodies (mAb) and as described previously [15]. In 
brief, mAb F3 was used to recognize FXII, mAb XI-5 to FXI, and mAb KOK 12 
specific for complexed C1 esterase inhibitor. Appropriate secondary antibodies 
were biotinylated using EZLink N-hydroxysuccinimide ester-biotin according to 
instructions from the manufacturer (Pierce, Rockford, IL, USA). Absorbance was 
read at 450 nm on an EL 808 Ultra microplate reader (Bio-tek Instruments Inc., 
Winooski, VT, USA). Results were expressed as a percentage of activated nor-
mal pooled plasma. Normal pooled EDTA plasma was maximally activated at 37 
°C by incubation with an equal volume of 0.2 mg/ml dextran sulfate (Mr 500 
000; Sigma Chemical Co., St Louis, MO, USA) to obtain reference curves for the 
FXIIa:C1 esterase inhibitor ELISA, whereas kaolin (final concentration 5 
mg/ml)-activated EDTA plasma was used for the FXIa:C1 esterase inhibitor 
ELISA. Activation was stopped by adding three volumes of phosphate-buffered 
saline (PBS) containing 0.1 mg/ml soybean trypsin inhibitor (Sigma Chemical 
Co.) and 0.05% (w/v) polybrene (Sigma Chemical Co.). Kaolin was removed by 
centrifuging the reaction mixture for 5 min at 13,000 x g. No signal was de-
tected in ELISAs performed on activated FXII- or FXI-deficient plasmas.  
 
Statistical analysis 
 
The data obtained for the thrombin generation experiments are expressed as 
median with inter quartile range (IQR). Differences in thrombin generation pa-
rameters between the groups treated with or without CTI were calculated with 
a non-parametric paired test (Wilcoxon signed rank test). A two-tailed proba-
bility value (p) of p< 0.05 was considered statistically significant. Statistical 
analysis was performed using the Graph Pad Prism 5 software (GraphPad Soft-
ware, La Jolla, CA, USA). 
Results 
Effects of blood collection method  
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Inter-laboratory variations in thrombin generation measurements can be the 
result of differences in equipment (including filter settings and temperature), 
reagent batches, as well as pre-analytical variables such as the method used for 
venous blood drawing. Using two different needle systems venous blood was 
simultaneously obtained from four healthy volunteers. Thrombin generation 
triggered with 5 pM TF in the prepared PPP was not different between the two 
collection methods. For the needle system (21-gauge needle) a median ETP of 
1,171 nM.min (IQR: 1,158-1,321) was observed whereas for the Winged Infu-
sion Set the ETP was 1,219 nM.min (IQR: 1,179-1,352), differences not signifi-
cant. Also, the peak height and lag time did not differ between the two systems 
(data not shown). For the 1 pM TF trigger, however, both the ETP and peak 
height were significantly increased for plasmas obtained with the Winged Infu-
sion Set compared to the needle system (Figure 1). On average, the ETP in-
creased by almost 15% or 151 nM.min whereas the peak height gained up to 
24% more thrombin (38 nM) by using a low TF trigger in the thrombin genera-
tion assay.  
The differences between the two blood drawing systems are most likely due to 
enhanced contact activation induced by the 30 cm long tubing in the Winged 
Infusion Set. In order to find out whether CTI selectively inhibits FXIIa and no 
other enzymes of the coagulation cascade, 0, 25 or 50 µg/ml CTI was added to 
normal pool plasma and FXII-deficient plasmas. Subsequently, thrombin gener-
ation was triggered with 1 or 5 pM TF. No differences in thrombin generation 
curves were observed for both triggers in the absence or presence of 25 or 50 
µg/mL CTI, suggesting selectivity of CTI for FXIIa. Since no differences were 
observed between 25 or 50 µg/ml CTI a “safe” concentration of 40 µg/mL CTI 
(which is two times the concentration previous used [10, 12-13]) was chosen 
for all further experiments.  
 
Figure 1: Effect of blood collection method on thrombin generation. Venous blood was col-
lected with a 21-gauge needle (Needle) or with a Winged Infusion Set equipped with a 30 cm long 
tubing (Butterfly). Thrombin generation was analysed using 1 pM TF as trigger. A) Lag time in min; 
B) ETP in nM.min thrombin; C) Peak height in nM thrombin. * Denotes p < 0.05. 
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Activation of FXII during blood collection 
 
To demonstrate activation of FXIIa during collection of blood the contact activa-
tion complexes FXIIa-C1 esterase inhibitor and FXIa-C1 esterase inhibitor were 
analyzed in plasmas obtained from blood collected in 3.2% (w/v) citrate blood 
collection tubes with and without 40 µg/ml CTI. Plasma collected without CTI 
from twelve healthy volunteers contained 0.16% (IQR 0.14-0.16) FXIIa-C1 este-
rase inhibitor complexes and this level was comparable to the concentrations in 
plasmas collected in the presence of CTI (0.16% IQR: 0.14-0.18). FXIa-C1 este-
rase inhibitor complexes, however, were decreased in plasmas containing CTI 
(0.17% IRQ: 0.14-0.29 vs. 0.27% IRQ: 0.22-0.33, p=0.01, Figure 2). 
 
To show that the presence of CTI in a venous blood collection tube effectively 
inhibits FXIIa, kaolin (1 mg/ml) was added to the tubes in order to activate FXII 
and thrombin generation was recorded subsequently. Kaolin was found to be a 
strong initiator of thrombin generation since the lag times shifted from 10.3 
min (IQR 8.1-12.2) towards 2.6 min (IQR 2.4-2.9, p<0.01). The ETP and peak 
height increased as well upon addition of kaolin to venous blood collection 
tubes. The ETP increased by almost 16% from 1,386 nM.min (IQR 1,109-1,448) 
to 1,603 nM.min (IQR 1,386-1,764) upon kaolin addition. The effect was even 
stronger for the peak height with an increase of 40% from 297 nM (IQR 226-
354) to 415 nM (IQR 403-442). Combined addition of kaolin and CTI to the 
blood collection tubes reduced thrombin generation to a level observed for ci-
trated plasma alone. The lag time prolonged to 8.3 min (8.0-13.6) and both ETP 
and peak height reduced to 1,490 nM.min (IQR 1,129-1,590, p<0.01 compared 
to kaolin) and 326 nM (IQR 209-365, p<0.01 compared to kaolin), respectively. 
 
Figure 2: Activation of FXII and FXI during blood drawing. FXIIa- and FXIa-C1 esterase inhibitor 
complexes were analysed in plasma prepared from blood collected without CTI (-CTI) or with 40 
μg/ml CTI present during drawing (+CTI). The FXIIa-C1 esterase inhibitor complexes are depicted 
in the left panel, whereas the FXIa-C1 esterase inhibitor complexes are shown in the right panel. 
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Effects of CTI addition to plasma on thrombin generation 
 
In order to demonstrate whether CTI addition to plasma influenced thrombin 
generation under conditions using the standard TF-triggers, CTI was added to 
plasmas from twelve healthy volunteers and thrombin generation was trig-
gered with 0.5, 1, 2, and 5 pM TF. For all TF triggers the measurement with CTI 
added to plasma was in accordance with the analysis without CTI added. To 
allow for intra-individual comparison of analyses without and with CTI, an ac-
ceptable within individual variability of 10% was arbitrarily chosen based on 
inter-assay and inter-individual variations published previously [11, 14]. Both 
the ETP and peak height from thrombin generation with CTI were within this 
10% range of the values obtained without CTI (Figure 3). Overall, ETP and peak 
height on average increased with increasing concentration TF trigger and were 
not different between analysis with or without CTI. ETP values in the absence of 
CTI were 1,126 nM.min (IQR 731-1,464), 1,281 nM.min (IQR 904-1,570), 1,369 
nM.min (IQR 1,015-1,663), and 1,602 nM.min (IQR 1,214-1,823) for 0.5, 1, 2, 
and 5 pM TF, respectively (Figure 3A). The corresponding ETP values obtained 
for analysis with CTI added to plasma were 1,132 nM.min (IQR 739-1,517), 
1,358 nM.min (IQR 971-1,646), 1,417 nM.min (IQR 1,093-1,688), and 1,585 
nM.min (IQR 1,200-1,821).  
 
Figure 3: Influence of CTI addition to plasma on thrombin generation triggered with 0.5, 1, 2, 
or 5 pM TF (from left to right) for 12 healthy individuals. Upper panel: ETP in nM.min thrombin, 
lower panel: Peak height in nM thrombin. ◊ Denotes thrombin generation analysis in the absence of 
CTI and ⊗ indicates measurement in the presence of 40 μg/ml CTI added to plasma. Error bars: 
individual range of 10%. 
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Peak height values obtained in analyses with and without the addition of CTI 
followed the same pattern as for ETP, with increasing maximum thrombin for-
mation with increasing TF concentrations and no differences between mea-
surements in the absence or presence of CTI (Figure 3B). 
 
Effects of CTI-addition to venous blood on thrombin generation 
 
Since the presence of CTI during blood collection could efficiently inhibit con-
tact activation, the influences of CTI addition to blood collection tubes was de-
termined through thrombin generation under conditions of the default TF trig-
gers. CTI (40 µg/ml) was added to 3.2% (w/v) citrate blood collection tubes 
and plasma was obtained from twelve healthy volunteers. Thrombin generation 
was triggered with 0.5, 1, 2, or 5 pM TF and compared between plasmas de-
rived from collection tubes with and without CTI (Figure 4).  
 
Figure 4: Influence of CTI addition to 3.2% (w/v) citrate blood collection tubes on thrombin 
generation triggered with 0.5, 1, 2, or 5 pM TF (from left to right) for 12 healthy individuals. 
Upper panel: ETP in nM.min thrombin, lower panel: Peak height in nM thrombin. ◊ Denotes throm-
bin generation analysis in the absence of CTI and ⊗ indicates measurement in the presence of 40 
μg/ml CTI added to 3.2%(w/v) citrate blood collection tubes. Error bars: individual range of 10%. 
 
 
 
For the higher TF concentrations thrombin generation was comparable be-
tween the two collection tubes. ETP values in the absence of CTI were 1,281 
nM.min (IQR 904-1,570), 1,369 nM.min (IQR 1,015-1,663), and 1,602 nM.min 
(IQR 1,214-1,823) for 1, 2, and 5 pM TF, respectively. Addition of CTI to blood 
collection tubes hardly altered these values: 1,259 nM.min (IQR 885-1,620), 
1,333 nM.min (IQR 1,036-1,693), and 1,662 nM.min (IQR 1,241-1,873) for 1, 2, 
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and 5 pM TF, respectively. For the 0.5 pM TF analysis, however, eight out of 
twelve analyses showed a lower ETP and peak height for thrombin generation 
in plasmas derived from collection tubes containing CTI (Figure 4A). On aver-
age the ETP at 0.5 pM TF reduced with 28% from 1,126 nM.min (IQR 731-
1,464) to 808 nM.min (IQR 367-1,414) upon addition of CTI to the collection 
tube. Whereas the peak height for the 1, 2, and 5 pM TF analyses followed the 
same pattern as the ETP, peak height measured at 0.5 pM TF trigger showed a 
reduction of 55% from 162 nM (IQR 85-253) to 74 nM (IQR: 29-182) when CTI 
was present during blood drawing (Figure 4B).  
Discussion  
In recent literature it has been argued that CTI can abrogate the influence of in 
vitro contact activation on thrombin generation [10, 12-13]. In this study the 
addition of CTI to a sample after plasma preparation had no influence on 
thrombin generation, whereas the presence of CTI during blood collection only 
altered thrombin generation triggered at TF concentrations below 1 pM.  
In the first part of this study the use of a Winged Infusion Set for blood collec-
tion resulted in markedly increased thrombin generation, most likely through 
contact activation since the presence of CTI in the blood collection tubes re-
duced the FXIa-C1 esterase inhibitor complexes. This was surprising because 
this needle system had been previously used assuming that it would provide a 
rather “atraumatic” sampling condition. Especially thrombin generation con-
ducted at 1 pM TF was altered when blood was collected using the Winged In-
fusion Set. Due to the presence of a 30 cm long tubing between the collecting 
and delivering needle activation of blood coagulation FXII is likely to occur. As 
reported previously, one of the potential problems with the thrombin genera-
tion test in routine clinical practice will be the interference of the contact sys-
tem [16]. Considering our data, the use of the standard needles used for va-
cuum blood collection is appears to be satisfactory.  
Addition of CTI to plasma has been shown to reduce or overcome the influence 
of contact activation on thrombin generation [10, 12-13]. Using 5 pM TF as trig-
ger, Luddington and Baglin observed an almost two-fold reduction in ETP upon 
addition of CTI to the blood collection tube [13]. This effect abolished at a TF 
concentration of 15 pM, suggesting a larger influence of contact activation at 
lower TF levels. Furthermore, Van Veen and colleagues observed an average 
reduction in ETP of 343 nM.min upon addition of CTI to plasma and using a TF 
trigger of 1 pM [12]. Even the use of a higher TF trigger (5 pM) did not com-
pletely attenuate the effects of contact activation on thrombin generation. And 
last, Dargaud and colleagues used the addition of CTI to plasma to reduce the 
inter laboratory variations in thrombin generation. In their study, addition of 
CTI to the collection tubes reduced the ETP on average with 178 nM.min at a 
1.5 pM TF trigger [10]. Again, the use of prefilled CTI/citrate tubes is feasible 
under research conditions, but major drawbacks exist for application in a hos-
pital laboratory. First of all, currently most hospitals use 3.2 or 3.8% (w/v) ci-
trate Vacutainer blood collection tubes for coagulation assays. Second, there is a 
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significant cost issue. Currently, CTI is sold for a list price of around €100 (app. 
$150 or £70) for 1 mg. Pre-filling 4.5 ml tubes to a final plasma concentration of 
40 µg/ml (used in this paper) will cost around €15 (app. $22 or £12) per tube. 
In conclusion, the use of pre-filled CTI blood collection tubes is not preferred 
given the major logistic and financial consequences.  
In contrast to the described inhibition of contact activation through addition of 
CTI and the beneficial effects on thrombin generation [10, 12-13], no influence 
on thrombin generation was observed when CTI was added to plasma. Using 
blood collection tubes pre-filled with CTI, however, thrombin generation trig-
gered with low TF (0.5 pM) was reduced, but this reduction was negligible or 
absent at higher TF concentrations. These data suggest that the extrinsic path-
way can overrule the contact activation pathway in thrombin generation when 
triggered with 1 pM TF or higher. The differences between our results and the 
data reported by Van Veen and Dargaud might stem from differences in the 
used plasma preparations and reagents used for thrombin generation. With 
regard to the used TF reagents a special note should be made. For all experi-
ments conducted within our laboratory the available CAT-reagents from 
Thrombinoscope (Maastricht, The Netherlands) were obtained and one batch of 
reagents was used to avoid differences between batches of reagents.  In the ab-
sence of an international TF standard, however, it is hard to claim that a given 
TF concentration is really the absolute concentration. Differences between la-
boratories might therefore stem from variations in both the TF sources and 
given concentrations. One striking difference between used protocols is the 
centrifugation method: in one paper plasma was obtained through double cen-
trifugation at 2000 x g for 10 minutes at room temperature (RT) [12] and in 
another by double centrifugation at 3000 x g for 15 minutes at RT [10]. Within 
our laboratory blood is first centrifuged at 2,000 x g for 15 minutes and the ob-
tained plasma is centrifuged a second time at 11,000 x g for 10 minutes (both at 
RT). The second step at a higher speed appears to be essential to remove re-
maining micro particles which possibly facilitate activation of FXII (Trappen-
burg, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands, personal 
communication). Secondly, the source of phospholipids and TF to trigger 
thrombin generation could be major determinants in variations in thrombin 
generation. We therefore agree with Van Veen and colleagues [12] and with 
Dargaud and colleagues [10] that there is a lack of standardization among dif-
ferent groups in studies on thrombin generation, which needs to be solved. 
Standardization without the introduction of pre-filled CTI blood collection tube 
is preferred since additional tubes will lead towards increasing costs and more 
complicated logistics in a clinical setting.  
Our study showed that there is no significant influence of contact activation on 
thrombin generation by means of the Calibrated Automated Thrombogram at a 
TF trigger of 1 pM or above. On the basis of these results and previous data 
[11], we propose that a standard thrombin generation protocol should include 
the following: 1: no addition of CTI during or after blood drawing, 2: venipunc-
ture through a 21-gauge needle and blood collection using 3.2%(w/v) citrate 
vacutainer (with the first 10 ml of venous blood discarded), 3: uniform plasma 
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preparation at high speed centrifugation, 4: uniform reagents, and 5: normali-
zation against an international reference plasma. 
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Abstract 
The platelet contribution to the thrombophilic state of patients with myelopro-
liferative neoplasms (MPNs), i.e. Essential Thrombocythemia (ET) and Polycy-
themia Vera (PV), remains uncertain. In this study we aimed to characterize the 
thrombin generation (TG) potential expressed by platelets from these subjects, 
compare it to normal platelets, and identify what factors might be responsible 
for platelet TG. In a group of 140 MPN patients (80 ET and 60 PV) and 72 
healthy subjects we measured the global procoagulant potential of platelet rich 
plasma (PRP) utilizing the TG assay by the calibrated automated thrombogram 
(CAT). To characterize the procoagulant contribution of platelets in PRP, the TG 
of both isolated platelets and platelet rich plasma was measured, and the plate-
let surface expression of TF was determined. Finally, the activation status of 
platelets was assessed by the levels of P-selectin expressed on platelet surface. 
MPN patients had significantly increased PRP and isolated platelet TG potential 
compared to controls. This was associated to the occurrence of platelet activa-
tion. Patients carriers of the JAK2V617F mutation showed the highest values of 
TG and platelet surface TF and P-selectin. Platelet TG potential was significantly 
lower in hydroxyurea (HU) compared to non-HU treated patients and was low-
est in HU-treated JAK2V617F carriers. In subjects not receiving HU, platelet TG 
significantly increased by JAK2V617F allele burden increment (p<0.05). This 
study demonstrates a platelet-dependent form of hypercoagulability in MPN 
patients, particularly in those carriers of the JAK2V617F mutation. The cytore-
ductive therapy with HU significantly affects this prothrombotic phenotype.  
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Introduction 
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are chronic mye-
loproliferative neoplasms (MPNs) characterised by increased production of 
mature functional blood cells (i.e. leukocytes, erythrocytes and platelets) and 
high incidence of thrombo-hemorrhagic complications [1]. Thrombosis is a ma-
jor cause of morbidity and mortality in these patients and occurs in arterial, 
venous and microcirculatory sites [2]. Advanced age, prior history of thrombo-
sis and vascular risk factors (smoking, hypercholesterolemia) contribute to the 
risk of thrombosis in these patients [3]. Recently, a high leukocyte count and 
the presence of the somatic V617F mutation of the Janus 2 tyrosine kinase 
(JAK2) gene have been associated with an increased thrombotic risk in both ET 
and PV patients [4-7].  
 
Platelets have been repeatedly involved in the pathogenesis of the hemostatic 
complications of these diseases. In the past, numerous platelet defects have 
been identified in ET and PV patients. The majority of these observations were 
related to a decreased functionality, and included abnormal platelet aggrega-
tion, reduced levels of membrane adhesion molecules (i.e. glycoproteins Ib, IIb-
IIIa, IV and VI), acquired storage pool disease, and defective platelet metabol-
ism (i.e. abnormal arachidonic acid metabolism) [8-10]. To the opposite, more 
recent studies have shown that platelets from these patients circulate in an ac-
tivated status, particularly in those carrying the JAK2V617F mutation [11-16], 
as assessed by the increased expression on their surface of P-selectin and tissue 
factor (TF). No information, however, are so far available on the procoagulant 
potential of platelets in these diseases. Platelets actively contribute to thrombin 
generation (TG) by supplying factors that support prothrombin activation (i.e. 
platelet factor V and phosphatidylserine), expressing TF, and providing a pro-
coagulant surface that strongly accelerates tenase and prothrombinase reac-
tions [17-18]. Therefore, in this study, we evaluated in a group of 140 MPN pa-
tients, the procoagulant phenotype of platelets, by measuring their TG potential 
by the Calibrated Automated Thrombogram (CAT) assay [19]. To characterize 
the procoagulant contribution of platelets in PRP, the TG of isolated platelets 
and platelet free plasma was also measured, in addition to the determination of 
platelet surface expression of TF. Finally, the activation status of platelets was 
assessed as the levels of P-selectin on platelets. The TG parameters of interest 
(i.e. lag time, peak height and slope) were evaluated in relation to platelet 
counts, platelet surface TF levels, JAK2V617F mutational status, and patients’ 
therapy. 
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Patients and Methods 
Patients 
 
The study subjects were recruited from the outpatient unit of the Hematology 
Department of Bergamo Hospital (Italy) in the period from January 2008 to 
January 2010. The study group consists of 140 consecutive patients, 80 patients 
with ET and 60 patients with PV diagnosed according to the WHO criteria [20]. 
Seventy two healthy subjects acted as the control group. Characteristics of the 
patients and healthy controls are summarized in Table I. The study was ap-
proved by the local Ethics Committee (Comitato di Bioetica, Ospedali Riuniti, 
Bergamo, Italy) and the procedures followed were in accordance with the Hel-
sinki Declaration of 1975 as revised in 2000. All blood samples were obtained 
with the subject informed consent. None of the patients were taking anticoagu-
lant drugs, oral contraceptives or hormone replacement therapy. None of the 
healthy controls were taking any anti-platelet or anti-inflammatory drugs in the 
last 10 days prior blood drawing and none of them had history of thrombosis or 
other diseases with high risk for thrombosis. In addition none of the female 
controls were taking oral contraceptives or hormone replacement therapy. 
Among patients, 72/140 were receiving cytoreductive therapy with hydroxyu-
rea (HU), either alone (n=10) or in combination with aspirin (n=62), 51/140 
were on aspirin alone, and 17/140 were not receiving any cytoreductive or as-
pirin treatment.  
 
Routine haematological assays 
 
White blood cell differential count, hematocrit, hemoglobin, red blood cell and 
platelet counts were determined on a Sysmex-XE 2100 hematology analyzer 
(Sysmex, Kobe, Japan). 
  
Collection of blood samples  
 
Blood samples from all patients (n=140) and controls (n=72) were drawn early 
in the morning before any therapy or food intake. After discarding the first 3ml, 
the blood was collected into sterile siliconized tubes containing K3-
ethylenediamine tetraacetic acid (K3-EDTA) for molecular biology studies or 
trisodium citrate (0,129 M, 1:9 vol:vol) for coagulation and cytofluorimetric 
studies.  
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Table I. Study Subject Characteristics. Data are reported as number or mean (range);  
* p<0.05 versus controls; ** p<0.01 versus controls. 
 
 
Platelet rich plasma, platelet free plasma and washed platelets prepara-
tion 
 
To fully characterize platelet TG, we utilized three different sample prepara-
tions, i.e.: 1) platelet rich plasma (PRP), as an overall platelet and plasma con-
taining sample; 2)  platelet free plasma (PFP); and 3) isolated washed platelets.  
1) Within 30 minutes from the blood draw, PRP was isolated by centrifu-
gation of whole blood for 10 min at 280xg at room temperature (RT). 
To obtain platelet poor plasma (PPP), the rest of the blood sample was 
centrifuged at 3,500xg for 20 min. PPP was utilised to dilute PRP in or-
der to obtain 150,000 platelets/µl.  
2) PFP was isolated by double centrifugation of citrated whole blood at 
3,000xg for 15 minutes at RT, aliquoted, snap-frozen in dry ice and 
stored at -80 ºC until testing.  
3) Platelets were further isolated from PRP of a subgroup of 48 subjects 
(17 ET, 13 PV subjects and 18 controls), according to a published me-
thod [21]. Briefly, PRP was diluted in 1:2 ratio with Krebs Ringer buffer 
(4mM KCl, 107mM NaCl, 20mM NaHCO3, 2mM Na2SO4, pH 5). After cen-
trifugation at 1,000xg for 10 min at RT, the platelet pellet was resus-
pended in Krebs Ringer buffer supplemented with glucose (0.9 g/L, pH 
6) and centrifuged a second time (1,000xg, 10min, RT). This washing 
procedure was repeated twice, and finally the platelets were resus-
pended at concentration of 150,000 platelets/µl in phosphate buffered 
saline (PBS; 154mM NaCl, 1.4 mM phosphate, pH 7.4), snap frozen in 
CONTROLS ET PV
Number 72 80 60
Males/Females 37/35 25/55 32/28
Age (years) 52 (26 – 75) 55 (23 – 80) 60 (20 – 82)
Platelets (109/L) 243 (144 – 398) 595** (208 – 1451) 477** (93 – 1278)
Leukocytes (109/L) 6.7 (3.8 – 9.2) 7.4* (3.6 – 14.4) 9.2** (3.1 – 39.9)
Hematocrit (%) 42.5 (35.2 – 45) 41 (35 – 48.9) 45** (37.8 – 50)
History of thrombosis (%)
arterial (%)
venous (%)
/
/
/
15 (19)
13 (87)
2 (13)
12 (20)
9 (75)
3 (25)
Microcirculatory symptoms (%) / 22 (28) 20 (33)
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dry ice, and stored at -80ºC until assays. The isolation procedure did 
not activate platelets as demonstrated by the same levels of P-selectin 
on platelet surface before and after isolation. On the test day, platelets 
were thawed in a warm bath at 37 ºC and lysed by 3 cycles of freezing 
at -80ºC and thawing at 37°C.  
 
CAT assay 
 
Measurement of TG of PRP and PFP samples and in platelet lysates was per-
formed using the CAT assay. For each experiment, 2 sets of readings in a 96 well 
micro-plate were used, one from a TG well and another from a thrombin cali-
brator (TC) well. The TG of PRP was measured in presence and in absence of 
exogenous TF. Briefly, 20 µl of 1pM TF or 20 µl of Hepes buffer were added into 
TG wells and 20 µl of calibrator with activity of 600 nM alpha2M-thrombin 
complex were added to TC well. Eighty µl of PRP were added to both wells (TG 
and TC well). To measure TG of PFP, 20 µl of 1pM TF and 4µM phospholipids 
were added in TG well and 20 µl of calibrator into TC well, followed by 80 µl of 
subject PFP in both wells. To measure TG induced by isolated platelet lysates, 
20 µl of platelet lysates were added in the TG well and 20 µl of calibrator into 
TC well. Eighty µl of normal pooled plasma (NPP) were added to both wells (TG 
and TC well).  
 
After 10 min prewarming at 37ºC inside the fluorimeter (Fluoroscan Ascent, 
Thermo Labsystems, Helsinki, Finland), the reaction was started with 20µl of a 
fluorogenic substrate (Z-Gly-Gly-Arg-AMC; Bachem, Bubendorf, Switzer-
land)/CaCl2 mixture. The TG curves were calculated using Thrombinoscope 
software (Thrombinoscope, Maastricht, The Netherlands) by comparing the 
signals from the TG and the TC well. TG curves were described in terms of lag 
time (time when minimum thrombin is formed), peak height (maximum con-
centration of TG), and slope (speed of TG) calculated using the formula: Slope = 
peak height / (time to peak – lag time).  
 
Cytofluorimetric analysis of surface platelet TF and P-selectin  
 
Flowcytometric analysis was used to characterize platelet surface antigens. Ci-
trated whole blood samples were diluted 1:20 with PBS and incubated for 20 
min at RT in the dark with the following FITC conjugated monoclonal antibo-
dies: isotype control IgG1 (Beckton Dickinson, San Jose, USA), anti-CD41 (AbD 
Serotec, Oxford, UK), anti-TF (American Diagnostica, Stamford, USA) and anti-P-
selectin (anti-CD62P, Bio Legend, San Diego, USA) as previously described [14]. 
After incubation, the samples were analysed using the FACS Calibur cytofluori-
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meter (Becton Dickinson, Mountain View, CA, USA). Using the forward and side 
scatter properties, the platelets were identified in a region that was 100% posi-
tive for CD41 expression (Figure 1). From each sample 5,000 events were col-
lected and the analysis was done using the Cell Quest software (Becton Dickin-
son). Results are expressed as percentage of positive cells or as mean fluores-
cence intensity (MFI). 
 
Figure 1. Flow cytometric analysis of platelets. A representative set of scattergrams from a flow-
cytometric analysis of platelets in a whole blood sample from a control subject. Panel A shows how 
the forward and side scatter was used to define the platelet gate. Panel B shows the events of plate-
lets marked by the isotype control IgG1. Panel C shows platelets positive for the anti CD-41 anti-
body. 
 
 
 
 
JAK2V617F mutation analysis 
 
The allele-specific polymerase chain reaction (PCR) was performed as pre-
viously described [14]. To analyse the burden of the mutant allele, PCR prod-
ucts were digested with the restriction enzyme-based assay as described by 
Marchetti et al. [22].  
A.
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Statistical analysis 
 
Student’s t-test or the nonparametric Mann-Whitney-Wilcoxon test were em-
ployed to compare the differences between groups, according to the distribu-
tion of the test variable. Differences were considered significant at a p-value < 
0.05. Correlation and linear regression analysis was performed using the SPSS 
15 statistical package (SPSS, Chicago, IL). Regression coefficients are expressed 
as B, which represents the absolute change of the dependent variable when the 
independent variable increases by 1 unit. 
Results 
Study population characteristics 
 
A total of 140 consecutive patients, 80 diagnosed with ET and 60 with PV, en-
tered the study. For comparison 72 healthy control subjects were enrolled. The 
subject characteristics are presented in Table I. The number of males and fe-
males were similar among PV and control subjects, whereas among ET patients 
two-thirds were females. Both ET and PV group had significantly higher plate-
let, leukocyte and neutrophil mean values compared to the control group. PV 
group also had significantly higher hematocrit mean value compared to the 
control group. JAK2V617F mutation was present in 46 ET patients (58%; all < 
50% allele burden) and 55 PV patients (92%; 45 with <50% and 10 with >50% 
allele burden). The carriers of the JAK2V617F mutation had significantly higher 
leukocyte, neutrophil and hematocrit values compared to wild type patients 
(p<0.01) (data not shown). Three PV patients, wild type for JAK2V617F, were 
carriers of exon-12 JAK2 mutation. 
At the time of enrolment, 46% of ET and 58% of PV patients were on cytoreduc-
tive treatment with HU. Twenty seven patients (15 ET and 12 PV) had a posi-
tive history for at least one major thrombotic event (i.e. acute myocardial in-
farction, ictus/transient ischemic attack, venous thromboembolism); 22 ET pa-
tients (28%) and 20 PV patients (33%) experienced microcirculatory symp-
toms (i.e. headache, paraesthesia, erythromelalgia). 
 
Thrombin Generation of PRP  
 
Figure 2 shows representative TG curves of PRP from ET and PV patients and 
healthy controls, triggered in the presence (left panel) and absence (right pan-
el) of exogenous 1pM TF. For all study subjects, the quantity of thrombin gener-
ated by PRP in the absence of exogenous TF was lower compared to that trig-
gered by the addition of 1 pM TF. However, in both experimental conditions, 
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the TG peak and slope were significantly increased (p<0.001) in ET and PV pa-
tients compared to controls. The TG peak showed low intra-individual coeffi-
cient of variation (CV) when repeatedelly measured from 5 controls (5.78%), 5 
ET (6.75%) and 5 PV (4.02%) patients in a period of one month.  
 
Figure 2. Representative curves of TG from ET and PV patients. PRP from ETand PV patients 
generated significantly higher maximum TG concentration compared to control subjects in both 
conditions, with and without exogenous 1 pM TF. TG in the absence of exogenous 1 pM TF was 
significantly lower compared to TG induced by 1 pM TF. 
 
 
 
As shown in Table II, PRP from ET and PV patients receiving HU at the time of 
the study, generated both in the presence and in the absence of exogenous TF 
less thrombin compared to non-HU treated patients and particularly in those 
carriers of the JAK2V617F mutation. In addition, TG triggered by exogenous TF 
in PRP from ET patients on ASA showed lower peak (155±33 nM) and slope 
(29±12 nM/min) compared to ET patients not taking any treatment (peak: 
167±57nM; slope: 37±27nM/min), without reaching a statistical significance. 
Similar results were observed in the absence of exogenous TF (data not shown). 
To evaluate the contribution of JAK2V617F mutation in determining the TG 
potential of PRP, the group of patients not on HU therapy at the time of the 
study were analysed according to JAK2V617F allele burden. These patients, all 
heterozygous for the mutation, were divided in 3 groups: i.e. negative (0%), < 
25% and 25-50% mutated alleles. The results (Figure 3) showed an increase in 
the TG peak that parallels the increase in the JAK2V617F allele burden. Fur-
thermore, in non-HU treated ET subjects, we observed significantly higher TG 
in JAK2V617F mutation carriers (peak=170±25nM) compared to JAK2 wild 
type (peak=145±34, p<0.05). This association was not observed in HU-treated 
patients.   
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Table II. TG parameters in PRP from MPN patients according to HU Therapy and JAK2V617F 
mutational status. Data are reported as mean±SEM; * P < 0.05 versus non-HU; ** P < 0.01 versus 
non-HU JAK2V617F. Three patients carriers for JAK2 exon 12 mutation are not included in the 
analysis. 
 
 
Figure 3. In non-HU-treated patients, JAK2V617F allele burden influence the TG potential of PRP. 
TG expressed as peak height (nM thrombin) significantly increased in parallel to JAK2V617F allele 
burden increment. Patients with allele burden <25% had significantly (P < 0.01) higher peak com-
pared to control subjects. Patients with 25–50% allele burden had the highest TG peak, significantly 
different (P < 0.001) from both control subjects and MPN patients wild type for JAK2 mutation. All 
patients with >50% allele burden were treated with HU.   
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n= Peak Slope Peak Slope
non-HU 65 164±5 34.4±2 149±6 41.6±3
JAK2 wt 21 156±9 32±4 139±11 38.4±6
JAK2V617F 44 171±6 36.6±3 157±7 44.4±4
HU 72 148±5* 28.4±2* 130±5* 32.4±2*
JAK2 wt 15 155±8 27.5±2 131±8 31.3±3
JAK2V617F 57 147±6** 28.7±2** 129±6* 32.7±3**
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Thrombin Generation of PFP 
 
To assess whether the increased TG produced by PRP from ET and PV patients 
was due to the plasma component of the PRP, we measured the TG in PFP of the 
same subjects. The results showed no significant differences in the different TG 
parameters between ET and PV patients and healthy controls (data not shown). 
No statistically significant differences were found when data were analyzed 
according to the JAK2V617F mutational status and HU therapy.  
 
The intra-assay CV of thrombin generation triggered with 1pM TF was 2.1% 
measuring the TG in triplicate of 5 control subjects. The inter-assay CV was 3% 
estimated by measuring the same PFP triggered by 1pM TF of 5 control subjects 
in consecutive 5 days.  
 
Thrombin Generation of isolated platelet lysates 
 
To further characterize the platelet-bound procoagulant activity, in a subgroup 
of 48 subjects (17 ET, 13 PV patients and 18 controls), platelets were further 
isolated from PRP and tested for the capacity to induce TG in NPP (Figure 4). 
The lag-time of TG was not different between patients (ET: 6.5±0.4; PV: 6.0±0.4 
min) and controls (6.1±0.6 min). The peak height (328±3.8 nM) and the slope 
(156±3.1 nM/min) were significantly increased (p<0.05) in platelets from ET 
patients compared to platelets from controls (Peak: 307±6.3 nM; Slope: 
142±5.5 nM/min). Similarly, platelets from PV patients presented with a higher, 
although not significant, peak height (320±7.3 nM) and slope (153±5.6 
nM/min) compared to controls. These differences became statistically signifi-
cant in the analysis of data from non-HU-treated PV patients, who had signifi-
cantly (p<0.05) higher TG peak (336±23nM) and slope (165±11nM/min) com-
pared to both HU-treated patients (peak: 306±21 nM; slope: 143±20 nM/min) 
and controls.  
 
While, no significant differences were observed between patients with and 
without a previous history of thrombosis, an increased TG potential was ex-
pressed by platelets isolated from MPN patients experiencing symptoms of im-
paired microcirculation (peak: 335±6 nM; slope: 166±3.6 nM/min) compared 
to asymptomatic patients (peak: 317±6.1 nM, p=0.07; slope: 150±5 nM/min, 
p=0.03).  
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Figure 4. TG triggered by platelet lysates in patients and controls. Platelets from ET and PV 
patients induce more TG in normal pooled plasma compared to healthy controls (CTR). Data are 
mean ± SEM. * 5 P < 0.05 vs. CTR. 
 
 
 
Platelet surface TF and P-selectin 
 
An analysis of cell membrane antigens was conducted for indentifying and 
quantifying procoagulant (TF) and activation/adhesive (P-selectin) molecules 
expressed on platelet surface (Figure 5). The % of platelets positive for TF was 
significantly (p<0.05) higher in ET (37±2.3 %) and PV (44±3 %) patients com-
pared to controls (28±2.5 %) (Figure 5, panel A). MPN patients carriers of the 
JAK2V617F mutation presented with higher % of TF-positive platelets (43±2.3 
%) compared to control subjects (p=0.001) (Figure 5, panel B).  
 
Regarding P-selectin (Figure 5, panel C), significantly increased % of platelets 
expressing this activation marker was found (p<0.05) in both ET (3.2±0.4 %) 
and PV (3.9±0.5 %) patients compared to controls (2.2±0.2 %). MPN patients 
carriers of the JAK2V617F mutation presented with higher % of P-selectin posi-
tive platelets (4.0±0.4 %) compared to controls (p=0.001) (Figure 5, panel D). 
The multivariate analysis adjusted for age and sex showed that increased plate-
let surface TF significantly determines shorter lag-time of the TG induced by 
platelets isolated from JAK2V617F positive patients (B=-0.74, p<0.05). No in-
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fluences of HU therapy and microcirculatory symptoms were observed on the 
% of platelets positive for TF and P-selectin. 
 
Figure 5. Baseline levels of TF and P-selectin on platelet surface. Platelet surface TF (Panel A) 
and P-selectin (CD62P, Panel C) levels are plotted according to the disease type (i.e., ET or PV) and 
to JAK2V617F allele burden (Panels B and D). Data are expressed as % of positive cells and bars 
represent mean ± SEM. CTR 5 controls; * P < 0.05 versus controls. 
 
 
Discussion 
The present study investigated for the first time the TG potential of PRP by the 
CAT assay in a group of 140 MPN patients (80 ET and 60 PV). The findings of 
our study showed an increased TG potential (i.e. higher TG peak height and 
slope) of fresh PRP and of isolated platelets from ET and PV patients compared 
to healthy control subjects. Differently, no statistically significant differences 
were observed in the TG potential of PFP from the same patients compared to 
controls, as previously observed [22]. These findings suggest that a platelet-
dependent form of hypercoagulability exists in this group of MPN patients and 
can be revealed by the TG assay when performed in PRP. A similar observation 
was reported in a study involving young stroke patients, where an increased TG 
was observed when the CAT assay was performed in PRP but not in PFP [23]. 
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The TG expressed by PRP samples has been useful to assess the procoagulant 
role of platelets in different clinical conditions, including liver cirrhosis, von 
Willebrand disease and congenital factor V deficiency [24-26]. The abnormal 
TG parameters have been associated in several different conditions to an im-
paired hemostasis, specifically low TG peak with an increased bleeding tenden-
cy in patients with von Willebrand disease and high ETP with an increased 
thrombotic tendency in stroke patients [23, 25]. 
 
Platelets contribute to TG by providing not only phospholipids but also TF. The 
results of the cytofluorimetric analysis of platelet surface TF showed, in agree-
ment with previous studies from our [14] and other groups [27], significantly 
increased % of platelet positive for TF in both ET and PV patients compared to 
controls. The highest values were observed in platelets from JAK2V617F muta-
tion carriers, which were also characterized by higher TG potential and higher 
platelet activation status (i.e. increased platelet P-selectin). Interestingly, in this 
subgroup of patients, platelet TF expression significantly determined shorter 
TG lag-time, thus showing an inverse correlation between platelet-associated 
TF and TG lag-time. This correlation is in line with a recent in vitro study by 
Ollivier et al. showing that endogenous TF influenced negatively TG lag-time 
[28].   
 
At the time of the study, about 51% of the patients were treated with HU on the 
basis of their clinical risk assessment [29]. Clinical studies supported the hypo-
thesis that cytoreductive therapy with HU exerts a protective effect against 
thrombosis by reducing the circulating number of blood cells, including both 
platelets and leukocytes, and by reducing JAK2V617F allele burden [30-32]. 
Therefore, in order to evaluate a possible influence of HU on the TG potential of 
platelets data were analyzed according to patients’ therapy. The results of this 
analysis showed a positive impact of HU therapy on the TG parameters. Particu-
larly, we found that the mean values of TG peak and slope of PRP from HU-
treated patients were significantly reduced compared to non-HU treated pa-
tients. Similar differences were obtained by measuring the TG potential of iso-
lated platelet, while no significant influence of HU therapy was found in TG po-
tential of PFP. As in the TG assay the number of platelets in PRP and lysates was 
adjusted to the same fixed concentration for each study subjects, our results 
suggest that HU may affect not only platelet count, but also some haemostatic 
properties of platelets. Recently, a study performed in a small group of MPN 
patients (6 ET and 6 PV patients) showed significantly lower TF expression on 
neutrophils and less circulating platelet-neutrophil aggregates in the subgroup 
of patients treated with HU compared to non-HU treated subjects [33]. In addi-
tion, in the same study, the in vitro treatment of neutrophils with HU prevented 
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both P-selectin-induced TF expression and mixed cell aggregate formation, sug-
gesting an antithrombotic activity of HU not related to its capacity to merely 
reduce the cell count. Furthermore, our recent study showed an increased le-
vels of nitric oxide (NO) production in HU treated compared to non-HU treated 
MPN patients [34]. NO is a potent inhibitor of the platelet activation and 
represents an important antithrombotic mechanism [35]. 
 
We could not show that HU treatment reduced TF expression on platelet sur-
face and studies are needed to investigate the effect of HU on some other plate-
let prothrombotic characteristics.  
 
It has been observed that JAK2V617F mutation is associated with an increased 
thrombotic risk in both ET and PV patients [36-38]. Additionally, the presence 
of the mutation is associated with higher hemoglobin level, higher leukocyte 
count, lower platelet count and recurrent thrombosis versus patients with wild 
type JAK2 [39-40]. The analysis based on the JAK2V617F mutational status 
showed two interesting findings. First, in patients HU naive, the increase in TG 
of PRP is associated to the increase in JAK2V617F allele burden, thus demon-
strating a direct association between JAK2V617F allele burden and increased 
platelet-associated TG potential. Second, in JAK2V617F positive patients, sub-
jects on HU showed the lowest TG potential. This suggests a more beneficial 
antithrombotic effect of the drug in this type of patients.  
Microvascular circulation disturbances including erythromelalgia, its microvas-
cular ischemic complications, and migraine-like atypical or typical transient 
ischemic cerebral, ocular, and coronary ischemic attacks are specific clinical 
manifestations of these diseases. It has been shown that the microvascular dis-
turbances are platelet-mediated processes in vivo which are relieved by treat-
ment with aspirin and by platelet reduction [41]. Interestingly, we found that 
TG induced by platelets isolated from patients experiencing microcirculatory 
symptoms was increased compared to patients without symptoms, despite be-
ing all treated with HU. Further studies are needed to explore the clinical relev-
ance of this finding.   
 
In conclusion, we have shown that platelets of patients with ET and PV have a 
higher prothrombotic potential as assessed by the increased TG produced in 
PRP or induced by isolated platelets. In addition, our data support the hypothe-
sis of an increased hypercoagulable state in subjects carriers of JAK2V617F mu-
tation, which in our study are characterized by the highest TG and TF values. A 
role of HU in modulating this phenotype is suggested. Prospective studies are 
needed to evaluate the contribution of platelet-triggered TG to the occurrence 
of thrombosis, and the preventive role of HU therapy, in ET and PV patients. 
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Abstract 
Immature platelets (IPF), which are hemostatically more active than mature 
platelets, have been found elevated in Essential Thrombocythemia (ET) and 
Polycythemia Vera (PV), two myeloproliferative neoplasms (MPN) characte-
rized by an increased risk of thrombosis. It is not known whether the IPF levels 
are influenced by pathogenetic factors including JAK2V617F mutational status, 
or by treatment regimen. To address this point, in 46 ET and 38 PV consecutive 
patients, we measured IPF and correlated the results to JAK2V617F mutation 
and myelosuppressive treatment with hydroxyurea (HU). This analysis pro-
vides two new elements regarding IPF and MPN. The first finding is that the 
JAK2V617F mutation is linked to the quantity of IPF in patients with MPN, 
which might contribute to the prothrombotic phenotype in these patients. The 
second finding is that IPF is susceptible to myelosuppressive treatment, which 
may additionally explain the favourable effect of HU therapy on MPN outcome 
as well as the associated thrombotic risk. 
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Introduction 
Circulating platelets are heterogeneous in size and structure. A small percen-
tage of circulating platelets (i.e. 2%) are the so-called reticulated or immature 
platelets (IPF), recently released from the bone marrow. In-vitro studies show 
that newly formed murine platelets have increased hemostatic activity com-
pared to mature platelets, as demonstrated by the increased response to 
thrombin and higher expression of surface P-selectin.[1]  
 
Elevated numbers of IPF population have been described in two myeloprolifer-
ative neoplasms (MPN) characterized by an increased thrombotic risk, i.e. Es-
sential Thrombocythemia (ET) and Polycythemia Vera (PV), as well as in other 
thrombotic disorders.[2-4] It is not known whether this increase is influenced 
by pathogenetic factors including JAK2V617F mutational status, or by treat-
ment regimen in ET and PV patients. Therefore, in this study we enrolled ET 
and PV patients to characterize immature platelet parameters according to 
JAK2V617F mutation and treatment.  
 
Methods 
IPF were measured in whole blood by the fully automated hematology analyser 
XE-2100 (Sysmex Co., Kobe, Japan) and are described as total IPF count, % of 
IPF and H-IPF, the latter representing the percentage of platelets within the IPF 
area with a major amount of m-RNA and thus with the highest fluorescent in-
tensity.[5-6] The collection of venous blood samples and JAK2V617F mutation 
analysis were performed as previously described.[7] All statistical analyses 
were done with SPSS version 15 (SPSS, Chicago, IL). The results are presented 
as mean ± standard deviation. The intergroup data comparisons were per-
formed using the Student t-test or the nonparametric Mann-Whitney-Wilcoxon 
U test, according to the distribution of the test variables. All reported P values 
are two sided with a type I error rate of 5%. 
 
Results and Discussion 
This study was conducted in 42 healthy subjects and in a consecutive series of 
46 ET and 38 PV patients. Twenty three ET and 18 PV were receiving cytore-
ductive therapy with hydroxyurea (HU), 35 (16 ET and 19 PV) were on aspirin 
alone and 8 (7 ET and 1 PV) were not receiving any cytoreductive or aspirin 
treatment. Twenty three ET patients (50%) and 34 PV patients (89%) have the 
JAK2V617F mutation. The mutation in all ET patients was heterozygous, whe-
reas among PV patients, 27 were heterozygous and 7 were homozygous for the 
JAK2V617F mutation. Two PV patients, negative for JAK2V617F, were positive 
for the JAK2 exon12 mutation. 
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Both ET and PV patients had significantly higher platelet and IPF counts com-
pared to controls (p<0.01). In addition, PV patients had significantly (p<0.01) 
higher hematocrit, white blood cell count, % of IPF and H-IPF compared to both 
controls and ET patients. Compared to control subjects, JAK2V617F positive 
patients showed significantly (p<0.05) higher platelet (522±260 vs 238±58 
x109/L) and IPF count (15±14 vs 5.0±2.0 x109/L), % of IPF (2.8±1.6 vs 2.2±1%) 
and H-IPF (0.9±0.6 vs 0.6±0.3%), whereas JAK2V617F negative patients had 
significantly higher platelet (594±283 x109/L) and IPF counts (12±8 x109/L). 
Figure 1 shows the data after grouping the patients according to both 
JAK2V617F mutation and HU treatment. Non-HU JAK2V617F positive patients 
showed significantly (p<0.05) higher platelet count (Figure 1A), IPF count (Fig-
ure 1B), % of IPF (Figure 1C) and of H-IPF (Figure 1D) compared to control sub-
jects. In addition, non-HU JAK2V617F positive patients showed significantly 
higher IPF count also compared to non-HU JAK2V617F negative patients and 
HU treated JAK2V617F positive and negative patients (Figure 1B). Within non-
HU treated subjects, JAK2V617F positive patients showed a significantly higher 
% of H-IPF compared to JAK2V617F negative patients (Figure 1D). Finally, 
within patients negative for JAK2V617F mutation, no significant differences in 
IPF parameters were observed between HU and non-HU treated patients. Diffe-
rently, within patients positive for JAK2V617F mutation, HU treated patients 
showed significantly lower (p<0.05) IPF parameters compared to non-HU 
treated patients (IPF count: 8.7±4 vs 22±18 x109/L; IPF%: 2.4±1.0 vs 3.3±2.1).  
 
Multivariate regression analysis adjusted for age, sex, JAK2V617F mutational 
status and HU therapy confirmed that JAK2V617F mutation is significantly as-
sociated (p<0.01) with higher % of IPF (B=0.42) and H-IPF (B=0.38), and IPF 
count (B=0.7); while HU treatment is significantly associated (p<0.01) with 
lower % of IPF (B=-0.43) and H-IPF (B=-0.32), and IPF counts (B=-0.45).  
 
The standard flow cytometric measurement of IPF is considered imprecise, 
time consuming, expensive and most importantly no inter-laboratory consen-
sus of the normal range has been obtained as yet.[5, 8] Therefore, we have eva-
luated the percentage of IPF in controls and patients by the recently established 
fully automated and rapid Sysmex XE-2100 method. The new XE-2100 expands 
the quantitative analytic range to reticulocytes, immature granulocytes and to 
optical fluorescent platelet count. The reference range in our study for the % of 
IPF in healthy subjects using this method was 0.7-6% with a mean value of 
2.2%, which is in agreement with other studies.[5, 9] 
 
The measurement of IPF has been considered useful in assessing the treatment 
response and thrombotic risk in patients with thrombocytosis, both primary 
and secondary.[10] Increased IPF has also been associated with increased 
thrombotic risk, i.e. in acute coronary syndromes and in cardioembolic 
stroke.[4, 11] In addition, increased % of IPF and H-IPF has been associated 
with increased platelet aggregation in high risk patients with coronary artery 
disease.[6] Similarly, renal transplant recipients which are at increased risk for 
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cardiovascular mortality showed higher % of IPF and H-IPF associated with 
increased platelet aggregation.[12] Due to an increased platelet turnover, MPN 
patients have a higher percentage of IPF compared to healthy controls.[3] In 
our study we found that the absolute counts of IPF, were significantly (p<0.01) 
increased in both ET and PV patients compared to controls, while the % of both 
IPF and H-IPF were significantly increased in PV patients only. The analysis 
according to JAK2V617F mutational status and HU treatment showed that non-
HU treated MPN mutation positive patients had significantly higher % of IPF 
and H-IPF compared to control subjects. These findings suggest that 
JAK2V617F mutation might be an important factor related to the increased % 
of IPF and H-IPF in MPN patients. The adjusted multivariate analysis demon-
strating that JAK2V617F mutation is associated with increased IPF count, % of 
IPF and H-IPF confirmed our results. Interestingly, our study showed that with-
in patients positive for JAK2V617F mutation, HU-treated patients have signifi-
cantly lower IPF parameters compared to non-HU treated patients, which was 
not observed within JAK2V617F negative patients. This finding is in line with a 
recently published study showing in MPN subjects positive for JAK2V617F mu-
tation an increased chemosensitivity to HU.[13] 
 
Figure 1: IPF parameters according to JAK2V617F mutation and therapy. The data are re-
ported as mean±SD. CTR=Controls; HU=Hydroxyurea; JAK2+=JAK2V617F positive patients; JAK2-
=JAK2V617F negative patients.*p<0.05 vs CTR; § p<0.05 vs HU JAK2+; £ p<0.05 vs HU JAK2+, HU 
JAK2-; &p<0.05 vs non-HU JAK2-, HU JAK2-, HU JAK2+; **p<0.05 vs non-HU JAK2-. 
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In conclusion, this study provides two new elements regarding the association 
between IPF and MPN. The first finding is that the JAK2V617F mutation is 
linked to the quantity of IPF in patients with MPN, which might contribute to 
the prothrombotic phenotype in these patients. The second finding is that IPF is 
susceptible to HU treatment, which may additionally explain the favourable 
effect of this therapy on MPN as well as the associated thrombotic risk. New 
prospective studies are warranted to evaluate the usefulness of IPF as a cellular 
marker to predict thrombosis in MPN patients. 
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Summary  
Antiplatelet therapy with aspirin (ASA) is now a standard regimen for preven-
tion of thrombosis in myeloproliferative neoplasm (MPN) patients. In this study 
we performed the PFA-100 assay in whole blood and the thrombin generation 
(TG) assay in platelet rich plasma (PRP) in a group of 46 essential thrombocy-
themia (ET) and 38 polycythemia vera (PV) patients to evaluate the effect of 
ASA on platelet adhesive and procoagulant properties. PFA-100 collagen-
epinephrine closure time was significantly (p<0.01) prolonged in both ET and 
PV patients compared to healthy controls. However, the PFA-100 also showed 
flow obstruction in 20% of MPN patients after collagen-adenosine diphosphate 
and in 15% of patients after collagen-epinephrine trigger, the majority of them 
while on ASA. Higher platelet count and immature platelet fraction were asso-
ciated with shorter collagen-adenosine diphosphate closure time (R=-0.5, 
p<0.05 for both). The results from the TG assay showed significantly increased 
TG measured in PRP from both ET and PV patients compared to controls. ASA 
treated JAK2V617F positive patients had higher TG compared to ASA treated 
JAK2V617F negative patients. Within JAK2V617F positive patients, we found a 
significant association between platelet and/or immature platelet count and TG 
(R=0.3, p<0.05 for both). 
 
This study demonstrates that PFA-100 and TG assay are potentially relevant 
methods for monitoring ASA effectiveness in MPN patients. Elevated immature 
platelet parameters are suggested important factors influencing increased 
platelet adhesive and procoagulant properties. New prospective studies are 
warranted to evaluate the usefulness of PFA-100 and TG assay in identifying 
MPN patients at higher risk for thrombosis. 
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Introduction 
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are two myelo-
proliferative neoplasms (MPN) characterized by a hypercoagulable state and an 
increased rate of thrombotic complications that significantly impact patients’ 
prognosis and quality of life. The pathogenesis of thrombosis is multifactorial 
and includes abnormalities in both quantitative and qualitative characteristics 
of circulating blood cells, including platelets, red and white blood cells [1]. 
 
A broad number of studies have investigated the contribution of platelets in the 
onset of the thrombophilic state in these diseases, and it is now clear that the 
increased platelet count does not play a dominant role  in the risk of thrombosis 
[2]. Rather, platelet qualitative abnormalities have been implicated in the pa-
thogenesis of hypercoagulability in ET and PV patients. Our and other groups 
have observed that platelets circulate in an activated state (i.e. higher surface 
expression P-selectin and tissue factor, TF), and show an increased tendency to 
form microaggregates with leukocytes [3-4]. The JAK2V617F mutation has been 
particularly correlated with an activation of hemostasis, leukocytes and plate-
lets [4-6]. More recently, we also described in these patients a greater capacity 
of platelets to induce thrombin generation (TG), which was in part attributable 
to a higher platelet surface TF activity [7]. In contrast, a recent study evaluating 
TG capacity of polymorphonucler neutrophils did not show any difference be-
tween MPN patients and healthy controls [8].  
 
Antiplatelet therapy with low dose aspirin (ASA) has been associated with re-
duced risk for thrombosis in PV patients [9].Despite the lack of data from ran-
domized controlled clinical trials in ET patients, ASA use has been shown effec-
tive in alleviating vasomotor (microvascular) disturbances in these patients 
[10-11]. Furthermore, ASA therapy has been considered beneficial in prevent-
ing complications during pregnancy (i.e. fetal loss, intrauterine growth retarda-
tion, pre-eclampsia and arterial hypertension), particularly in patients positive 
for JAK2V617F mutation [12]. Therefore, ASA is now a standard treatment re-
gimen for prevention of thrombosis in both low and high risk for thrombosis ET 
and PV patients [13]. However, despite the standard low dose ASA use, some 
MPN patients continue to show abnormal platelet aggregation and persistent 
thromboxane biosynthesis [14-15]. Whereas no information is available for the 
percentage of MPN patients as ASA non responders, in patients with cardiovas-
cular diseases this phenomenon ranges from 1% to 45%.[16]  
 
The present study has been designed to characterize the effect of ASA on plate-
let adhesive and procoagulant function in ET and PV patients. Particularly, the 
PFA-100 was used to evaluate platelet adhesion capacity in response to platelet 
physiological agonists (i.e. collagen/adenosine diphosphate and colla-
gen/epinephrine), and the Calibrated Automated Thrombogram (CAT) assay 
was used to measure platelet thrombin generation (TG) potential. Furthermore, 
we have evaluated the potential use of PFA-100 and CAT assay in detecting ET 
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and PV non-responders on ASA. The results of our study were analysed accord-
ing to patients’ haematological characteristics, treatment regimen and 
JAK2V617F mutational status. 
 
Subjects and methods 
Subjects 
 
This study has been conducted in blood samples obtained from 41 healthy sub-
jects, 46 consecutive ET and 38 PV patients. The healthy subjects were hospital 
employees while the patients were recruited from Bergamo hospital between 
June 2008 and June 2009. The local Ethics committee (Comitato di Bioetica, 
Ospedali Riuniti, Bergamo, Italy) approved the study and all blood samples 
were obtained after informed consent. ET and PV patients were diagnosed ac-
cording to the WHO criteria [17] and the procedures followed were in accor-
dance with the Helsinki declaration of 1975 as revised in 2000. None of the pa-
tients were taking anticoagulant drugs, oral contraceptives or hormone re-
placement therapy. Among the patients, 41 (23 ET and 18 PV) were receiving 
cytoreductive therapy with hydroxyurea (HU), 35 (16 ET and 19 PV) were on 
ASA alone and 8 (7ET and 1PV) were not receiving any cytoreductive or ASA 
treatment. Twenty three ET patients (50%) and 34 PV patients (89%) carried 
the JAK2V617F mutation. All ET patients positive for JAK2V617F were hetero-
zygous, whereas among PV patients, 27 were heterozygous and 7 homozygous 
for the mutation. Two PV patients negative for JAK2V617F were positive for 
JAK2 exon12 mutation. None of the healthy controls were taking any anti-
platelet or anti-inflammatory drugs in the last 10 days prior to blood drawing.  
 
Collection of blood samples 
 
Blood samples were drawn early in the morning after applying a light tourni-
quet. After discarding the first 3ml, the blood was collected into sterile silico-
nized tubes containing K3-ethylenediamine tetraacetic acid (K3-EDTA) for mo-
lecular biology studies and blood cell count analysis or trisodium citrate 
(0.129M, 1:9 vol:vol) for coagulation studies. 
 
Platelet Rich Plasma (PRP) preparation 
 
Within 30 minutes from blood draw, platelet rich plasma (PRP) was separated 
by centrifugation of whole blood for 10 min at 280g at room temperature (RT). 
The rest of the blood sample was centrifuged at 3,500g for 20 min to obtain 
platelet poor plasma, which was utilized to dilute PRP to obtain a concentration 
of 150,000 platelets/µl.  
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Routine haematological assays 
 
Whole blood analysis of white blood cell differential count, hematocrit, platelet 
count, mean platelet volume and immature platelet parameters (IPF count, % of 
IPF and H-IPF) were determined by a Sysmex-XE 2100 haematology analyzer 
(Sysmex Co., Kobe, Japan).  
 
Platelet function analysis by PFA-100 
 
PFA-100 analysis was performed in whole blood as described previously 
[5].The result, expressed in seconds (sec.), is the closure time reflecting the 
platelet function in primary haemostasis after collagen and adenosine diphos-
phate (CADP) or collagen and epinephrine (CEPI) stimulation.  All measure-
ments were performed in duplicate. In case of a result > 300 sec., and/or flow 
obstruction (defined as sudden stoppage of blood flow during the test) addi-
tional two consecutive measurements have been performed from the same 
sample. When the status remained the same, the result of the sample has been 
recorded as 300 sec. and/or null result respectively.  
 
Thrombin generation assay 
 
TG was performed in PRP using the CAT assay. Briefly, 20 µl of 1pM TF were 
added into TG wells and  20 µl of calibrator (with activity of 600 nM alpha2M-
thrombin complex) into thrombin calibrator (TC) well. Eighty µl of PRP were 
added to both wells (TG and TC well). After 10 min prewarming at 37ºC inside 
the fluorimeter (Fluoroscan Ascent, Thermo Labsystems, Helsinki, Finland), the 
reaction was started by the addition of 20 µl of CaCl2/fluorogenic substrate (Z-
Gly-Gly-Arg-AMC; Bachem, Bubendorf, Switzerland) mixture. The TG curves 
were calculated using Thrombinoscope software (Thrombinoscope, Maastricht, 
The Netherlands) by comparing the signals from the TG well and the TC well. 
TG curves were described in terms of peak height, the maximum concentration 
of thrombin formed, expressed in nM thrombin. 
 
JAK2V617F mutation analysis 
 
The presence of the somatic V617F mutation of the Janus 2 tyrosine kinase 
(JAK2) gene was tested on DNA obtained from K3-EDTA anticoagulated blood 
samples using the Puregene DNA isolation kit (Gentra systems, Minneapolis 
MN, USA). Polymerase chain reaction was performed as described previously 
[5]. 
  
Statistical analysis 
 
All statistical analyses were done with SPSS version 15 (SPSS, Chicago, IL). Con-
tinuous variables are expressed as mean ± standard deviation (SD). All re-
ported P values are two sided with a type I error rate of 5%. The intergroup 
data comparisons were performed using the Student t-test or the nonparame-
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tric Mann-Whitney-Wilcoxon U test, according to the distribution of the test 
variables. Correlation and linear regression analysis was performed and the 
regression coefficient expressed as B represents the absolute change of the de-
pendent variable when the independent variable increases by 1 unit. 
Results 
Subjects’ hematological characteristics 
 
Baseline and hematological characteristics are described in Table 1. The mean 
platelet count in healthy subjects was 238 x 109/L, with range 144-398 x 109/L. 
Both ET and PV patients had significantly higher platelet and IPF count com-
pared to controls (p<0.01). In addition, PV patients had significantly (p<0.01) 
higher hematocrit, white blood cell, % of IPF and H-IPF compared to both con-
trols and ET patients. The analysis according to treatment showed no signifi-
cant differences for all hematological characteristics between ASA treated and 
non-treated patients (data not shown). Differently, patients on HU showed sig-
nificantly lower platelet (408±162 x109/L) and IPF count (9.2±4.4x109/L) 
compared to non treated patients (platelet:767±382; IPF count:21±11 x109/L ) 
and ASA treated patients (platelet:637±234; IPF count:18 ±17x109/L).  
 
Table 1. Study subjects characteristics. IPF= Immature Platelet Fraction; * p<0.05 and **p<0.01 
vs Controls; & p<0.01 vs ET. 
 
 
 
CONTROLS 
(41)
ET
(46)
PV 
(38)
Males/Females 21/20 15/31 17/21
Age (years) 55 (27 – 76) 54 (23-79) 60 (20 – 79)
Hematocrit (%) 41.7 (36 – 45) 41 (31 – 47.3) 45.6 (37.8 – 50)**,&
White Blood Cells (109/L) 6.3 (3.9-9.2) 6.9 (3.6 – 14.4) 10 (3.6 – 39.9)**,&
Platelets  (109/L) 238 (144-398) 574 (208 – 1413)** 495 (93-1278)**
Mean Platelet Volume (fL) 10.6 (8.3-12.4) 10.4 (8.5 – 12.5) 10.3 (8.8-11.3)
IPF (109/L) 5 (1.6-9.7) 12.1 (3.3 – 40.6)** 16.7 (3.3 -103)**
IPF (%) 2.2 (0.7-6) 2.2 (0.5 -6.5) 3.3 (1.4-11.2)**,&
H-IPF (%) 0.6 (0.1-2) 0.7 (0.2 – 2.3) 1.1 (0.4-4.2)**,&
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PFA-100 results  
 
The mean closure time in healthy controls was 95±19 sec with CEPI, and 73±10 
sec with CADP, and the two measurements were significantly and highly corre-
lated (R= 0.85, p<0.001). CEPI closure time was significantly (p<0.01) pro-
longed in both ET (149±105 sec) and PV (179±95 sec) subjects compared to 
healthy controls, while CADP closure times were not significantly different vs 
controls (ET: 63±34; PV: 66±38 sec).  No significant differences were observed 
in CEPI and CADP closure times between ET and PV patients.   
 
ET and PV patients on ASA (n=35) and on HU+ASA (n=33) had significantly 
(p<0.05) prolonged CEPI closure times compared to control subjects (Figure 
1A). Thirteen patients on ASA (37%) and 9 on HU+ASA (27%) showed a CEPI 
closure time >300 sec (Figure 1A). No significantly different CADP closure time 
was observed between different subgroups (Figure 1B). In addition, no influ-
ence of JAK2V617F mutational status was found in CEPI and CADP closure 
times (data not shown). 
 
Figure 1. CEPI and CADP closure time in MPN patients according to therapy. CTR=Control; NT= 
non treated; ASA= Aspirin; HU= Hydroxyurea; * p<0.01 vs CTR. 
 
 
 
Flow obstruction, which was not observed in control subjects, occurred in 
blood samples from 17 patients (9 ET and 8 PV) with CADP (20%) and from 13 
patients (9 ET and 4 PV) with CEPI (15%). The majority of patients were on 
ASA (CADP: 11; CEPI: 9 patients) or NT (CADP: 3; CEPI: 2 patients) while only 
few on HU+ASA (CADP: 2; CEPI: 1 patient) and HU (CADP:1; CEPI:1 patient). 
Seventeen patients experiencing flow obstruction with the CADP assay, had 
platelet count, IPF count, % of IPF and H-IPF significantly higher (p<0.05) com-
pared to the remaining patients (Table 2). Only platelet and IPF counts were 
significantly different between subjects with and without flow obstruction by 
the CEPI assay. These 2 groups of subjects had no significantly different hema-
tocrit and white blood cell values.  
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Table 2. PFA-100 analysis in MPN patients. 
 
 
 
The correlation analysis (Table 3) showed that higher total platelet and IPF 
counts, % of IPF and H-IPF are associated with shorter CADP, while higher total 
platelet and IPF counts are associated with shorter CEPI closure time only. 
 
Table 3. Correlation analysis in MPN patients. 
R=Pearson correlation coefficient; p significant <0.05. 
 
 
 
Thrombin Generation in PRP  
 
In agreement with our previous findings [7], the TG potential measured in PRP 
was significantly (p<0.01) higher in both ET and PV patients compared to 
healthy controls. The further analysis according to treatment showed that ET 
patients on ASA (149±35 nM thrombin) and HU (148 ±39 nM thrombin) had 
CADP (seconds) CEPI (seconds)
Flow obstruction Yes
(n=17)
No
(n=67)
p= Yes
(n=13)
No
(n=71)
p=
Hematocrit (%) 42.3 3.4 42.8 4.4 n.s. 42 3.8 42.8 4.3 n.s.
WBC (109/L) 10 3.6 7.9 4.9 n.s. 8.8 2.8 8.2 5 n.s.
Platelet (109/L) 847 342 459 174 0.000 879 302 470 199 0.000
IPF (109/L) 28.1 22 10.6 5.4 0.000 25.8 24 11.8 7.4 0.000
IPF (%) 3.8 2.8 2.4 1.1 0.003 3.1 3 2.6 1.4 n.s.
H-IPF (%) 1.3 1.1 0.8 0.4 0.005 1.06 1.1 0.8 0.5 n.s.
CADP
R (p)
CEPI
R (p)
Platelet (x109/L) -0.503 (0.000) -0.330 (0.002)
IPF (x109/L) -0.460 (0.000) -0.221 (0.043)
IPF (%) -0.263 (0.016) -0.030 (n.s.)
H-IPF (%) -0.232 (0.034) -0.022 (n.s.)
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lower TG compared to NT patients (177±61 nM thrombin) however without 
reaching a statistical significance (p=0.1). While no significant differences were 
observed for ET patients on ASA and HU, PV patients on HU (148±49 nM 
thrombin) showed significantly lower (p<0.05) TG compared to ASA treated 
patients (175±25 nM thrombin). Only one PV patient was untreated, therefore 
the comparison analysis to ASA and HU treated PV patients was not possible.  
 
The analysis based on JAK2V617F mutation showed that ASA treated 
JAK2V617F positive patients (174±26 nM thrombin) had higher TG compared 
to ASA treated JAK2V617F negative patients (151±37 nM thrombin, p=0.05). 
No significant differences were observed for TG between JAK2V617F positive 
(146±41 nM thrombin) and negative patients on HU (154±33 nM thrombin, 
p=0.59).  
 
In healthy and JAK2V617F negative subjects no significant correlations were 
found between TG and hematological parameters. Differently, in JAK2V617F 
positive patients, we found a significant association between platelet and/or 
IPF count and TG (R=0.3, p<0.05 for both).  
 
Correlation analysis: PFA-100 and CAT assay 
 
In ASA treated patients positive for JAK2V617F mutation we observed a signifi-
cant and negative correlation between CADP closure time and TG (R=-0.452, 
p=0.04). No significant correlations were observed in the other patient sub-
groups between the both assays. 
Discussion 
ASA use has been widely employed for prevention of thrombosis in MPN pa-
tients [13]. Large metaanalysis showed a significant benefit of ASA use in reduc-
tion of occlusive vascular events.[18-19]. However, recent observations have 
highlighted wide biological variability in the interindividual response to ASA’s 
antiplatelet effects. In 10-20% of patients recurrent vascular events occurred 
despite treatment with ASA, referred to as treatment failure [20]. Understand-
ing the mechanisms responsible for this phenomenon may be useful in improv-
ing management of patients whose biological response to ASA is impaired. The 
platelet adhesive function measured by PFA-100 has been extensively utilized 
in monitoring antiplatelet therapy, predominantly ASA but also clopidogrel and 
non steroidal antiinflamatory drugs that strongly influence closure time results. 
  
Our study showed that CEPI closure time is significantly influenced by ASA 
treatment in MPN patients. Further, we observed that MPN patients with short-
er CADP and CEPI closure times have significantly higher platelet and IPF count. 
In addition, the shorter CADP time was associated with higher % of IPF and H-
IPF. Therefore, the results of our study might suggest the importance of IPF as a 
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more reactive fraction of platelets to increased platelet adhesiveness, particu-
larly to collagen and ADP stimulus. 
 
While PFA-100 assay is primarily used as a screening tool for von Willebrand’s 
disease, recent research has been focused more on the potential for the PFA-
100 to identify patients at higher risk for thrombosis.[21] Indeed, shorter CEPI 
closure time as well as shorter CADP time has been linked to higher risk for 
thrombosis.[22] Primarily ASA nonresponders have been identified among old-
er patients, patients with acute vascular events and those with type 2 diabetes 
[20]. A shorter CADP closure time has been identified in patients with ST seg-
ment elevation myocardial infarction and was an independent predictor of a 
poor outcome [23]. In addition, shorter CEPI closure time found more frequent 
in patients with recent myocardial infarction, followed by patients with unsta-
ble angina and less frequent in patients with stable coronary artery disease, 
may reflect an ongoing thrombotic state and reduced responsiveness to ASA 
[24].  
 
PFA-100 has been shown to be a reliable and rapid method in measuring ASA 
antiplatelet effects in patients with a high platelet count, such as ET or reactive 
thrombocythosis patients when compared to optical aggregometry [25]. This 
assay might be potentially useful in MPN patients to evaluate both the respon-
siveness to ASA treatment by the CEPI assay and platelet adhesiveness by the 
CADP assay. Prospective studies are needed to investigate whether CADP assay 
can be a potential marker in identifying MPN patients at higher risk for throm-
bosis. 
 
We have recently demonstrated that platelet-associated TG is significantly in-
creased in both ET and PV patients compared to controls [7]. In the present 
study, we observed higher TG in ASA treated JAK2V617F positive patients com-
pared to ASA treated JAK2V617F negative patients. No difference was observed 
in TG between JAK2V617F positive and negative patients on HU. Our recent 
study showed elevated IPF parameters in both ET and PV patients, and particu-
larly in JAK2V617F positive patients [26]. In the present study we found that 
higher IPF count is associated with higher TG, and particularly in patients posi-
tive for JAK2V617F mutation. Therefore, we suggest that the increased IPF 
count is a relevant factor influencing increased TG in these patients. In addition 
we showed that MPN patients on HU have significantly lower TG, particularly in 
JAK2V617F positive patients [7]. Our recent study showed that HU-treated pa-
tients had lower levels of IPF, suggesting another potential protective mechan-
ism of HU, through reducing the most reactive fraction of the platelets, the IPF 
[26]. 
 
The characteristics of newly formed platelets may explain the pathological PFA-
100 assay results and the increased TG assessed by the CAT assay in MPN pa-
tients. Several mechanisms can explain the increased prothrombotic potential 
of IPF in patients with an increased platelet turnover. IPF are greater in mass 
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and are enzymatically and metabolically more active than mature platelets. 
These platelets aggregate faster after collagen stimulation and have an in-
creased levels of platelet surface proteins, such as P-selectin and GPIIb/IIIa 
[27].  
 
Our study showed that despite taking ASA, patients with higher IPF had shorter 
CADP and CEPI closure time and higher TG. Indeed, we observed a significant 
correlation between shorted CADP closure time and higher TG in ASA treated 
JAK2V617F positive patients. Recent studies suggest a possible role of IPF in 
resistance to antiplatelet therapy by expressing more COX-2 resulting in an in-
creased thromboxane production [28]. In addition, hyperreactivity while on 
ASA and increased ASA resistance has been associated with the presence of un-
inhibited COX-1 and COX-2 due to increased levels of immature platelets [29]. 
Dragani et al. have recently shown that residual thromboxane A2 production in 
ASA treated ET patients is likely due to expression of unacetylated COX-1 and 
COX-2 in newly formed platelets [15]. Furthermore, a recent study in high risk 
patients with coronary artery disease, has demonstrated increased residual 
platelet reactivity in patients with increased % of IPF and H-IPF while on dual 
antiplatelet therapy [30].  
 
This study provides new insight into platelet pathophysiology of patients with 
ET and PV. In addition it demonstrates that PFA-100 and CAT assay are poten-
tially useful methods in monitoring ASA effectiveness in MPN patients. Elevated 
IPF parameters are suggested important factors influencing increased platelet 
adhesive and procoagulant properties.  New prospective studies are warranted 
to evaluate the reliability of PFA-100 and CAT assay in identifying MPN patients 
at higher risk for thrombosis.   
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Abstract 
Background: Patients with Essential Thrombocythemia (ET) and Polycythemia 
Vera (PV) are characterized by an increased rate of thrombotic complications 
and by several abnormalities of platelets, more pronounced in JAK2V617F posi-
tive patients.  
 
Objectives: The objective of this study was to evaluate the platelet aggregation 
and procoagulant potential induced by several different agonists in ET and PV 
patients. 
 
Patients/Methods: Samples from 65 ET and 51 PV patients were analysed by 
whole blood impedance aggregometry and by Calibrated Automated Thrombo-
gram (CAT) assay in platelet rich plasma (PRP), respectively. In addition, we 
evaluated the platelet phospholipid contribution to thrombin generation (TG) 
by addition of Annexin V in both resting and ADP induced conditions.  
 
Results: The results show that ET and PV patients presented with significantly 
higher ADP induced whole blood platelet aggregation and TG compared to con-
trols. The highest values were observed in JAK2V617F positive patients and in 
patients on aspirin. JAK2V617F positive patients on aspirin also showed signifi-
cantly less inhibited TG compared to control subjects upon addition of Annexin 
V in both resting and ADP stimulated conditions.  
 
Conclusions: For the first time we demonstrated that platelets from ET and PV 
patients are more reactive to ADP, in terms of both increased platelet aggrega-
tion in a whole blood system, and as an enhanced TG, particularly in JAK2V617F 
positive patients. These data support the hypothesis that the use of ADP recep-
tor-inhibitors, in addition to aspirin, might be considered in the prevention of 
thrombosis in these conditions, by allowing a more complete inhibition of 
platelet functions. 
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Introduction 
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are myeloproli-
ferative neoplasms (MPN) characterized by an increased rate of thrombotic 
complications, more pronounced in JAK2V617F positive patients [1]. The fre-
quency of thrombosis (arterial, venous and microcirculatory) at the initial 
presentation vary from 11-25% in ET patients and from 12-39% in PV patients 
[2]. Numerous platelet abnormalities, both quantitative and qualitative, have 
been identified in ET and PV patients, however none of these findings have 
been clearly linked to thrombotic complications [3]. Studies on platelet expres-
sion of procoagulant and adhesive molecules revealed that platelets circulate in 
an activated status in ET and PV patients [4-5]. In general, the activation of 
platelets results in exposure of phosphatidylserine (PS) on their surface that 
strongly propagates the coagulation process by assembly of tenase and proth-
rombinase complexes [6]. In addition, activated platelets express increased tis-
sue factor (TF), the major initiator of the coagulation process, on their surface 
[7].  
 
The use of aspirin for prevention of thromboembolic complications is widely 
recommended and utilised in both ET and PV patients, either at low or at high 
risk for thrombosis [8-10]. In the randomized controlled trial including 518 PV 
patients, low dose aspirin was associated with reduced risk of the combined 
end point of nonfatal myocardial infarction, nonfatal stroke, or death from car-
diovascular causes [9]. Despite the lack of data from randomized controlled 
trials in ET patients, aspirin use has been shown effective in alleviating vasomo-
tor (microvascular) disturbances in these patients [11]. However, a recent 
study in ET patients has demonstrated that low-dose aspirin given in the rec-
ommended dosing interval once daily is unable to fully inhibit thromboxane 
production [12]. Furthermore, platelet adhesion and aggregation in vivo is in-
fluenced by a number of different agonists that act on pathways that are not all 
blocked by thromboxane inhibition.  
 
In this study we applied whole blood aggregometry, determined by Multiplate 
analysis, to assess overall platelet aggregability induced by several different 
agonists in both ET and PV patients, as compared with healthy controls. In addi-
tion, the procoagulant effect of platelets activated by adenosine diphosphate 
(ADP), was evaluated using the Calibrated Automated Thrombogram (CAT) 
assay. ADP is a strong platelet agonist that acts on two platelet receptors, P2Y1 
and P2Y12. Binding of ADP to the P2Y12 receptor results in dense granule re-
lease, platelet aggregation and thrombus growth and stabilization [13]. In addi-
tion, ADP enhances alpha granule release, facilitating TF and P-selectin translo-
cation to the platelet surface [14]. While the platelet’s phospholipid contribu-
tion to thrombin generation (TG) in healthy subjects is well recognised, the po-
tential platelet phospholipid contribution to TG in patients at risk of thrombo-
sis, including MPN patients, is unknown. To address this question, we used, for 
the first time, the CAT assay to evaluate the contribution of platelets to TG in 
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both resting and ADP induced conditions. All the results were analysed accord-
ing to patients’ presence of JAK2V617F mutation and treatment regimen. 
 
Subjects and methods 
Subjects 
 
This study has been conducted in blood samples obtained from 76 healthy sub-
jects, as compared to 65 consecutive ET and 51 PV patients. The healthy sub-
jects were hospital employees while the patients were recruited from the Ber-
gamo hospital between June 2008 and June 2009. The local Ethics committee 
(Comitato di Bioetica, Ospedali Riuniti, Bergamo, Italy) approved the study and 
all blood samples were obtained after informed consent. ET and PV patients 
were diagnosed according to the WHO criteria [15] and the procedures fol-
lowed were in accordance with the Helsinki declaration of 1975 as revised in 
2000. None of the patients were taking anticoagulant and hormone replace-
ment therapy. None of the controls were taking antiplatelet or antiinflammato-
ry agents in the past 10 days prior the blood drawing.  
 
Collection of blood samples 
 
Blood samples were drawn early in the morning after applying a light tourni-
quet. After discarding the first 3ml, the blood was collected into sterile silico-
nized tubes containing K3-ethylenediamine tetraacetic acid (K3-EDTA) for mo-
lecular biology studies and blood cell count analysis or trisodium citrate 
(0,129M, 1:9 vol:vol) for coagulation studies. 
 
Platelet Rich Plasma (PRP) preparation 
 
Within 30 minutes from the blood draw, PRP was separated by centrifugation 
of whole blood for 10 min at 280g at room temperature (RT). The rest of the 
blood sample was centrifuged at 3500g for 20 min to obtain platelet poor plas-
ma, which was utilized to dilute PRP at a fixed concentration of 150,000 plate-
lets/µl.  
 
Routine haematological assays 
 
Whole blood analysis of white blood cell differential count, hematocrit, platelet 
count and mean platelet volume were determined by a Sysmex-XE 2100 haema-
tology analyzer (Sysmex Co., Kobe, Japan).  
 
Whole blood aggregometry 
 
Whole blood aggregation was performed in a subgroup of subjects, 19 controls 
and 26 patients (15 ET and 11 PV patients), using a new generation impedance 
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aggregometer “Multiplate” (Dynabyte, Munich, Germany) according to the 
manufacturer instructions. The assay is based on platelet adhesion upon activa-
tion resulting in aggregation onto the metal sensor wires present in the test 
tube, thus increasing the electrical impedance between the wires. Platelet ag-
gregation was initiated using collagen (100µg/ml), ADP (0.2mM), thrombin 
receptor activating peptide (TRAP, 1mM) and arachidonic acid (ASPI test, 
15mM) provided by the manufacturer (Dynabyte, Munich, Germany). In the test 
cell, whole citrated blood (300 µL) was diluted in 1:2 vol/vol with 0.025 
mmol/L CaCl2 in saline solution for collagen, ADP and TRAP test and with 0.9% 
saline solution for ASPI test, all maintained at 37°C for 3 minutes. At the end of 
the incubation time, agonists were added and the increased impedance due to 
attachment of platelets to the electrodes was continuously measured over a 
period of 6 minutes. Aggregation measured was reported as area under the ag-
gregation curve, AUC, expressed in AU*min. 
 
CAT assay 
 
TG was continuously measured in freshly isolated PRP using the CAT assay. 
Briefly, 20 µl of Hepes buffer were added into TG wells while 20 µl of calibrator 
(with activity of 600 nM alpha2M-thrombin complex) into thrombin calibrator 
(TC) well. Eighty µl of PRP were added to both wells (TG and TC well). After 10 
min prewarming at 37ºC inside the fluorimeter (Fluoroscan Acsent, Thermo 
Labsystems, Helsinki, Finland), the reaction was started by the addition of 20 µl 
of CaCl2/ fluorogenic substrate (Z-Gly-Gly-Arg-AMC; Bachem, Bubendorf, Swit-
zerland) mixture. The TG was studied in 3 different conditions, i.e. in presence 
of ADP, recombinant human Annexin V (rh Annexin V) and in presence of both 
ADP and rh Annexin V. For the ADP induced TG, the PRP was preincubated for 
10 min inside the fluorimeter with low (1.6 µM) and high (8.3 µM) concentra-
tion of ADP. Furthermore, in a subgroup of subjects (34 controls, 33 ET and 29 
PV patients), the isolated PRP was preincubated with rh Annexin V (PS binding 
protein) for 10 min while shaking inside the fluorimeter, whereas for the TG 
induced by both ADP and Annexin V, the isolated PRP was preincubated with 
Annexin V and high (8.3 µM) concentration ADP. ADP (1mM) was purchased by 
Mascia Brunelli (Milan, Italy) and rh Annexin V (30µg) was purchased by Bend-
er MedSystems (Vienna, Austria). The TG curves were calculated using Throm-
binoscope software (Thrombinoscope, Maastricht, The Netherlands) by com-
paring the signals from the TG well and the TC well. TG curves were described 
in terms of peak height (maximum concentration of thrombin formed).  
 
JAK2V617F mutation analysis 
 
The presence of the somatic V617F mutation of the Janus 2 tyrosine kinase 
(JAK2) gene was tested on DNA obtained from K3-EDTA anticoagulated blood 
samples using the Puregene DNA isolation kit (Gentra systems, Minneapolis 
MN, USA). Polymerase chain reaction was performed as described previously 
[7].  
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Statistical analysis 
 
Data were compared between groups using the Student t test or the nonpara-
metric Mann-Whitney-Wilcoxon U test, according to the distribution of the test 
variables. The multiple intergroup comparisons were performed using the non-
parametric Dunn’s multiple comparison test. All statistical analyses were done 
with GraphPad Prism 5 (La Jolla, CA, USA). 
 
Results 
Basic haematological characteristics 
 
Table 1 shows the study population clinical and hematological characteristics. 
ET and PV patients had significantly higher total platelet, leukocyte and neutro-
phil counts compared to controls. In addition, PV patients had significantly 
higher neutrophil counts compared to ET patients. Among ET patients, 38 
(58%) were JAK2V617F positive with < 50% allele burden while the rest were 
JAK2 negative. Differently, 48 (94%) PV patients were positive for JAKV617F 
mutation of which 41 (85%) had <50% allele burden and 7 (15%) had >50% 
allele burden for the JAKV617F mutation. Three PV patients negative for 
JAK2V617F mutation were positive of JAK2 exon 12 mutation.  
 
Table 1. Study subject characteristics. Data are reported as number or mean (range);*p<0.05 vs 
controls; **p<0.01 vs ET. 
 
 
CONTROLS ET PV
Number 76 65 51
Males/Females 35/41 24/41 31/20
Age (years) 55 (28 – 75) 58 (23 – 81) 62 (20 – 84)
Platelets (109/L) 243 (151 – 419) 570* (208 – 1451) 484*(168 – 1278)
Leukocytes (109/L) 6.3 (3.7 – 11.3) 7.4* (3.1 – 16.3) 8.8*(3.1 – 39.9)
Neutrophils (109/L) 3.5 (1.4 – 7.7) 4.7* (1.6 – 11.1) 6.4*,**(2 – 36.4)
Hematocrit (%) 42 (35.2 – 45) 41 (35 – 49) 44 (34 – 49)
History of thrombosis (%) / 11 (17%) 11 (22%)
JAK2V617F (%) / 38 (58%) 48 (94%)
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At enrolment into the study, 56 MPN (27 ET and 29 PV) patients were receiving 
cytoreductive treatment with HU. Twenty seven ET and 21 PV patients received 
aspirin (ASA) alone. Eleven ET and 1 PV patient were not taking any cytoreduc-
tive and/or antiplatelet therapy.  
Twenty two patients (11 ET and 11 PV) had a positive history for at least one 
major thrombotic event.  
 
Platelet aggregation in whole blood by the Multiplate analyser 
 
Both ET and PV patients showed significantly higher (p<0.05) ADP (ET: 
800±240; PV: 824±223AU*min) and TRAP (ET: 1102±199; PV: 
1153±150AU*min) induced aggregation compared to control subjects (ADP: 
558±235; TRAP: 967±165 AU*min). No significant differences were observed 
for collagen and ASPI induced whole blood aggregation between the control 
subjects and MPN patients. The analysis according to JAK2V617F mutation 
demonstrated that compared to controls, JAK2V617F positive patients showed 
significantly higher ADP (817±119AU*min) and TRAP (1104±194AU*min) in-
duced aggregation, while JAK2 negative subjects showed no significant differ-
ences (ADP: 725±265; TRAP: 1077±165AU*min). No significant differences 
were observed between JAK2V617F positive and negative subjects. Figure 1 
shows the results of whole blood platelet aggregation in MPN patients accord-
ing to treatment regimen. Non treated subjects showed the highest platelet ag-
gregating potential in all four agonists induced conditions (Figure 1), however 
the statistical analysis was limited by the small sample size (n=3). Compared to 
controls, ASA treated patients (n=12) showed significantly higher (p<0.005) 
aggregation induced by ADP (Figure 1A) and TRAP (Figure 1B). Compared to 
HU treated patients (n=11), ASA treated patients showed significantly higher 
aggregation induced by TRAP only (Figure 1B). Platelet aggregation induced by 
collagen (Figure 1C) and ASPI (Figure 1D) showed no significant differences 
between ASA treated patients and control subjects. Differently, HU treated pa-
tients showed significantly reduced aggregation when induced by collagen 
compared to control subjects (Figure 1C).  
 
TG of PRP triggered by ADP  
 
PRP from both ET and PV patients generated significantly (p<0.05) higher peak 
levels in basal (hepes buffer; ET: 130±30, PV: 140±54 nM thrombin), as well as 
after low (1.6 µM; ET: 138±32, PV: 149±53 nM thrombin) and high (8.3 µM; ET: 
159±36, PV: 174±60 nM thrombin) ADP stimulated conditions compared to 
control subjects (basal: 110±28, low ADP: 114±23, high ADP: 135±30 nM 
thrombin).  
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Figure 1. Platelet aggregation in whole blood by the Multiplate analyser. *p<0.005 vs CTR; 
**p<0.05 vs CTR; &p<0.05 vs HU+ASA ;NT=non treated; ASA=Aspirin; HU=hydroxyurea; 
 
 
 
Figure 2. TG of PRP induced by low and high concentration ADP. *p<0.05 vs CTR; NT=non 
treated, ASA=Aspirin, HU=hydroxyurea, neg.=JAK2 negative;  pos.=JAK2V617F positive. 
 
 
 
JAK2V617F positive patients showed a significant increase of basal TG from 
139±44 nM thrombin to 146±45 nM and 171±52 nM thrombin after low or high 
ADP stimulation, respectively (p<0.0001 for all). In contrast, JAK2 negative sub-
jects, showed significantly different TG at the high (164±35 nM thrombin), but 
not at the low ADP induced condition (139±35 nM thrombin), as compared to 
the basal condition (133±32 nM thrombin). Figure 2 shows the TG induced by 
low and high ADP in patients according to both JAK2V617F mutational status 
and treatment regimen. The multigroup comparison analysis showed that ASA 
treated JAK2V617F positive patients generated the highest TG peak when sti-
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mulated by low (Figure 2A) and high ADP (Figure 2B), which were significantly 
different (p<0.01) from control subjects.   
 
Effect of Annexin V on TG in basal and in ADP induced conditions 
 
To investigate the participation of anionic phospholipids on activated platelets 
in TG process, we have preincubated the isolated PRP with the PS binding pro-
tein, rh Annexin V. As shown in Figure 3, preliminary experiments were per-
formed in PRP from five control subjects with increasing concentration of An-
nexin V (i.e. 0.25 ng/ml, 1.25 ng/ml and 2.5 ng/ml). The results showed that 
already at a low concentration of Annexin V (0.25 ng/ml) TG resulted in lagtime 
delay to 30 min, and in reduced TG peak. Complete inhibition of TG was ob-
served at 1.25 ng/ml of Annexin V, and further increasing the concentration did 
not result in any additional change. The concentration of 1.25 ng/ml Annexin V 
was used for the further analysis in both ET and PV patients and control sub-
jects.  
 
As presented in Figure 4A, in the presence of Annexin V, PV patients (n=29) 
showed significantly (p<0.05) higher TG (18±23 nM thrombin) compared to 
control subjects (n=34; 5±11 nM thrombin), while no significant difference was 
observed for ET patients (n=33; 6±10 nM thrombin). The analysis according to 
JAK2V617F mutation showed that both ET and PV mutation positive patients 
(n=48) generated significantly more thrombin compared to control subjects 
(Figure 4B). In addition, JAK2V617F positive patients showed higher TG values 
compared to JAK2 negative subjects (n=14), however without reaching statis-
tical significance (p=0.18). The further analysis according to both JAK2V617F 
mutation and therapy, showed that JAK2V617F positive patients on ASA had 
the highest TG, significantly different from control subjects (Figure 4C).  
 
When the CAT assay was measured in PRP stimulated by the high concentration 
of ADP and in the presence of 1.25 ng/ml Annexin V, the TG in controls, ET and 
PV patients were restored on average with 45%, 47% and 59%, respectively 
(not significantly different in ET and PV patients compared to control subjects) 
compared to TG in the presence of 1.25 ng/ml Annexin V only. The analysis 
based on JAK2V617F mutation and therapy showed that JAK2V617F positive 
patients on ASA had less inhibited TG by Annexin V in presence of high ADP 
concentration, significantly higher compared to control subjects (Figure 5). 
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Figure 3. TG of PRP from control subjects in presence of increasing concentrations of An-
nexin V. 
 
 
 
 
 
Figure 4. TG of PRP according to disease, JAK2V617F status and therapy 
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Figure 5. Effect of Annexin V on TG in ADP-stimulated condition 
 
 
 
Discussion 
Recent studies indicate that platelets in MPN patients circulate in an activated 
state, particularly in JAK2V617F positive patients [4-5, 16]. In this study we 
have evaluated in a group of ET and PV patients, the platelet reactivity to differ-
ent agonists in terms of proaggregating potential by using the multiple elec-
trode platelet aggregometry and the platelet reactivity to ADP in terms of pro-
coagulant responses by using the CAT assay. We demonstrated for the first time 
that platelets from ET and PV patients are more reactive to ADP, not only in 
terms of increased platelet aggregation in a whole blood system, but also en-
hanced thrombin generation, particularly in those positive for the JAK2V617F 
mutation. We also observed evidence of ASA failure, chronically administered 
to MPN patients, to fully inhibit platelet reactivity as shown by increased ADP 
and TRAP induced platelet aggregation, as well as ADP induced TG. Finally, we 
demonstrated a powerful inhibitory effect of Annexin V on platelet associated 
TG suggesting the critical participation of PS on activated platelet surface in 
thrombin formation process.  
 
In vivo, the most important platelet aggregating agents are collagen in the ves-
sel wall, ADP from the red blood cells or released from the activated platelets, 
thromboxane A2 from stimulated platelets and thrombin. The synergistic effect 
of different platelet agonists on the increased platelet reactivity and therefore 
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inability of ASA alone to adequately reduce the risk of thrombosis in high risk 
for thrombosis has been observed in many studies. Combined treatment with 
ASA and ADP receptor inhibitors (i.e. clopidogrel, prasugrel and ticagrelor) has 
now been established in patients with coronary artery disease [17-19]. Wheth-
er this combined antiplatelet therapy would also be more effective and suffi-
ciently safe in other patient populations, such as with  MPN, is however uncer-
tain [20].  
 
Platelet function inhibitors are widely utilized for thromboprophylaxis in ET 
and PV patients [10]. An increased reactivity of platelets to ADP from these pa-
tients, despite taking ASA, has previously been shown by light transmission 
platelet aggregometry studies, which might explain the failure of ASA to fully 
protect these patients from thrombosis, mainly those at high risk [21]. While 
the ADP activation pathway is critical for platelet aggregation, less is known 
about its role to the initiation of blood coagulation by platelets.   
 
The results of platelet aggregometry analysis showed significantly higher ADP 
and TRAP induced platelet aggregation for both ET and PV patients compared 
to control subjects. The highest ADP and TRAP induced platelet aggregating 
potential was observed in JAK2V617F positive patients. Interestingly, ASA 
treated patients even showed significantly higher ADP and TRAP induced ag-
gregation compared to control subjects suggesting persistent platelet reactivity 
while on ASA. A study limitation is that we were unable to compare patients 
before and after ASA exposure, such that the degree of absolute lack of inhibi-
tion by ASA cannot be assessed.   
 
The initial effect of platelets on the thrombin generating process can be readily 
assessed by the CAT assay performed in PRP. We have recently shown that 
MPN patients have an increased platelet-associated TG potential compared to 
controls [22]. The results of the TG assay in the present study also showed that 
platelets from both ET and PV patients are more responsive to ADP compared 
to control subjects’ platelets. In particular, platelets from JAK2V617F positive 
patients when stimulated by high-ADP generated the highest peak compared to 
both basal and low-ADP induced TG. The analysis according to both JAK2V617F 
mutation and therapy showed that ASA treated mutation positive patients have 
the highest thrombin generating potential, significantly different from controls 
subjects.  
 
ADP influences platelet activation mediated by the three ADP receptors P2X1, 
P2Y1 and P2Y12 which are responsible for rapid calcium entry, rapid calcium 
mobilization by phospholipase Cß activation and inhibition of adenylyl cyclase 
activity essential for full platelet aggregation, respectively [23-24]. In-vitro stu-
dies have demonstrated that ADP receptors are also implicated in the exposure 
of platelet stored TF and P-selectin. In particular, the inhibition of P2Y12 recep-
tor resulted in 33% decreased TF-dependent factor Xa activity in healthy sub-
jects receiving clopidogrel [14]. The findings of our and other groups have 
demonstrated an increased platelet surface TF and P-selectin expression par-
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ticularly in ET and PV JAK2V617F positive patients [7, 25]. Our study found an 
increased platelet reactivity to ADP as observed by higher platelet aggregating 
and procoagulant potential particularly in subjects positive for JAK2V617F mu-
tation. Further studies are needed to investigate the particular prothrombotic 
mechanisms of ADP stimulation and the possible implication and contribution 
of the consequently increased TF expression on platelet surface on hypercoagu-
lability in MPN patients.  
 
The externalization of anionic phospholipids on platelet surface, particularly PS, 
is a crucial determinant of platelet–associated TG. Indeed, in control subjects 
we observed complete inhibition of TG when Annexin-V protein was added in 
the system. However, PRP from PV patients, despite the large reduction of TG in 
the presence of Annexin V, still generated significantly higher thrombin com-
pared to control subjects. Further analysis showed that the highest TG is de-
termined by the presence of JAK2V617F mutation. Indeed, both ET and PV 
JAK2V617F positive patients showed significantly higher TG compared to con-
trol subjects. Compared to controls, only ASA treated subjects showed signifi-
cantly higher TG in presence of Annexin V. The increased TG in MPN patients, 
particularly in JAK2V617F positive patients, in the presence of Annexin V, sug-
gests an increased PS expression in these patients compared to controls and 
JAK2 negative subjects, as previously published.[26] However, other or addi-
tional mechanisms have been proposed, including Annexin V inhibited TF de-
encryptation process, inhibition of tenase and prothrombinase and interference 
with the action of factor VIIa-TF complex on blood coagulation [27-29]. 
 
In conclusion, our results support the hypothesis that the use of ADP receptor-
inhibitors, in addition to ASA, might be of help in the prevention of thrombosis 
in these conditions, by allowing a more complete inhibition of platelet func-
tions. In addition, our study suggests that negatively charged phospholipids 
exposed on activated platelets might be a specific target for the antithrombotic 
therapy in MPN patients at high risk for thrombosis. These targets may be a 
suitable subject for further clinical studies in patients with MPN. 
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Summary 
Essential thrombocythaemia (ET) and polycythemia vera (PV) are characte-
rized by a high incidence of thrombotic complications due to high shear stress 
of the vessel wall, blood hyperviscosity and hypoxaemia, all factors responsible 
for chronic endothelial dysfunction and platelet and leukocyte activation. We 
evaluated the activation status of vascular cells in 18 consecutive ET and 14 PV 
patients by measuring the plasma levels of the nitric oxide derivatives (NOx) 
(i.e. nitrites and nitrates) and of soluble selectins of platelet (P-selectin), endo-
thelial cell (P-selectin and E-selectin) and leukocyte (L-selectin) origin. The ef-
fect of hydroxyurea (HU) therapy on these parameters was also investigated. 
NOx were significantly (p<0.01) increased in ET patients treated with HU (11.5 
± 2.6 nM) compared to non-HU treated ET (1.41 ± 0.3 nM) and to controls (4.78 
± 2.49 nM). Multivariate analysis confirmed HU therapy as an independent pre-
dictor of higher NOx levels in ET. In addition, NOx significantly correlated with 
haematocrit. Plasma P-selectin was significantly elevated in ET (350 ± 40 
ng/106 platelets) and PV (482 ± 53 ng/106 platelets) patients compared to 
controls (120 ± 8 ng/106 platelets). In PV, also E-selectin (23.8 ± 4.2 ng/ml) 
was significantly increased compared to controls (11.2 ± 1.1 ng/ml; p<0.01). P-
selectin was significantly correlated to platelet (R=0.33; p=0.01) and leukocyte 
count (R=0.6; p=0.000), while E-selectin (R=0.34; p=.014) and sL-selectin 
(R=0.3; p=0.03) were correlated with leukocyte count only. In the multivariate 
analysis, NOx predicted increased levels of E-selectin in ET, but not in PV pa-
tients. Our data demonstrate that ET and PV are characterised by an altered 
pattern of soluble selectins and NOx. HU-mediated increase of NOx levels could 
represent an additional antithrombotic mechanism of this drug. 
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Introduction 
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are chronic mye-
loproliferative neoplasms (MPN) characterized by a high incidence of thrombo-
haemorrhagic complications and microvascular ischemic manifestations (i.e. 
erythromelalgia, paresthesias, acrocyanosis and dizziness) [1]. These two dis-
eases present with high peripheral blood hyperviscosity due to an increased 
number of circulating leukocytes, platelets and erythrocytes. This favors cell-
cell interaction, leading to the formation of increased numbers of platelet-
leukocyte aggregates [2-3]. In addition, in these subjects, neutrophils circulate 
in an activated state and release high quantity of proteases (i.e. elastase and 
metalloproteases) in circulation which can induce a procoagulant phenotype of 
endothelial cells and platelets, thus contributing to a hypercoagulable state [4]. 
Furthermore, high-shear stress of the vessel wall in association with blood 
hyperviscosity and hypoxemia has been advocated as responsible for the occur-
rence of chronic endothelial dysfunction and platelet activation in ET and PV 
patients [5].  
 
The endothelium plays a pivotal role in regulating blood flow. In part, this re-
sults from the capacity of quiescent endothelial cells to generate an active an-
tithrombotic surface that facilitates the transit of plasma and cellular constitu-
ents throughout the vasculature [6]. Perturbations, such as those that may oc-
cur at sites of inflammation or high hydrodynamic shear stress, disrupt these 
activities and induce endothelial cells to create a prothrombotic microenviron-
ment [7]. Blood flow is also regulated, in part, through secretion and uptake of 
vasoactive substances by the endothelium such as nitric oxide (NO)  and endo-
thelin [8].  
 
Selectins constitute a family of adhesion molecules designated by the prefixes E 
(endothelial), P (platelet) and L (leukocyte). E- and P-selectin are expressed by 
endothelial cells, while P-selectin is expressed also by platelets. L-selectin is 
expressed by leukocytes only [9]. They are up-regulated in a variety of disease 
states, and, in some instances are released into the circulation where they can 
be detected in soluble form [10-12]. The plasma levels of the different selectins 
have been used as indexes of endothelial, platelet, and leukocyte activation. 
Raised soluble E-selectin levels have been found in patients with cancer, coro-
nary-artery disease, hypertension and diabetes [13-14]. Similarly, raised levels 
of soluble P-selectin have been found in patients with cardiovascular diseases 
and diabetes mellitus [15-16]. 
 
It has been previously shown that patients with MPN present with endothelial 
dysfunction, a well-known risk factor for vascular disease [17-19]. This de-
rangement may play a role in the thrombotic diathesis of patients with ET and 
PV [3, 7]. However, the pathogenesis of endothelial dysfunction in ET and PV 
still remains incompletely defined. In this study we evaluated whether a pecu-
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liar pattern of NO metabolities (nitrites and nitrates, NOx) and circulating selec-
tins may characterize subjects affected by ET and PV subjects.  
 
Materials and methods 
A total of 32 consecutive patients diagnosed with ET and PV attending the out-
patients’ clinic of the Hematology Department of the Ospedali Riuniti of Berga-
mo (Italy) entered the study. Of these, 18 subjects (6 males, 12 females; age 
range 23-74 years) were diagnosed with ET and 14 subjects (8 males and 6 fe-
males; age range 20-87 years) were diagnosed with PV. A group of 19 healthy 
subjects (11 females, 8 males; age range 26-81 years) acted as controls for the 
study. Both ET and PV patients were diagnosed according to the Polycythemia 
Vera Study Group criteria [20]. None of the patients were on anticoagulant 
therapy and none of the healthy controls were taking any medication at the 
time of enrolment. The study was approved by the local ethics committee 
(Comitato di Bioetica, Ospedali Riuniti di Bergamo, Italy). All blood samples 
were obtained with the subject’s informed consent. 
 
Blood sample collection 
 
Venous blood was collected early in the morning (after at least 12-hour fasting), 
and before any drug administration, into sterile siliconized tubes containing 
trisodium citrate (0.129 mol/l, 1:10 vol/vol) or ethylenediaminetetraacetic acid 
(EDTA). Platelet-poor plasma was obtained by centrifugation of blood at 3,000 
x g for 20 min at room temperature, snap-frozen in aliquots and stored at -80°C 
until testing. 
 
Routine hematological assays 
 
White blood cell differential count (WBC), haematocrit, haemoglobin, red blood 
cell (RBC) and platelet counts were determined by automated method using a 
NE800 Analyzer (Dasit, Milan, Italy). 
Nitric oxide 
Plasma levels of NO were determined as a measure of nitrate (NO2) + nitrite 
(NO3) metabolites using a commercial ELISA kit (Cayman, Ann Arbor, MI, USA). 
Results are expressed as nM. 
 
Soluble selectins 
 
The plasma levels of E-, L, and P-selectin were measured using commercially 
available ELISA kits (R&D Systems Inc., Minneapolis, MN, USA). The results are 
expressed in ng/ml, and for P-selectin also as ng/106 platelets. 
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JAK2 V617F mutation analysis 
 
The presence of the somatic V617F mutation of the Janus 2 tyrosine kinase 
(JAK2) gene was tested on DNA obtained from K3-EDTA anticoagulated blood 
samples using the Puregene DNA isolation kit (Gentra systems, Minneapolis 
MN, USA). Polymerase chain reaction was performed as described previously 
[3]. 
 
Statistical analysis 
 
All results are expressed as mean  standard error of the mean (SEM). Analysis 
of the differences was performed by Mann Whitney U test. Differences were 
considered significant at a p-value <0.05. Linear regression analysis was per-
formed using the SPSS software 15 statistical package (SPSS, Chicago, IL, USA).  
 
Results 
Study population characteristics 
 
The haematological characteristics of the subjects enrolled into the study are 
shown in Table 1. Platelet, leukocyte counts and haematocrit values were sig-
nificantly increased (p<0.01) in both ET and PV patients compared to healthy 
controls. Additionally, ET patients had significantly increased (p<0.01) platelet 
count compared to PV patients, while PV patients had significantly higher 
(p<0.01) haematocrit value compared to ET patients. At the time of enrolment, 
nine ET patients (50%) and five PV patients (35.7%) were treated with hydrox-
yurea (HU). Three PV patients were on phlebotomy treatment. The JAK2 V617F 
mutation was detected in eight ET and 13 PV patients. The occurrence of 
thrombosis was registered in 10 patients (4 ET and 6 PV). Particularly, five pa-
tients (2 ET and 3 PV) were diagnosed with cerebrovascular accidents, and five 
patients (2 ET and 3 PV) with deep vein thrombosis (DVT).  
 
In the follow-up period between 2000 and 2009, two patients primarily diag-
nosed with ET transformed in PV, while new thrombotic events were diagnosed 
(4 cerebrovascular events and 5 DVT) in nine patients (4 ET and 5 PV). The un-
ivariate analysis showed that patients carriers of the JAK2V617F mutation had 
more vascular events (n=21, both prior diagnosis and in the follow-up period) 
compared to wild-type patients (n=11, p=0.06). The multivariate analysis ad-
justed for age, sex, JAK2V617F mutational status,  therapy and platelet count at 
baseline, showed that a thrombotic event at follow-up was significantly pre-
dicted by male sex (B=-0.434, p=0.02), JAK2V617F (B=0.508, p=0.016), and 
platelet count (B=0.5, p=0.017). Additionally, the Chi-square test revealed that a 
high leukocyte count (>10x109/L) at enrolment significantly predicted throm-
bosis in the follow-up period (Yates chi-square = 3.2). 
  
 
 Nitric oxide derivatives and soluble plasma selectins in patients with MPN 
 
149 
 
Table 1. Characteristics of MPN patients and controls at enrolment into the study.  
DVT: deep venous thrombosis; PE: pulmonary embolism; CVA: cerebrovascular accident. HU: Hy-
droxyurea *p<0.01vs Controls; § p<0.01 vs ET. 
 
 Controls ET PV 
Male/female (n)  8/11 6/12 8/6 
Age, years (range) 57.7 (26-81) 51 (23-74) 66 (20-87) 
White blood cells 
(x109/L) 
5.9 (4-8.3) 9.9 (6.3-15.9)* 12.2 (7.8-25.5)* 
Platelets (x109/L) 
 
248 (124-432)
  
785 (333-1500)* 418 (208-996)* ,§ 
Hemoglobin (g/L) 136 (12.5-15.8) 146 (12.1-20.1) 182 (15.7-22.3)* ,§ 
Hematocrit (%) 40 (38-43) 45 (37-67)* 58 (46-68)* ,§ 
JAK-V617F (%) - 8 (44) 13 (93)  
N. of patients on HU - 9 5 
Thromboembolic 
events 
- 4 6 
PE/DVT  2 3 
CVA  2 3 
 
Plasma levels of NOx 
 
We measured nitrites and nitrates plasma levels as a surrogate of NO. As shown 
in Figure 1 (left panel), NOx plasma levels were significantly higher in PV pa-
tients (8.35  1.48 nM) compared to control subjects (4.33  0.52 nM; p<0.01). 
Additionally, PV patients had higher NOx values compared to ET patients but 
without reaching a statistical significance. No significant differences were ob-
served between ET patients and controls.  
 
MPN patients receiving HU had significantly increased plasma concentration of 
NOx (10.61.9 nM, p<0.05) compared to non-HU treated patients (4.71.2 nM). 
The analysis according to disease subgroup (i.e. ET or PV) showed that ET pa-
tients on HU had significantly higher (p<0.01) levels of NOx (11.5  2.6 nM) 
compared to non-HU treated ET patients (1.41  0.3 nM) (Figure 1, right panel). 
Differently, NOx levels were similar among HU-treated and non-HU treated PV 
patients (Fig.1, right panel). After adjusting for age, sex, JAK2 V617F muta-
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tional status and therapy, HU treatment significantly predicts an increased level 
of plasma NOx in ET (B=0.57, p<0.01), but not in PV patients.  
 
The correlation analysis showed that in all subjects, plasma NOx were directly 
correlated with haematocrit value (R=0.45, p=0.001). However, the analysis 
performed according to the disease type, showed that NOx remained signifi-
cantly correlated with the haematocrit value in ET patients only (R=0.8, 
p<0.001).  
 
Figure 1: Plasma levels of NOx. Histograms represent the average plasma levels of NOx in controls, 
ET and PV patients (left panel), and of NOx levels in ET and PV according to HU therapy (right 
panel). *=p<0.05 vs. C; **=p<0.05. 
 
 
 
Plasma soluble selectins 
 
Soluble E-selectin (17.8  2.3 ng/ml) and P-selectin (408  33.8 ng/106 plate-
lets) were significantly increased in MPN patients compared to controls (E-
selectin: 11.2  1.1 ng/ml; p<0.05, P-selectin: 120.2  8 ng/106 platelets; 
p<0.01). Soluble L-selectin levels were not significantly different in patients 
compared to controls.  
 
As shown at Figure 2, ET patients had increased levels of E-, P- and L-selectin 
compared to controls reaching the statistical significance for P-selectin only 
(ET: 351  41; p<0.01 vs controls). PV patients had significantly increased val-
ues of E-selectin (23.8  4.2 p<0.001) and P-selectin (481.5  53 ng/ml; 
p<0.001) compared to controls and to ET patients (p<0.05 for both); whereas 
L-selectin was slightly increased but not statistically different. HU treatment did 
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not affect E-, P- and L-selectin plasma concentrations in either ET or PV pa-
tients. 
 
Figure 2: Plasma levels of selectins. Histograms show the average levels of E-selectin, P-selectin 
and L-selectin in controls (C), ET and PV patients.*=p<0.05 vs. C; §=p<0.05 vs. ET. 
 
 
 
P-selectin was directly correlated to either platelet (R=0.33; p=0.01) and leuko-
cyte counts (R=0.6; p=0.001), while E-selectin (R=0.34; p=.014) and L-selectin 
(R=0.3; p=0.03) with leukocyte count only. In addition, in ET patients, E-selectin 
was significantly and directly correlated to NOx levels (R=0.5, p<0.01). As 
shown in Table 2, after adjusting for age, sex, JAK2V617F status and therapy, 
NOx levels significantly predicted an increased E-selectin levels in ET patients 
(B=1.072. p=0.012). 
 
Table 2: Multiple regression analysis in MPN patients. The plasma levels of E-selectin (depend-
ent variable) were adjusted for age, sex, JAK2V617F status, therapy (HU) and plasma NOx levels. 
 
Variable 
regression 
coefficient ß 
p= 
Age -0.002 0.995 
Sex -0.167 0.428 
JAK2 0.234 0.361 
Therapy -0.547 0.085 
NO 1.072 0.012 
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As HU treatment may directly affect NO generation, patients on HU therapy 
were stratified according to the weekly dosage (<5g or >5g) of the anti-
metabolite. As shown in Table 3, MPN patients on higher dosage of HU (i.e. 
>5g/week) showed higher NOx plasma levels but this difference was not statis-
tically significant. At the same time, higher dosage of HU did not significantly 
affect selectin plasma levels. 
 
Table 3: Haematological parameters, selectins and NOx levels according to weekly HU dos-
age. 
 
Discussion 
The present study investigated the plasma levels of NO derivatives, and soluble 
E-, P- and L-selectins as markers of endothelial, platelet and leukocyte activa-
tion in 32 patients with MPN. NO is produced by vascular endothelium and 
platelets and it mediates vascular relaxation in response to vasoactive sub-
stances and shear stress. It provides anti-proliferative and antithrombotic func-
tions by inhibiting vascular smooth muscle cell proliferation, monocyte adhe-
sion, platelet aggregation, and thrombosis [17].  
 
Our study found an increased level of circulating NOx in MPN patients com-
pared to healthy controls. The sub-analysis of data according to therapy regi-
men showed that ET patients on treatment at the time of study enrolment with 
HU presented with the highest levels of plasma NOx. The results were also con-
firmed by the adjusted multivariate analysis. This suggests that, in this type of 
disease, the administration of HU can be responsible of the increased plasma 
NOx levels, as observed in patients with sickle cell anaemia [18].  The effect of 
HU on NOx levels may contribute to the well known ability of HU to prevent 
thromboembolic complications in ET patients [19]. The group of ET patients 
HU  (grams)/week
<5 gr. 
(n=7)
>5 gr. 
(n=7)
P=
Platelet (x109/L) 465.7±275 658±442 0.34
WBC (x109/L) 14.4±6 10.7±5.3 0.24
Hematocrit (%) 55.7±7.7 49.7±11.7 0.27
NO (nmol/L) 5.6±4.4 9.6±6.1 0.18
sL (ng/ml) 1,406.6±497 1,204±294 0.37
sE (ng/ml) 18.5±4.3 16±16.2 0.71
sP (ng/106  platelets) 463±245 340±202 0.32
 
 Nitric oxide derivatives and soluble plasma selectins in patients with MPN 
 
153 
 
not receiving HU at the time of enrolment presented with the lowest levels of 
NOx, when compared to both controls and PV patients. This is in agreement 
with a study demonstrating that in MPN patients with thrombocytosis the pro-
duction of NO by platelets is impaired [21].  
 
Differently, in PV patients, plasma NOx levels were increased independently 
from HU treatment, therefore in this type of MPN, other mechanisms can be 
responsible for this observation. It has been described that in patients with vas-
cular haemodynamic disorders (i.e. recent acute myocardial infarction, and 
progressive renal dysfunction) the plasma levels of NOx are significantly in-
creased, probably due to NO production by perturbed endothelial cells a s a 
protective antithrombotic mechanism [22-24]. We can hypothesise that in our 
PV patients the same mechanism is active compensating blood flow distur-
bances secondary to the high haematocrit values. In addition, regarding HU 
therapy, it might be possible that we could not detect appreciable differences in 
NOxlevels between HU-treated and non HU-treated patients because of the high 
levels of NOx even in the absence of treatment, and of the small group of pa-
tients. Our findings have significant clinical implications as increased NOx levels 
have been shown to represent an important antithrombotic mechanism in the 
presence of extremely high erythrocyte concentrations [25]. 
 
The main drawback of the use of total NOx as a measure of NO synthesis is that 
nitrates may arise from sources other than the metabolism of NO. Among the 
most important confounding factors, the contribution of dietary nitrite/nitrate 
intake to plasma NO is of relevance. To minimize the dietary interference blood 
samples were collected after at least 12 hours fasting and before any drug ad-
ministration. In fact, as the half-life of nitrate is about 8 hours, about 70% of 
exogenously derived nitrate seems to be cleared from the plasma after over-
night fasting. In our and others experience, this approach can be considered 
effective in measuring the basal production of NO derivatives [26].  
 
Our results on plasma selectin levels show that all three markers (E-, P- and L-
selectins) were increased in MPN patients compared to controls. P-selectin is an 
adhesion molecule stored within the Weibel–Palade body of endothelial cells as 
well as the alpha-granule of platelets and can be detected in soluble form after 
shedding from the cell membrane. Several studies have reported increased le-
vels of this marker in several thrombotic diseases like vascular disorders and 
MPN [27]. In addition, high levels of P-selectin membrane expression have been 
found on platelets from ET patients with thrombosis, suggesting a role of P-
selectin and platelet activation in the pathogenesis of thrombosis in ET [26]. 
Our data confirm that P-selectin is increased in MPN patients, with highest le-
vels observed in PV patients. As P-selectin can also be released from activated 
endothelium, the fact that E-selectin was concomitantly found to be significant-
ly higher in PV patients, might further support the occurrence of endothelial 
perturbation in these patients. Musolino et al. found increased plasma levels of 
P- and E-selectins in both ET and PV patients, suggesting that sustained endo-
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thelium and platelet activation in these patients might contribute to the patho-
genesis of thrombosis [28]. We found a direct correlation between plasma P-
selectin levels and platelet count in all subjects.  
 
In addition, we found a significant correlation between E-selectin and NOx le-
vels suggesting an increased endothelial activation in MPN patients. Of interest, 
plasma selectins have been shown to correlate with bone marrow proliferation 
[29], therefore this may also account for the increased levels of selectins in a 
condition of hypercellular bone marrow as occurred in patients with MPN.   
L-selectin is known to be expressed and shed only by leukocytes. We found 
higher levels of L-selectin in ET and PV patients compared to healthy controls. 
The increased plasma levels of L-selectin might suggest an activation of leuko-
cytes in MPN patients. This phenomenon has been previously observed by the 
finding of an increased expression of cell surface (i.e. CD11b, CD14, LAP and TF) 
and plasma levels (i.e. elastase and myeloperoxidase) of markers of neutrophil 
activation.[3, 7]  
 
To identify possible predictors for thrombosis in the follow-up period in our 
group of patients, we performed a multivariate analysis. The results showed 
that the platelet count at enrollment, male sex and JAK2V617F mutation were 
all significantly associated with higher risk for thrombosis in the follow-up pe-
riod. The nine patients who developed thrombosis were 67% males, 89% carri-
ers of JAK2V617F mutation, with a mean platelet count higher that the non-
thrombotic patients. This is in agreement with a recently published study that 
found a significant association between the presence of JAK2V617F mutation 
and the vascular events [30]. Furthermore, a recent study from our group found 
that a leukocyte count at baseline >10x109/L in MPN patients is associated with 
an increased risk of thrombosis in the follow-up period [31]. The same analysis 
performed in our study further confirmed this observation.  
 
In conclusion, our data demonstrate, for the first time, that HU is associated to 
increased plasma levels of NOx in patients with MPN. Whether HU-induced NO 
production and cytotoxicity may be relevant in the treatment of MPN would 
deserve further studies. 
 
What is known on this topic:  
 
1. Patients with ET and PV have endothelial dysfunction, a well-known 
risk factor for vascular disease.  
2. Endothelial dysfunction may play a role in the thrombotic risk of pa-
tients with ET and PV.  
3. Plasma levels of selectins and nitric oxide (NO) are important factors 
regulating endothelium function.  
4. It is unclear whether an interplay between selectins and NO does exist 
and how the cytoreductive treatment with HU does affect these mark-
ers in patients with ET and PV. 
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What this paper adds:  
 
1. We demonstrate for the first time that HU is associated to increased le-
vels of NO in patients with MPN.  
2. HU-induced NO production may be relevant in ameliorating endotheli-
al dysfunction in patients with ET and PV. 
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Summary and General Discussion  
Thrombosis is a frequent clinical complication in cancer patients. Since its first 
recognition in the 19th century by Armand Trousseau, many investigators con-
tributed to further enlighten the link between cancer and thrombosis. While 
now it is a common knowledge that thromboembolic disease is often an early 
manifestation and frequent cause of morbidity and mortality in cancer patients, 
the specific pathogenetic mechanisms are still under investigation. Whereas 
much is known about the role of platelets in hemostasis, in recent years it is 
more and more recognized that platelets play a more complex role in cancer. As 
presented in Chapter 1, the interaction between platelets and tumor cells sup-
ports the growth and dissemination of malignant cells. In addition, platelets 
participate in tumor progression by generating thrombin, a central enzyme of 
the coagulation cascade. Thrombin generation has been linked to several steps 
of tumor progression, most likely acting through protease activated receptor 
(PAR) mediated cell signaling pathways.  
 
In part one, Chapter 2, a review on tumor cell-induced procoagulant mechan-
isms summarizes important current concepts regarding the interactions be-
tween cancer cells and hemostasis, supporting a hypercoagulable state in pa-
tients resulting in a greater risk of  thromboembolic complications. In Chapter 
3, the current recommendations for prevention and treatment of venous 
thromboembolism (VTE) are discussed. Low molecular weight heparin 
(LMWH) remains the best treatment option for initial and long term treatment 
of VTE in cancer patients. In addition, numerous studies suggest a survival ben-
efit for cancer patients treated with LMWH.[1-2]  
 
The main objective of this thesis was to evaluate platelet-associated hypercoa-
gulability in patients with Myeloproliferative Neoplasms (MPN), particularly in 
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) patients. These 
particular clinical conditions have been chosen because their clinical course is 
strongly affected by the disease-related thrombosis. Also, management of these 
patients remains highly dependent on the patient’s thrombotic risk (in Chapter 
1).      
 
The thrombotic tendency in this population has been evaluated using the new 
calibrated automated thrombogram (CAT) assay, measuring thrombin genera-
tion (TG) in platelet poor plasma, platelet rich plasma and in platelet lysates. 
Part two, Chapter 4, explores pre-analytical conditions that might influence in-
vitro measurements of TG. Effects of blood collection method and addition of 
corn trypsin inhibitor to abolish in-vitro contact activation in TG measurements 
are investigated. Our study showed no need of corn trypsin inhibitor in TG as-
says with 1pM tissue factor initiation or higher.    
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Part three of this thesis focuses on hypercoagulability in ET and PV patients, 
and particularly on platelet associated hypercoagulability. As described in 
Chapter 5 a study was performed in a group of 140 MPN patients (80 ET and 60 
PV) in order to characterize for the first time the TG potential expressed by 
platelets from these subjects, as compared to platelets obtained from 72 
healthy subjects and to identify what factors might be responsible for platelet 
TG. The TG parameters of interest (i.e., lag time, peak height, and slope) were 
evaluated in relation to platelet counts, platelet surface tissue factor (TF) and P-
selectin levels, JAK2V617F mutational status, and patients’ therapy. The analy-
sis showed that patients positive for the JAK2V617F mutation were characte-
rized by the highest TG potential, platelet surface TF and P-selectin levels. Pa-
tients on hydroxyurea (HU) were characterized by a significantly lower TG po-
tential compared to non-HU treated patients, with the lowest values observed 
in HU treated JAK2V617F positive patients. Patients not receiving HU showed 
higher TG potential associated with JAK2V617F allele burden increment. This 
study suggests a platelet-dependent form of hypercoagulability in MPN pa-
tients, particularly in those positive for the JAK2V617F mutation. In addition, it 
shows a more beneficial effect of HU in subjects positive for JAK2V617F muta-
tion, which significantly affects their prothrombotic phenotype. 
 
While it is known that ET and PV patients are characterized by an increased 
number of circulating immature platelets, no information was available on 
whether this increase is influenced by pathogenetic factors including 
JAK2V617F mutational status, or by treatment regimen in these patients.[3] 
Therefore, we enrolled 46 ET and 38 PV patients to characterize the immature 
platelet parameters (IPF) measured by a new automated hematology analyzer 
(Chapter 6). Our results revealed two new elements regarding the association 
between MPN patients and IPF. The first finding is that the JAK2V617F muta-
tion is linked to the quantity of IPF in patients with MPN, which might contri-
bute to the prothrombotic phenotype in these patients. The second finding is 
that IPF is susceptible to HU treatment, which may additionally explain the fa-
vorable effect of this therapy on MPN as well as the associated thrombotic risk. 
 
Antiplatelet therapy with low dose aspirin has been shown to reduce the risk of 
thrombosis (i.e. major venous thrombosis, pulmonary embolism, myocardial 
infarction and stroke) in PV patients.[4] Recently, low dose aspirin has been 
shown effective in reducing the incidence of venous thrombosis in JAK2V617F 
positive ET patients and to lower the rate of arterial thrombosis in patients 
with associated cardiovascular risk factors.[5] However, the large multicenter, 
controlled randomized clinical trial ECLAP, showed that low dose aspirin does 
not significantly reduce overall or cardiovascular mortality in PV patients.[4] So 
far, no study has investigated this issue in ET patients. Therefore, it remains 
uncertain whether low dose aspirin completely inhibits platelet function in 
MPN patients. In Chapter 7 we performed the PFA-100 assay in whole blood 
and the CAT assay in platelet rich plasma in a group of 46 ET and 38 PV patients 
to evaluate the effect of aspirin on platelet adhesive and procoagulant characte-
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ristics. Our results showed higher TG in aspirin treated JAK2V617F positive 
compared to aspirin treated JAK2V617F negative patients. In the PFA-100 assay 
flow arrest was noted in 20% of MPN patients after collagen-adenosine diphos-
phate (CADP) and in 15% of these patients after collagen-epinephrine (CEPI) 
trigger, the majority taking aspirin. Higher immature platelet parameters from 
both ET and PV patients were significantly associated with shorter CADP clo-
sure time. In addition, in JAK2V617F positive patients, we found a significant 
and positive association between immature platelet count and TG. Our study 
suggests that elevated immature platelet parameters are important factors in-
fluencing increased platelet adhesive and procoagulant properties. Despite tak-
ing aspirin, patients with higher immature platelets had shorter CADP and CEPI 
closure time and higher TG. Recent observations have highlighted a wide bio-
logical variability in the interindividual response to aspirin’s antiplatelet ef-
fects. 10-20% of patients experienced recurrent vascular events despite treat-
ment with aspirin, referred to as treatment failure.[6] Recent studies suggest a 
possible role of immature platelets in so called resistance to antiplatelet thera-
py by expressing more COX-2 resulting in an increased thromboxane produc-
tion.[7] In addition, hyperreactivity of younger platelets and incompletely inhi-
bited COX-1 and COX-2 have been advocated for reduced antiplatelet effect of 
aspirin and aspirin resistance in patients with increased levels of immature 
platelets.[8] A recent study by Dragani et al. showed that low dose aspirin is 
unable to fully inhibit thromboxane A2 biosynthesis in ET patients. The residual 
thromboxane A2 in these patients is likely due to expression of unacetylated 
COX-1 and COX-2 in newly formed platelets [9]. 
 
Platelet adhesion and aggregation in vivo are influenced by a number of differ-
ent agonists acting also through other than thromboxane dependent pathways. 
As described in Chapter 8 a study was performed in a group of 65 ET and 51 PV 
patients to evaluate platelet reactivity to different agonists using the multiple 
electrode platelet aggregometry and platelet reactivity to ADP in terms of pro-
coagulant responses by using the CAT assay. We demonstrated that platelets 
from ET and PV patients are more reactive to ADP, not only in terms of in-
creased platelet aggregation in a whole blood system, but also enhanced TG, 
particularly in those positive for the JAK2V617F mutation. We also observed 
evidence of aspirin failure, chronically administered to MPN patients, to fully 
inhibit platelet reactivity as shown by increased ADP and thrombin receptor 
activating peptide induced platelet aggregation, as well as ADP induced TG.  
 
While the platelet’s phospholipid contribution to TG in healthy subjects is well 
recognized, the potential platelet phospholipid contribution to TG in patients at 
risk of thrombosis, including MPN patients, is unknown. We demonstrated a 
powerful inhibitory effect of Annexin V on platelet associated TG indicating the 
critical participation of phosphatidylserine on the activated platelet surface in 
the thrombin formation process.     
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Hydroxyurea (HU) is a recommended treatment approach in high risk pa-
tients.[10] It has been demonstrated efficient in reducing thrombotic events in 
high risk patients for thrombosis in a seminal randomized clinical trial.[11] Be-
sides its myelosuppressive actions, additional mechanisms have been advo-
cated to explain the anti-thrombotic effect of HU, including qualitative changes 
in circulating blood cells (i.e. decreased expression of tissue factor), decreased 
expression of endothelial adhesion molecules and enhanced nitric oxide pro-
duction.[12] Nitric oxide is produced by vascular endothelium and platelets and 
it mediates vascular relaxation in response to vasoactive substances and shear 
stress. It provides anti-proliferative and antithrombotic functions by inhibiting 
vascular smooth muscle cell proliferation, monocyte adhesion, platelet aggrega-
tion, and thrombosis.[13] Our study found an increased level of circulating ni-
tric oxide metabolites in MPN patients, particularly in ET patients, compared to 
healthy controls (Chapter 9). In addition, we observed increasing levels of nitric 
oxide metabolites upon increasing weakly dosage of HU.[14] Whether HU-
induced nitric oxide production may be relevant in the treatment of MPN would 
deserve further studies. 
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Conclusions and recommendations 
Thrombosis is a frequent complication in patients with cancer. In patients with 
hematological malignancies, such as MPN, thrombotic events are a major cause 
of increased morbidity and mortality. The pathogenesis of the activation of 
blood coagulation in these patients is complex. Platelets have an important role 
in this process. 
 
This thesis presents studies exploring the platelet-associated hypercoagulabili-
ty in patients with ET and PV. Measurements of the overall coagulation by the 
new thrombin generation technique provide important information of the coa-
gulation state in these patients. Our results indicate that platelets of patients 
with ET and PV have a higher prothrombotic potential as assessed by the in-
creased TG produced in platelet rich plasma or induced by isolated platelets.  
 
The JAK2V617F mutation has been reported in nearly all patients with PV and 
in more than half of patients with ET. This acquired mutation has been asso-
ciated with severity of disease and increased expression of soluble or cellular 
biomarkers of clotting system activation. Indeed, our study confirmed a hyper-
coagulable state in patients positive for the JAK2V617F mutation, associated 
with the highest TG values. We also observed that the JAK2V617F mutation is 
linked to a larger number of immature platelets, which might contribute to the 
prothrombotic phenotype in these patients. Furthermore, in these patients we 
showed increased platelet reactivity to ADP, in terms of both increased platelet 
aggregation in a whole blood system, and as an enhanced TG.  
 
The results of the studies presented provide a starting point to further research 
on the association between platelet TG and/or immature platelets and throm-
botic events in these patients. The current formal risk categorization includes 
only age and history of thrombosis in classifying patients as low or high risk for 
thrombosis. However, the results from the epidemiological studies suggest that 
better stratification of patients is necessary to improve prevention of thrombo-
sis. Our studies suggest that particular attention is needed for JAK2V617F posi-
tive patients who despite aspirin use show higher TG potential and a higher 
percentage of immature platelets. Future research should also focus on design-
ing an improved risk assessment model including both clinical and laboratory 
variables to better predict thrombosis in MPN patients. TG and immature plate-
let count could be included in such a risk model. Prospectively, such a model 
may be used by clinicians for assessing risk for thrombosis in patients seen in 
clinical practice.  
Dual antiplatelet therapy has proven successful in patients with cardiovascular 
diseases. Our finding for an increased platelet reactivity to ADP, measured by 
whole blood aggregometry and TG assay, necessitates  further research on the 
mechanisms involved that may potentiate the platelet associated hypercoagu-
lability in MPN patients. Whether the use of ADP receptor-inhibitors, in addi-
tion to aspirin, might be of help in the prevention of thrombosis in MPN pa-
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tients, by providing a more complete inhibition of platelet functions, remains to 
be investigated. The potential benefit from such approach can only be proven in 
comparative, clinical trials.   
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